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Abstract 
Acyl-­‐‑carrier-­‐‑protein   (ACP)   is   the   principal   transporter   of   fatty   acids,  
coordinating   acyl-­‐‑transfer   among   a   vast   network   of   diverse   enzymes   and   biochemical  
processes.    ACP  association  with  protein  partners  is  thought  to  be  exceedingly  transient.    
This   paradigm   has   posed   challenges   for   understanding   the   molecular   basis   for   acyl-­‐‑
delivery  and  dissociation.    During  biosynthesis  of  the  lipid  A  component  (endotoxin)  of  
lipopolysaccharides,   ACP   shuttles   acyl-­‐‑intermediates   thioester-­‐‑linked   to   its   4′-­‐‑
phosphopantetheine   arm  among   four   acyltransferases:   LpxA,  LpxD,  LpxL,   and  LpxM.    
LpxA  and  LpxD  are  essential  cytoplasmic  enzymes,  which  not  only  provide  an  excellent  
model   system   to   study   the   ACP-­‐‑based   interaction,   but   also   offer   an   important  
therapeutic   target   for   development   of   novel   antibiotics.   This   dissertation   reports   the  
crystal  structures  of  three  forms  of  Escherichia  coli  ACP  engaging  LpxD,  which  represent  
stalled   substrate   and  breakage  products   along   the   reaction   coordinate.      The   structures  
reveal   the   intricate   interactions   at   the   interface   that   optimally   position   ACP   for   acyl-­‐‑
delivery   and   directly   involve   the   pantetheinyl   group.      Conformational   differences  
among   the   stalled   ACPs   provide   the   molecular   basis   for   the   association-­‐‑dissociation  
process.    An  unanticipated  conformational  shift  of  4′-­‐‑phosphopantetheine  groups  within  
the  LpxD   catalytic   chamber   reveals   an  unprecedented   role   of  ACP   in  product   release.  
Moreover,  the  crystal  structure  of  E.  coli  LpxA  in  complex  with  one  form  of  ACP  (holo-­‐‑
ACP)  is  presented.  The  structure  reveals  three  molecules  of  holo-­‐‑ACP  localize  to  the  C-­‐‑
   v  
terminal  domain  of  the  LpxA  homotrimer,  and  shows  the  functional  role  of  this  domain  
is   two-­‐‑fold:   ACP   recognition   and   nucleotide   binding   of   UDP-­‐‑GlcNAc.   A   comparison  
with  the  LpxD:ACP  complexes  uncovers  that  ACP  utilizes  different  surface  residues  for  
recognition  even  amongst  closely  related  acyltransferases,  yet  still  relies  on  “electrostatic  
steering”   for   docking   to   its   enzyme   partner.   Insights   gleaned   from   the   presented  
structures   have   provided   not   only   a   better   understanding   of   ACP   interaction   with  
acyltransferases,   but   also   has   identified   the   “drugable   molecular   landscape”   for   the  
development  of  novel  antibiotics  against  infective  Gram-­‐‑negative  bacteria.  
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Chapter 1. Introduction 
1.1 Lipopolysaccharide and innate immune response  
The  cell  envelope  of  Gram-­‐‑negative  bacteria  is  a  complex  structure  that  provides  
protection  against  internal  turgor  pressure  and  external  stressors  such  as  detergents  and  
antibiotics  (1,  2).  This  structural  feature  is  characterized  by  the  presence  of  an  inner  and  
an  outer  membrane  that  are  separated  by  a  thin  layer  of  peptidoglycan  and  membrane-­‐‑
derived  oligosaccharides  (Fig.  1.1)  (3,  4).  The  inner  membrane  bilayer  as  well  as  the  inner  
monolayer   of   the   outer   membrane   is   composed   mainly   of   phospholipids   such   as  
phosphatidylglycerol,   and  phosphatidylethanolamine,  whereas   the  outer  monolayer  of  
the   outer  membrane   is   primarily  made   of   lipopolysaccharide   (LPS)   (4).  Gram-­‐‑positive  
bacteria   lack   the   outer   membrane   and   alternatively   possess   a   thicker   layer   of  
peptidoglycan.  LPS  of  Gram-­‐‑negatives   is   comprised  of  a  hydrophilic  and  hydrophobic  
domain.   The   hydrophilic   domain   can   be   subdivided   into   two   parts:   distal   O-­‐‑antigen  
polysaccharide,   and   core   oligosaccharide   (4,   5).   The   O-­‐‑antigen   structure   is   highly  
variable   among   different   Gram-­‐‑negative   serotypes.   In   Escherichia   coli,   for   example,  
approximately  170  forms  of  O-­‐‑antigen  stereotypes  have  been  identified  (4).  Conversely,  
variation   in   the   composition   and   structure   of   core   oligosaccharides   within   a   given  
species  is  limited  (4,  6).  The  O-­‐‑antigen  and  core  saccharides  are  not  necessary  for  growth  
(7,   8);   yet,   they   are   needed   for   maintaining   an   effective   permeability   barrier   and  
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virulence  (2,  9),  and  in  their  absence  bacteria  do  not  correctly  insert  porins  (10,  11),  and  
are  more  susceptible  to  antibiotics  such  as  polymyxins  (2,  12).  The  hydrophobic  domain  
of  LPS  is  a  disaccharide  glucosamine-­‐‑based  lipid,  termed  lipid  A  (endotoxin).  With  a  few  
exceptions,  lipid  A  is  essential  for  bacterial  growth  and  its  structure  is  highly  conserved  
(5,   8,   13-­‐‑15).   In  E.   coli,   the  diglucosamine   backbone   is   decorated  with   two  phosphoryl  
groups  at  positions  1  and  4′,  and  contains  four  primary  and  two  secondary  acyl-­‐‑chains  
(Fig.  1.2)  (5).  
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Figure  1.1:  Schematic  structure  of  the  E.  coli  cell  envelope.  The  cell  envelope  is  
composed   of   the   inner   and   outer   membranes   separated   by   peptidoglycan   and  
membrane-­‐‑derived   oligosaccharide   (MDO).   The   inner   membrane   is   comprised   of  
phospholipids   such   as   phosphatidylethanolamine   (dark   green)   and  
phosphatidylglycerol   (light   green),   and   peripheral   and   integral   membrane   proteins  
(cyan).     The  inner  leaflet  of  the  outer  membrane  is  composed  mainly  of  phospholipids,  
whereas   the  outer   leaflet   is  composed  mostly  of   lipopolysaccharide   (LPS).  Lipid  A   is  a  
hexa-­‐‑acylated  disaccharide  that  anchors  LPS  into  the  outer  membrane.  The  inner  core  is  
linked  to  lipid  A  through  a  3-­‐‑deoxy-­‐‑D-­‐‑manno-­‐‑oct-­‐‑2-­‐‑ulosonic  acid  sugar  (Kdo)  molecule.  
The   composition   of   the  O-­‐‑antigen   varies   among  Gram-­‐‑negative   serotypes.  E.   coli  K-­‐‑12  
strains  do  not  produce  O-­‐‑antigen  except  when  a  point  mutation  in  the  O-­‐‑antigen  operon  
is   fixed.   Kdo2-­‐‑lipid   A   is   the   minimal   LPS   structure   sufficient   for   growth   of   Gram-­‐‑
negative  bacteria.    
Figure  is  adapted  from  Raetz  and  Reynolds  2007.  
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Figure   1.2:   Chemical   composition   of   E.   coli   lipid   A.   The   lengths   of   attached  
acyl-­‐‑chains  are   indicated.  The  glucosamine  backbone   can  vary   in   some  Gram-­‐‑negative  
bacteria.   In   Leptospira   interrogans   and   Acidithiobacillus   ferrooxidans   the   acyl-­‐‑chains   at  
position  3  and  3’  are  amide-­‐‑linked  instead  of  ester-­‐‑linked.  The  length  of  acyl-­‐‑chains  can  
also   vary   in   different   bacteria.  Rhizobium   leguminosarum,   and   Sinorhizobum  meliloti   can  
incorporate  a  secondary  acyl-­‐‑chain  at  the  2’  position  that  measures  28-­‐‑carbons  in  length.  
Lipid  A  can  be  modified  after  synthesis.  For  example,  a  phosphoethanolamine  or  an  L-­‐‑4-­‐‑
amino-­‐‑4-­‐‑deoxy-­‐‑arabisone  molecule  can  be  added  to  the  1  and  4’  positions,  respectively.  
In  Francisella  tularensis  and  various  Rhizhobium  species  lipid  A  can  be  dephosphorylated.    
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During   Gram-­‐‑negative   infection   of   the   mammalian   host,   LPS   is   transferred   to  
surface   of  monocytes,   lymphocytes,   and   endothelial   cells   through   the   actions   of   LPS-­‐‑
binding  protein  (LBP),  cluster  differentiation  antigen  14  (CD14),  myeloid  differentiation  
2   (MD2),   and   toll-­‐‑like   receptor   4   (TLR4)   to   initiate   a   series   of   events   that   leads   to  
production  of  inflammatory  mediators  and  eventual  clearance  of  infection  (16-­‐‑19).  LPS  is  
extracted   from   the   surface   of   bacterium   by   LBP,   and   subsequently   transferred   to   the  
phosphatidylinositol-­‐‑anchored   CD14   protein,   and  MD2/TLR4   complex   (19).   MD2   is   a  
soluble  protein  that  binds  the  extracellular  domain  of  TLR4  to  form  a  heterodimer  (18).  
Upon  recognition  of  lipid  A  moiety  of  LPS  by  MD2,  the  MD2/TLR4  complex  dimerizes  
to   form   a   (LPS/MD2/TLR4)2   multimer.   The   crystal   structure   of   (LPS/MD2/TLR4-­‐‑
extracellular  domain)2  multimer  has  been  recently  reported,  which  revealed  the  details  
of  interactions  between  all  subunits  (Fig.  1.3a)  (20).    MD2  is  predominantly  composed  of  
antiparallel   β-­‐‑strands   and   possesses   a   narrow   hydrophobic   pocket   that   is   capable   of  
accommodating  five  acyl-­‐‑chains  of  lipid  A  (Fig  1.3b).  The  sixth  acyl-­‐‑chain  interacts  with  
a   hydrophobic   surface   feature   provided   by   the   second   TLR4   subunit,   and   the   two  
phosphates   of   lipid   A   are   coordinated   by   MD2   and   two   TLR4   subunits.   The  
dimerization   of   MD2/TLR4   triggers   the   homodimerization   of   the   intracellular  
toll/interleukin  (IL)-­‐‑1  receptor  (TIR)  domains  of  TLR4  subunits,  which  in  turn  activates  
two  major   signaling  pathways   (21).  One  pathway   involves   the   recruitment  of  myeloid  
differentiation   primary   response   protein   88   (MyD88)   and  MyD88-­‐‑adaptor-­‐‑like   protein  
(MAL),   and   another   response   pathway   involves   TIR   domain-­‐‑containing   adaptor  
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inducing   interferon-­‐‑β   (TRIF)  and  TRIF-­‐‑related  adaptor  molecule   (TRAM)  (Fig.  1.4)   (19,  
22).   The   MyD88/MAL   cascade   signals   through   a   kinase-­‐‑dependent   pathway,   which  
leads   to   the   activation   and   translocation   of   nuclear   factor   κ-­‐‑B   (NF-­‐‑κB)   to   the   nucleus  
where   it   induces  the  production  of  pro-­‐‑inflammatory  cytokines  such  as  tumor  necrosis  
factor   α   (TNF-­‐‑α),   interleukin   6   (IL-­‐‑6),   and   IL-­‐‑12.  Overproduction   of   pro-­‐‑inflammatory  
cytokines   can   lead   to   septic   shock,   a   life-­‐‑threatening   clinical   syndrome   that   can   be  
characterized  by  organ  dysfunction  and  failure,  as  well  as  severe  blood  pressure  drop  (4,  
23).    
The  TRIF/TRAM  signaling  pathway  is  less  inflammatory.  This  pathway  leads  to  
expression  of  interferon  (IFN)-­‐‑inducible  genes  through  the  activation  of  IFN  regulatory  
factor   3   (IRF3),   and   results   in   adaptive   immunity   and   adjuvanticity.   The   degree   of  
acylation   and   phosphorylation   of   lipid   A   appears   to   affect   the   extent   of   pro-­‐‑
inflammatory   response   by   TLR4/MD2   complex   (24-­‐‑26).   Missing   acyl   or   phosphate  
groups  from  the  lipid  A  backbone  compromises  the  dimerization  of  TLR4/MD2  complex  
and   leads   to  partial   activation  of   the  TIR  domain.  For   example,  underacylated   lipid  A  
(lipid   IVA),  and  monophosphorylated   lipid  A  act  as  partial  agonists  of  human  TLR4  to  
block  pro-­‐‑inflammatory  cytokine  production  and  promote  adaptive  immunity  (27,  28).  It  
is  worth  mentioning   that  monophosphorylated   lipid  A  has  been   recently  approved  by  
US  Food  and  Drug  Agency  to  be  used  as  vaccine  adjuvant  (28,  29).  
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Figure  1.3:  Structure  of  human  TLR4/MD2  in  complex  with  lipid  A.     (a)  Kdo2-­‐‑
lipid  A  bound   to  MD2   (pink)   and   the   extracellular  domain  of  TLR4   (green).  The   acyl-­‐‑
chains  of  Kdo2-­‐‑lipid  A  (ball  and  stick  representation)  are  colored  black,  the  glucosamine  
rings  are   in  blue,  and   the  Kdo2   sugars  are   in   light   cyan  and  colored  by  atom.      (b)  The  
acyl-­‐‑chains   are   packed   inside   MD2.      The   molecular   surface   of   MD2   is   shown   with  
semitransparency.  
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Figure  1.4:  Human  immune  response  to  LPS.  LBP  enhances  transfer  of  the  LPS  
to  CD14,  which  in  turn  delivers  LPS  to  the  MD2  portion  of  TLR4/MD2  heterodimer  on  
the   surface   of  macrophages.     Upon   binding,   two  TLR4/MD2   complexes   dimerize,   and  
the   TLR4s   cytoplasmic   domain   activates   MyD88/MAL   or   TRIF/TRAM   signaling  
pathway.   These   events   lead   to   production   of   pro-­‐‑inflammatory   cytokines   and  
interferons  mediated  by  NF-­‐‑κB  and  IRF3  transcription  factors,  respectively.   Interferons  
are   important   for   adaptive   immunity,   whereas   overproduction   of   pro-­‐‑inflammatory  
cytokines  can  cause  sepsis  and  be  lethal.  
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Bacterial  infection  caused  by  Gram-­‐‑negative  pathogens  is  a  major  public  concern  
(30).  This  is  especially  true  with  infections  caused  by  multi-­‐‑drug  resistant  Gram-­‐‑negative  
bacteria   (31).   Historically,   antibacterial   agents   combat   infectious   bacteria   through  
targeting  three  essential  cell  processes  that  include  DNA  replication  and  repair,  protein  
synthesis,   and   peptidoglycan   biosynthesis.   However,   the   rapid   development   of  
antibiotic  resistance  by  bacteria  demands  new  biosynthetic  pathways  to  be  explored  for  
discovery  of  novel  antibiotics  (32,  33).    Given  the  essential  role  of  lipid  A  in  viability  and  
pathogenesis  of  Gram-­‐‑negative  microorganisms,  understanding   lipid  A  biosynthesis   is  
of  great  interest.    
  
1.2 Raetz pathway of lipid A biosynthesis 
The   biosynthesis   of   lipid   A   has   been   studied   and   characterized   over   the   past  
three   decades   by   Raetz   and   coworkers.   In   E.   coli,   nine   conserved   constitutively  
expressed  enzymes  convert  uridine  diphosphate  N-­‐‑acetylglucosamine  (UDP-­‐‑GlcNAc)  to  
a  hexa-­‐‑acylated  glucosamine-­‐‑based  disaccharide  termed  Kdo2-­‐‑lipid  A  (Fig.  1.5)  (5).  LpxA  
catalyzes   the   first   step   of   lipid   A   production   by   transferring   an   R-­‐‑hydroxymyristoyl  
group  from  acyl-­‐‑carrier-­‐‑protein  (ACP)  to  the  3-­‐‑position  hydroxy  group  of  UDP-­‐‑GlcNAc.    
The   3-­‐‑O-­‐‑acylation   of   UDP-­‐‑GlcNAc   by   LpxA   is   thermodynamically   unfavorable   (Keq   ≅  
0.01)   (34),   therefore,   the   deacetylation   of   the   LpxA   product,   UDP-­‐‑3-­‐‑O-­‐‑(R-­‐‑3-­‐‑
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hydroxymyristoyl)-­‐‑GlcNAc,   by   the   zinc-­‐‑dependent   deacetylase,   termed   LpxC,   is   the  
committed   reaction   of      the   lipid  A   pathway   (35).   LpxD   is   responsible   for   transferring  
another  β-­‐‑hydroxy  containing  acyl-­‐‑chain  that  measures  14-­‐‑carbons  in  length  from  ACP  
to   the  2-­‐‑position  amino  group  of  UDP-­‐‑3-­‐‑O-­‐‑(R-­‐‑3-­‐‑hydroxymyristoyl)-­‐‑glucosamine   (UDP-­‐‑
3-­‐‑O-­‐‑acyl-­‐‑GlcN)  (36).  The  first  three  enzymes  of  lipid  A  pathway  (LpxA,  –C,  and  –D)  are  
cytoplasmic   proteins,   and   their   structures   have   been   reported   (37-­‐‑39).   Interestingly,  
LpxA   and   –D   display   significant   structural   homology   and   catalyze   very   similar  
chemistry.    
The   fourth   and   fifth   step   in   lipid  A   biosynthesis   are   carried   out   by   LpxH   and  
LpxB,  which  are  peripheral  proteins,  and  their  structures  have  yet  to  be  determined  (40,  
41).   LpxH   catalyzes   the   cleavage   of   the   pyrophosphate   of   UDP-­‐‑2,3-­‐‑diacyl-­‐‑GlcN   to  
generate   UDP-­‐‑2,3-­‐‑diacyl-­‐‑GlcN-­‐‑1-­‐‑phosphate   (lipid   X)   and   uridine   monophosphate  
(UMP).  Subsequently,  LpxB  condenses  a  molecule  of  UDP-­‐‑2,3-­‐‑diacyl-­‐‑GlcN  with  lipid  X  
through  a  β,1’→6  linkage  to  form  tetra-­‐‑acylated  disaccharide-­‐‑1-­‐‑phosphate  and  UDP.    
The   last   four   enzymes   of   the   pathway   (LpxK,   KdtA,   LpxL,   and   LpxM)   are  
integral   inner   membrane   proteins   with   one   predicted   transmembrane   helix   at   their  
amino  (N)-­‐‑terminal  end.  The  LpxB  product  is  phosphorylated  at  the  4’-­‐‑position  hydroxy  
group  by  LpxK  kinase,  yielding  lipid  IVA  (42).  KdtA  glycosyltransferase  decorates   lipid  
IVA  with   two   Kdo   sugars   (3-­‐‑deoxy-­‐‑D-­‐‑manno-­‐‑oct-­‐‑2-­‐‑ulosonic   acid)   at   the   6’-­‐‑position   to  
form  Kdo2-­‐‑lipid   IVA  species   (43).      LpxL  acyltransferase   adds   a   lauroyl  group   to   the   2’-­‐‑
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acyl  group  of  Kdo2-­‐‑lipid  IVA  (44),  and  lastly,  LpxM  adds  a  myristoyl  group  to  the  3’-­‐‑acyl  
group  to  generate  Kdo2-­‐‑lipid  A  (45).  Because  the  substrates  of  these  enzyme  are  water-­‐‑
soluble,  it  is  presumed  that  the  their  active  sites  face  the  cytoplasm  (5).    
Once   assembled,   Kdo2-­‐‑lipid   A   can   be   decorated   with   the   core   sugars   on   the  
cytoplasmic   face   of   the   inner  membrane   by   the  Waa   family   of   glycosyltransferases   (5,  
46).  The  ATP-­‐‑binding  cassette  transporter  MsbA  flips  the  glycosylated  Kdo2-­‐‑lipid  A  into  
the  outer  monolayer  of  the  inner  membrane  (47).  In  the  periplasmic  space  WaaL  ligase  
transfers   O-­‐‑antigen   sugars,   which   are   linked   to   an   undecaprenyl-­‐‑diphosphate,   to   the  
nascent  LPS  precursor  (48).  The  details  of  LPS  translocation  from  the  inner  to  the  outer  
membrane   remain   to   be   fully   understood.   However,   it   has   been   proposed   that   a  
complex   of   seven   LPS   transport   (Lpt)   proteins   (LptA–G)   extracts   the   LPS   from   the  
periplasmic   surface  of   the   inner  membrane  and   shuttle   it   to   the  outer  membrane   (Fig.  
1.6)  (49).    
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Figure  1.5:  Biosynthetic  pathway  of  lipid  A  production  in  E.  coli.  Nine  highly  
conserved   enzymes   (red   text)   perform   an   array   of   reactions   including   acylation,  
deacetylation,  hydrolysis,   condensation,  phosphorylation,   and  glycosylation   to   convert  
UDP-­‐‑GlcNAc  to  Kdo2–lipidA.  The  blue  and  black  numbers  indicate  the  carbon  number  
of  the  glucosamine  ring,  and  the  acyl-­‐‑chain  length,  respectively.  
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Figure  1.6:  LPS  transport  in  E.  coli.  Once  Kdo2-­‐‑lipid  A  is  charged  with  the  core  
oligosaccharides  (white  boxes),  MsbA  transporter  flips  the  nascent  LPS  across  the  inner  
membrane.  The  O-­‐‑antigen  sugars  (yellow  boxes),  which  are  assembled  on  undecaprenyl  
pyrophosphate,   are   ligated   to   the   core   sugars   by   WaaL.   LPS   is   extracted   from   the  
periplasmic  side  of  the  inner  membrane  by  LptB,  LptC,  LptF,  and  LptG,  and  shuttled  to  
the  outer  membrane  by  LptA.  The  essential  outer  membrane  proteins,  LptD  and  LptE,  
are  believed  to  flip  LPS  to  the  outer  leaflet  of  the  outer  membrane.  
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1.3 Acyl-carrier-protein  
Acyl-­‐‑carrier-­‐‑protein   is   central   to   acyl-­‐‑chain   delivery   in   the   cell,   and   represents  
one   of   the  most   highly   conserved   proteins   across   all   organisms   (50).   Inactive   ACP   is  
referred   to   as   apo-­‐‑ACP,   which   is   activated   post-­‐‑translationally   by   attachment   of   a   4'ʹ-­‐‑
phosphopantetheine   (4′-­‐‑PPT)   group   donated   by   coenzyme   A   (CoA).   This   reaction   is  
catalyzed   by   holo-­‐‑ACPS   synthase   (ACPS,   also   known   as   phosphopantetheinyl  
transferase),  and   the  activated   form  of   the  carrier-­‐‑protein   is   termed  holo-­‐‑ACP   (Fig.  1.7)  
(51).   The   4'ʹ-­‐‑phosphopantetheine   prosthetic   group   is   covalently   attached   through   a  
phosphodiester   linkage   to   a   conserved   serine   residue   (Ser36   in  E.   coli)   that   is   usually  
flanked  by  an  aspartate  and  a  leucine  residue.  Subsequently,  the  sulfhydryl  group  of  the  
phosphopantetheine  arm  of  holo-­‐‑ACP  is  used  to  form  a  thioester  bond  with  fatty  acids  to  
generate  acyl-­‐‑ACP  (50).    
The  vast  majority  of  ACPs   charged  with   acyl-­‐‑chains   are  generated  by   the   fatty  
acid  synthesis  machinery   (52).  The  biosynthesis  of   fatty  acids   is  highly  conserved,  and  
initiates   with   the   ATP-­‐‑dependent   carboxylation   of   acetyl-­‐‑CoA   to   malonyl-­‐‑CoA   by  
acetyl-­‐‑CoA  carboxylase  (AAC).  The  generated  malonyl  group  is  then  thioester-­‐‑linked  to  
the   prosthetic   4′-­‐‑phosphopantetheine   group   of   holo-­‐‑ACP   by  malonyl/acetyl-­‐‑CoA–ACP  
transacylase  (MAT),  which  also  transacylates  the  acetyl  group  from  acetyl-­‐‑CoA  to  holo-­‐‑
ACP.   The   malonyl-­‐‑ACP   enters   the   elongation   process   by   going   through   a   chain   of  
chemical  reactions   involving   i)  decarboxylative  condensation  with  the  acetyl-­‐‑ACP  by  a  
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β-­‐‑ketoacyl   synthase   (KS),   ii)  NADPH-­‐‑dependent   reduction  of   the  oxoacyl   intermediate  
through  β-­‐‑ketoacyl  reductase  (KR),   iii)  dehydration  of   the  β-­‐‑hydroxy-­‐‑acyl   intermediate  
by   a   dehydratase   (DH),   and   iv)   further   NADPH-­‐‑dependent   reduction   by   a   β-­‐‑enoyl  
reductase  (ER)  to  form  a  saturated  nascent  fatty-­‐‑acyl  chain  attached  to  ACP.    The  cycle  
continues   through   the   condensation   of   the   acyl-­‐‑ACP   with   another   malonyl-­‐‑ACP,   and  
repeats  to  grow  the  acyl-­‐‑chain  by  2-­‐‑carbon  units  at  a  time  (Fig.  1.8).    
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Figure  1.7:  Activation  of  ACP  by  ACPS  phosphopantetheinyl  transferase.  Apo-­‐‑
ACP   is  post-­‐‑translationally  modified  by  holo-­‐‑ACP   synthase   (ACPS),  which   transfers   a  
4′-­‐‑phosphopantheteine   group   from  CoA   to   Ser36   in   a  magnesium-­‐‑dependent   reaction.  
The   activated   form   of   ACP   is   termed   holo-­‐‑ACP.   The   4′-­‐‑phosphopantheteine   group   of  
holo-­‐‑ACP  can  bind  different  fatty  acids  through  a  high-­‐‑energy  thioester  bond.    
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Figure  1.8:  Generalized  pathway  of  fatty  acid  synthesis.  After  the  initiation  step  
in  which  an  acetyl  and  a  malonyl  group  are  transferred  to  ACP  by  malonyl/acetyl-­‐‑CoA–
ACP  transacylase  (MAT),  a  series  of  cyclical  chemical  reactions  involving  condensation  
(KS),   dehydration   (DH),   and   reduction   (KR,   ER)   are   performed   on   the   nascent   acyl-­‐‑
chain.  The  cycle  repeats  to  generate  acyl-­‐‑chains  of  various  lengths.  
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   In   mammals,   fungi,   and   some   bacteria,   ACP   is   found   integrated   with   large  
multifunctional   enzyme   complexes,   for   example   with   the   type   I   fatty   acid   synthase  
(FAS)  system  (53-­‐‑55).  Conversely,  ACP  in  most  microorganisms,  such  as  E.  coli,  and  also  
in   specialized   eukaryotic   organelles,   such   as   mitochondria   and   plastids   in   plants,  
functions   in   the  dissociated   type   II   system  (56).  The  discretely  expressed  enzymes  and  
soluble   ACP   of   the   type   II   prokaryotic   systems   are   structurally   and   functionally  
analogous   to   their   counterparts   in   the   eukaryotic   type   I   system   (Table   1.1)   (57).   These  
enzymes   are   believed   to   associate   noncovalently,   but   little   is   known   about   their  
stoichiometry  and  organization   in  vivo.   In  this  manner,  type  II  ACP  is  highly  diffusible  
in  the  cell  facilitating  association  with  a  vast  number  of  protein  partners,  for  the  efficient  
delivery  of  a  broad  assortment  of  acyl-­‐‑substrates   for  diverse  biosynthetic  pathways.   In  
addition   to   the   classical   roles   of   ACP   such   as   fatty   acid   (58),   phospholipid   (59),  
polyketides   (60),  nonribosomal  peptide   (61),  and   lipid  A  biosynthesis   (62),  ACP   is  also  
essential  in  many  other  processes,  such  as  quorum  sensing  (63),  lipoic  acid  biosynthesis  
(64),  acylation  of  toxic  proteins  (hemolysin)  (65),  and  membrane-­‐‑derived  oligosaccharide  
synthesis  (66).  ACP  interacts  with  over  25  partners  in  Gram-­‐‑negative  bacteria  (Table  1.2),  
of  which   the  majority   are   acyltransferases   (56).   In   this  way,   bacterial  ACP,   along  with  
ribosome   associated  proteins,  RNA  and  DNA  polymerases,   represents   one   of   the   four  
major  protein–protein  interaction  “hubs”  in  the  cell  (67).  
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Table  1.1:	  Domains  of  FAS  I  elongation  cycle  and  their  type  II  
functional  analogs.  
Mammalian  FAS  domain*   Related  bacterial  FAS  enzymes  
MAT   FabD  
KS   FabB,  FabF,  FabH  
KR   FabG  
DH   FabA,  FabZ  
ER   FabI,  FabK,  FabL  
*  MAT,  malonyl/acetyl-­‐‑CoA–ACP   transacylase,  KS,   β-­‐‑ketoacyl   synthase,              




Table  1.2:  ACP  Partners  in  Gram-­‐‑negative  Bacteria.  
Protein(s)   Activity  or  function  
ACPS   Holo-­‐‑ACP  synthase  
ACPH   Holo-­‐‑ACP  phosphodiesterase  
FabA,  FabB,  FabD,  FabE,  
FabF,  FabG,  FabH,  FabI,  
FabK,  FabL,  FabZ  
Fatty  acid  synthase  component  enzymes  
PlsB,  PlsC,  PlsX   Phospholipid  acylation  
HlyC   Protein  acylation  (hemolysin)  
LipB   Lipoic  acid  biosynthesis  
LpxA,  LpxD,  LpxL,  LpxM   Lipid  A  biosynthesis  
LuxI,  Ains  (e.g.,  Vibrio  
fischeri)  
Quorum  sensing:  AHL  synthesis  
LuxD   Bioluminescence:  acyl-­‐‑ACP  esterase  
Aas   Acyl-­‐‑ACP  ligation/phospholipid  
reacylation  
AasS  (vibrio  harveyi)   Acyl-­‐‑ACP  ligation  
MdoH   Membrane-­‐‑derived  oligosaccharide  
synthesis  
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1.4 Structure of acyl-carrier-protein  
  ACP   is  a   small  globular  protein   that   consists  of  70   to  100  amino  acid   residues,  
and  is  an  essential  cofactor  of  many  primary  and  secondary  metabolic  pathways.  Over  
the  past  25  years,  NMR  and  crystallographic  studies  of  type  II  ACP  from  a  wide  variety  
of  organisms  have  revealed  that  the  overall  fold  of  the  carrier-­‐‑protein  is  a  4–helix  bundle  
(I-­‐‑IV)  with  several  loop  regions  (L1-­‐‑L3)  (Fig.  1.9)  (68,  69).  Unlike  the  well-­‐‑studied  type  II  
family,   only   the   rat,   human,   and   yeast   Saccharomyces   cerevisiae   type   I   ACPs   are  
structurally  characterized  to  date  (Fig  1.10)  (70-­‐‑72).  Despite  the  low  amino  acid  sequence  
identity  between  rat  and  human  ACPs,   the  structures  of  both  display  a  4–helix  bundle  
fold  that  is  reminiscent  of  type  II  ACPs.  Interestingly,  the  X-­‐‑ray  structure  of  yeast  ACP,  
which   was   solved   as   part   of   the   mega-­‐‑synthase,   revealed   an   additional   domain  
composed  of  4  α-­‐‑helices  (72).  The  NMR  structures  of  the  isolated  ACP  domain  of  yeast  
FAS   are   consistent   with   the   X-­‐‑ray   structure,   nonetheless   the   exact   role   of   this   added  
domain  remains  unknown  (73).    
Type   II   ACP   accommodates   its   covalently   attached   acyl-­‐‑chain   inside   a   central  
hydrophobic   pocket   formed   by   the   four   α-­‐‑helices   (Fig.   1.11)   (69,   74).   The  
phosphopantetheine  places  the  thioester  bond  at  the  opening  of  the  hydrophobic  pocket  
that  is  formed  by  L1,  N-­‐‑terminus  of  helix  II,  helix  III,  and  L3.  By  doing  so,  the  reactive  
thioester   bond   is   protected   from   hydrolysis,   an   event   that   would   lead   to   release   of  
immature  fatty  acids.  The  acyl-­‐‑chain  adopts  a  linear  conformation  and  runs  through  the  
   22  
core   of   ACP,   almost   parallel   with   helix   II   and   IV,   and   points   toward   L2   and   the   C-­‐‑
terminal  end  of  helix  IV.      
Although  the  yeast,  human,  and  rat  studies  of  ACP  integrated  within  FAS  have  
revealed   some   structural   information,   the   acyl-­‐‑moiety   of   ACP   was   absent   in   these  
structures.  The  current  structures  of  type  I  ACP  display  that  the  entrance  to  the  central  
hydrophobic   cavity   is   barricaded   by   the   C-­‐‑terminal   region   of   L1,   helix   III,   and   L3,  
suggesting   that  ACP   in   type   I  machinery   does   not   accommodate   its   acyl-­‐‑chain   inside  
this   cleft   (Fig.   1.12).   The   fact   that   ACP   is   integrated   within   its   own   biosynthetic  
compartment  in  the  type  I  system  may  explain  why  the  acyl-­‐‑chain  does  not  need  to  be  
sealed  inside  the  hydrophobic  pocket  as  is  the  case  for  the  dissociated  system  of  type  II  
(70).   Further   structural   and   biochemical   experiments   are   necessary   to   understand   the  
architecture  of  type  I  acyl-­‐‑ACP.  
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Figure  1.9:  Molecular  structure  of  type  II  ACP.  The  overall  fold  of  type  II  ACP  is  
a  4-­‐‑helix  bundle.  Helix  I  is  connected  to  helix  II  via  a  long  loop  (L1).  L2  connects  helix  I  
to  helix  III,  and  L3  connects  helix  III  to  helix  IV.  (a)  Crystal  structure  of  E.  coli  apo-­‐‑ACP  
(PDB  code:  1T8K).  The  NMR  structure  of  (b)  Bacillus  subtilis  apo-­‐‑ACP  (PDB  code:  1HY8),    
(c)  Geobacter  metallireducens   holo-­‐‑ACP   (the   4′-­‐‑phosphopantheteine   group   is   not   shown;  
PDB   code:   2LML)   and   (d)   Rickettsia   prowazekii   apo-­‐‑ACP   (PDB   code:   2LOL).   ACP   is  
phosphopantetheinylated  at  a  serine  residue  situated  at  the  beginning  of  helix  II.  The  N-­‐‑  
and  C-­‐‑termini  are  labeled.    
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Figure   1.10:   Molecular   structure   of   type   I   ACPs.   Type   I   ACP   is   structurally  
similar  to  Type  II  ACP.  (a)  Crystal  structure  of  human  fatty  acid  synthase  ACP  domain  
(PDB  code:  2CG5).  (b)  NMR  solution  structure  of  rat  ACP  (PDB  code:  2PNG).  (c)  Crystal  
structure  of  yeast  ACP  domain  solved  as  part  of  fatty  acid  synthase  complex  (PDB  code:  
2UV8).  Yeast  ACP  has  an  additional  domain  (yellow)  with  unknown  function.  
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Figure   1.11:   Structure   of   type   II   acyl-­‐‑ACP.   Type   II   ACPs   accommodate   their  
acyl-­‐‑substrate   cargo   inside   a   hydrophobic   pocket   formed   by   the   four   helices.   The  
thioester  bond  is  situated  at  the  opening  of  the  hydrophobic  cavity,  which  is  formed  by  
the  C-­‐‑terminal   end  of   L1,  N-­‐‑terminal   region   of   helix   II,   helix   III,   and  L3.   (a,b)  Crystal  
structure  of  decanoyl-­‐‑ACP  (PDB  code:  2FAE).  (a)  Side-­‐‑view  of  decanoyl-­‐‑ACP.  The  acyl-­‐‑
chain  is  oriented  parallel  to  helix  II  and  helix  IV.  The  4′-­‐‑phosphopantheteine  (4′-­‐‑PPT)  is  
colored   orange   and   by   atom   type.   The   acyl-­‐‑chain   is   colored   black,   and   its   length   is  
indicated.  (b)  The  opening  of  the  hydrophobic  pocket.  The  thioester  bond  (green  sphere)  
is  protected  from  hydrolysis.  (c,d)  Crystal  structure  of  butyryl-­‐‑ACP  (PDB  code:  1L0I).  (c)  
The   4′-­‐‑PPT   tucks   the   short   acyl-­‐‑chain   inside   ACP.   (d)   The   conformation   of   4′-­‐‑PPT   is  
similar  to  that  of  decanoyl-­‐‑ACP.  
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Figure  1.12:  Comparison  between  type  I  and  type  II  ACPs.  In  type  I  ACPs,  the  
pocket  opening  is  closed  off  by  L1,  helix  III,  and  L3.  (a)  Overlay  of  rat  ACP  (cyan,  PDB  
code:   2PNG)   and   type   II   decanoyl-­‐‑ACP   (blue,   PDB   code:   2FAE).   An   arginine   residue  
(indicated  by  an  asterisk)  from  helix  III  of  yeast  ACP  overlaps  with  the  4′-­‐‑PPT  group  of  
decanoyl-­‐‑ACP.   (b)   Overlay   of   yeast   ACP   (magenta,   PDB   code:   2UV8)   and   type   II  
decanoyl-­‐‑ACP.  A  lysine  residue  (indicated  by  an  asterisk)  blocks  the  pocket  opening  and  
overlaps  with  the  4′-­‐‑PPT  group  of  decanoyl-­‐‑ACP.  
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1.5 Structural flexibility of type II Acyl-carrier-protein 
Bacterial  ACP  has  a  relatively  high  ratio  of  charged  to  hydrophobic  residues,  and  
exhibit  resistance  to  precipitation  by  heating  or  organic  solvents  (56).  Moreover,  ACP  is  
highly  acidic  (pIE.  coli  ACP  =  4.1),  which  gives  rise  to  abnormal  SDS-­‐‑PAGE  migration  (75).  
These  physical  properties  are  a  hallmark  of  intrinsically  unstructured  proteins,  and  the  
repulsive  electrostatic  forces  resulting  from  the  high  concentration  of  acidic  residues  in  
the  central  region  of  ACP  contribute  to  the  structural  flexibility  of  ACP  (56).  The  region  
that   spans   from  residue  Glu30   to  Glu60   in  E.  coli  ACP   includes  14  acidic  and  no  basic  
residues.  Two  clusters  of  highly  conserved  acidic  residues  exist  within  this  region,  site  A  
(Glu30,  Asp35,  and  Asp38)  and  site  B  (Glu47,  Asp51,  Glu53,  and  Asp56),  which  display  
low  affinity  for  divalent  cations  (dissociation  constant/site  =  ~  80  µμM)  (76,  77).  Unlike  E.  
coli  ACP,  Vibrio  harveyi  holo-­‐‑ACP  is  largely  unfolded  at  neutral  pH.  Interestingly,  binding  
of  Ca2+  or  Mg2+  to  the  aforementioned  acidic  sites  (site  A  and  B),  or  the  neutralization  of  
helix  II  through  mutagenesis  induces  a  stabilized  protein  fold  with  a  α-­‐‑helix  content  of  
40–50%   (78,   79).   Furthermore,   interaction   with   partner   enzymes   such   as  
phosphopantetheinyl   transferase   and   the   O-­‐‑acyltransferase   of   lipid   A   biosynthesis  
(LpxA)  can  induce  protein  folding  (79).    
Although   the   physical   properties   of   ACP   are   not   adequate   to   substantiate   the  
notion  of  ACP  being  natively  unfolded,  perhaps  they  could  affect  mechanisms  through  
which   ACP   recognizes   its   partners.   Moreover,   ACP   needs   to   undergo   a   significant  
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conformational   change   to   sequester   and   eject   its   cargo   to   the   active   site   of   partner  
enzymes.  Hence,   it  appears   that  ACP  flexibility   is   required   for   sampling   the  necessary  
conformations  in  order  to  stabilize  and  efficiently  deliver  thioester-­‐‑linked  acyl-­‐‑chains.    
 
1.6 Recognition of type II Acyl-carrier-protein 
ACP   has   evolved   the   ability   to   transiently   associate   with   a   vast   number   of  
protein  partners  for  efficient  delivery  of  fatty  acyl-­‐‑substrates  that  are  thioester-­‐‑linked  to  
its  prosthetic   4'ʹ-­‐‑phosphopantetheine  group.  This   attribute   is   reflected  by   the   relatively  
low   micromolar   dissociation   constant   (Kd)   of   ACP   with   a   wide   variety   of   protein  
partners,   which   enables   it   to   rapidly   exchange   among   its   partnering   enzymes,   thus  
maximizing  its  efficiency  in  delivering  acyl-­‐‑substrates  (80-­‐‑82).  All  the  while,  ACP  relies  
on  the  high  degree  of  selectivity  displayed  by  its  protein  partners.    
Mutagenesis  and  binding  assay  studies  have  shown  that  helix  II  of  ACP  and  its  
acidic  residues  are   involved  in  recognition  of  various  enzymes  (79,  83,  84).  There   is  no  
known  ACP  binding  sequence  motif,  however  it  is  well  established  that  ACP  recognizes  
basic  patches  on   its  partner  enzymes   (56,   81,   82).  Various  binding  studies   suggest   that  
ACP   partners,   such   as   phosphopantetheinyl   transferase   and   fatty   acid   biosynthetic  
enzymes   like   FabD,   FabG,   FabH,   and   FabI,   possess   arginine   or   sometimes   lysine  
residues  that  have  been  shown  to  be  critical  in  ACP  binding  (80-­‐‑82,  85).    
   29  
Significant   effort   has   been   devoted   to   understand   the  molecular   basis   of   ACP  
association  through  X-­‐‑ray  crystallography,  however,  due  to  the  highly  transient  nature  
of   ACP-­‐‑based   interactions,   structural   studies   of   ACP   complexes   have   been   hindered.  
Very   few   crystal   structures   of   the   type   II   carrier-­‐‑protein   in   complex   with   an   enzyme  
have   been   solved   in   recent   years.   The   trimeric   structure   of   the   phosphopantetheinyl  
transferase  ACPS   from  Bacillus  subtilis  bound   to   three  molecules  of  holo-­‐‑ACP  provided  
the  first  glimpse  into  the  charge  complementation  mechanism  of  ACP  recognition  (86).  
The  acidic  residues   localized  on  helix   II  and  III  of  ACP  form  direct  contacts  with  basic  
residues  on  ACPS   (Fig.   1.13a).   In   the   co-­‐‑crystal   structure  of   enoyl   reductase  FabI  with  
dodecenoyl-­‐‑ACP,   the   details   of   interaction   between   ACP   and   FabI   could   not   be  
elucidated  due  to  missing  electron  density  of  side  chains  and  phosphopantetheine  (85).  
Cytochrome   P450   from   B.   subtilis   was   crystalized   with   E.   coli   acyl-­‐‑ACP,   which   also  
revealed  the  same  trend  of  electrostatic  interactions  with  helix  II  and  III  (Fig.  1.13b)  (87).  
Interestingly,  for  the  first  time  it  was  discovered  that  the  acyl-­‐‑chain  was  ejected  from  the  
core  of  ACP  and  was  placed  within  the  active  site  of  P450.  More  recently,  3-­‐‑hydroxyacyl-­‐‑
ACP  dehydratase   (FabA)  was   crystalized  with   acyl-­‐‑ACP   through   crosslinking   the   two  
protein  partners  together  (88).  This  co-­‐‑complex  structure  also  showed  that  the  acyl-­‐‑chain  
flips  out  of  ACP  and  key  hydrophobic  residues  on  helix  II  and  III  collapse  to  block  the  
hydrophobic  pocket.  Although  these  structures  have  provided  considerable  insight  into  
how   ACP   recognizes   its   partner   enzymes,   the   mechanism   by   which   these   enzymes  
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discriminate   between   ACP   molecules   that   are   loaded   with   various   acyl-­‐‑chains   of  
differing  length,  degree  of  saturation,  or  hydroxylation  is  not  well  understood.    
A   series   of  NMR   structures   of   Streptomyces   coelicolor   ACP   bound   to   fatty   acyl-­‐‑
chains  that  represent  a  complete  cycle  of  fatty  acid  biosynthesis  have  been  reported  (89).    
In  all  of  these  structures,  the  hydrophobic  portion  of  the  acyl-­‐‑chain  is  tucked  inside  the  
central   hydrophobic   pocket   with   the   first   hydrophilic   group   of   the   acyl-­‐‑chain   that  
precedes   the  non-­‐‑polar  portion   stuck   at   the   entrance  of   the  pocket,  preventing   further  
insertion  of  the  acyl-­‐‑chain  into  the  pocket  (Fig.  1.14).  The  degree  of  exposure  of  the  acyl-­‐‑
chain   and   the   conformation   of   the   4'ʹ-­‐‑phosphopantetheine   group   are   associated   with  
reorganizations   of   helix   III.   These   structures   suggest   that   the   conformation   of   the   4'ʹ-­‐‑
phosphopantetheine  group  and  helix  III  contribute  to  a  specific  surface  feature,  helping  
ACP-­‐‑partners   to   recognize   their  preferred   acyl-­‐‑ACP   intermediates.  On   the  other  hand,  
regardless   of   the   arrangement   of   the   acyl-­‐‑chain,   the   conformation   of   helix   II   remains  
unaffected,  suggesting  that  it  may  act  as  a  universal  “recognition  helix”  though  it  does  
not   contribute   to   the   mechanism   by   which   enzymes   select   the   proper   acyl-­‐‑ACP  
intermediate.      
Further  structural  and  functional  experiments  are  necessary  to  understand  i)  the  
molecular   basis   for   recognition   of   ACP   by   its  multiple   partners,   ii)   the   role   of   the   4′-­‐‑
phosphopantetheine   arm   in   complex   formation,   iii)   the   mechanism   of   acyl   substrate  
ejection,  and  iv)  the  way  by  which  ACP  disengages  from  its  protein  partners.  Presented  
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in   the   chapters   that   follow   are   structural   and   biochemical   data   that   have   contributed  
greatly   to   the   understanding   of  ACP-­‐‑based   interactions   by   exploiting   two   of   the   four  
acyltransferases  of  the  Raetz  pathway  –  LpxA  and  LpxD.  
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Figure  1.13:  ACP  in  complex  with  ACPS  and  cytochrome  P450.  Helix  II  and  III  
of   ACP   provide   electrostatic   interactions   with   the   partner   enzymes.   (a)   Three   ACP  
molecules   (brown)   are   bound   to   the   ACPS   trimer   (green),   which   performs  
phosphopantetheinyl   transfer.   The   4′-­‐‑PPT   group   (cyan)   is   located   at   the   interface  
between  the  two  protein  partners,  and  adopts  a  conformation  similar  to  that  of  free  acyl-­‐‑
ACP.  The   inset  shows  only  those  residues  that  provide  strong  electrostatic   interactions  
at  the  binding  interface.  (b)  Acyl-­‐‑ACP  (green)  bound  to  cytochrome  P450  (blue).  The  4′-­‐‑
PPT   (orange)   is   rotated   to  place   the  acyl-­‐‑chain   (black)   in   the  active  site  of  P450,  which  
performs   oxidative   cleavage   of   fatty   acyl-­‐‑chains.   The   inset   shows   electrostatic  
interactions  of  P450  with  helix  II  and  helix  III  of  ACP.    
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Figure  1.14:  Comparison  of  ACPs  charged  with  acyl-­‐‑intermediates  of  a  single  
cycle  of  fatty  acid  biosynthesis.  Closest  to  average  NMR  structures  are  shown.  The  
arrows   indicate   movement   of   helix   III.   Overlay   of   (a)   hexanoyl-­‐‑   (salmon)   and   3-­‐‑
oxooctanyl-­‐‑ACP   (yellow),   (b)   3-­‐‑oxooctanyl-­‐‑   (yellow)   and   R-­‐‑3-­‐‑hydroxyoctanoyl-­‐‑ACP  
(pink),   (c)   and  R-­‐‑3-­‐‑hydroxyoctanoyl   (pink)   and   2-­‐‑octenoyl-­‐‑ACP   (cyan),   (d)  2-­‐‑octenoyl-­‐‑  
(cyan)   and  octanoyl-­‐‑ACP   (orange),   and   (e)   octanoyl-­‐‑   (orange)   and  hexanoyl-­‐‑ACP.  The  
right-­‐‑hand  panel  is  a  schematic  representation  of  the  hydrophobic  pocket  (dashed  lines)  
and  the  buried  acyl-­‐‑chain.  The  first  polar  oxygen  preceding  the  hydrophobic  portion  of  
the  acyl-­‐‑chain  is  stuck  at   the  pocket  entrance.  The  carbon  number  of  each  acyl-­‐‑chain  is  
indicated.  Hexanoyl-­‐‑ACP  (PDB  code:  2KOO),  3-­‐‑oxooctanyl-­‐‑ACP  (PDB  code:  2KOP),  R-­‐‑3-­‐‑
hydroxyoctanoyl-­‐‑ACP   (PDB   code:   2kOQ),   2-­‐‑octenoyl-­‐‑ACP   (PDB   code:   2KOR),   and  
octanoyl-­‐‑ACP  (PDB  code:  2KOS).    
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1.7 UDP-GlcNAc acyltransferase (LpxA) 
LpxA  is  an  ACP-­‐‑dependent  acyltransferase  that  catalyzes  the  first  step  of  lipid  A  
biosynthesis   (Fig.   1.5).   The   crystal   structure  E.   coli   LpxA   (EcLpxA)  was   first   solved   in  
1995  in  the  absence  of  bound  ligands,  classifying  a  new  family  of  enzymes  that  adopt  an  
unusual  left-­‐‑handed  β-­‐‑helix  (LβH)  fold  (Fig.  1.15a)  (37).  Each  β-­‐‑helical  turn  resembles  an  
equilateral   triangle,  and   is  characterized  by  three  repeating  hexapeptide  units  with   the  
consensus  sequence  of  [LIV]-­‐‑[GAED]-­‐‑X2-­‐‑[STAVE]-­‐‑X  (Fig.  1.15b)  (37,  90).  More  structures  
with  this  structural  motif  have  emerged,  including  bacterial  acetyl-­‐‑  and  acyltransferases  
such   as   N-­‐‑acetylglucosamine-­‐‑l-­‐‑phosphate   uridyltransferase   (91),   galactoside  
acetyltransferase   (92),   tetrahydrodipicolinate   N-­‐‑succinyltransferase   (93),   xenobiotic  
acetlytransferase   (94),   serine   acetyltransferase   (95),   and   Vat(D)   streptogramin  
acetyltransferase   (96).   Examples   of   the   LβH   architecture   can   also   be   found   in  
archaebacterial   and   eukaryotic   proteins   (97,   98).   The   oligomeric   structure   of   enzymes  
containing  the  LβH  fold  is  trimeric,  with  each  monomer  being  related  to  the  neighboring  
subunit   by   a   120°   rotation   about   the   three-­‐‑fold   axis   of   symmetry   that   runs   in   parallel  
with   the  LβH  domains.  The   length  of  LβH  domains  can  vary  considerably  among   this  
protein   family,   however   the   LβH   found   in   LpxA   is   rather   extended   measuring,  
approximately  50  Å  in  length.  In  addition,  LpxA  contains  a  globular  C-­‐‑terminal  domain,  
which  is  composed  of  four  α-­‐‑helices  localized  to  one  end  (37).  
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Figure  1.15:  Crystal  structure  of  E.  coli  LpxA.  (a)  Side  view  of  LpxA  (PDB  code:  
1LXA).  Each  monomer  of  LpxA  is  composed  of  a  LβH  domain  (green)  and  an  α-­‐‑helical  
C-­‐‑terminal   domain   (CTD,   purple).   The  N-­‐‑   and  C-­‐‑termini   are   indicated.   (b)   Top-­‐‑down  
view   of   LpxA   trimer.   The   trimeric   axis   of   symmetry   runs   in   parallel   with   the   LβH  
domain.  Each  β-­‐‑helical  coil  resembles  an  equilateral  triangle.  
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Sequence   alignment   of  LpxAs   from  diverse  bacteria   revealed   that   several   basic  
residues   such   as   Lys76,   His122,   His125,   His144,   His160,   and   Arg204   are   highly  
conserved   (99).  The  LpxA  structure  showed  these  residues  are   localized  around  a  cleft  
between  two  neighboring  LβH  domains.  Because  of  the  trimeric  symmetry,  three  clefts  
are   present   in   the   LpxA   structure.   Alanine   substitution   of   His125,   which   is   strictly  
conserved,  completely  abrogated  LpxA  activity,  suggesting  that  it  may  act  as  a  catalytic  
base   by   activating   the   3-­‐‑hydroxy   group   of   UDP-­‐‑GlcNAc   (99).   Furthermore,   it   was  
proposed   that   the   remaining   basic   residues   are   involved   in   substrate   recognition   as  
mutating  them  to  alanine  reduced,  but  did  not  completely  eliminate,  LpxA  activity  (99).  
The   structure  of  E.   coli   LpxA  with  UDP-­‐‑GlcNAc  was   later   solved,  which   corroborated  
the  role  of  these  residues  in  UDP-­‐‑GlcNAc  binding,  and  revealed  the  involvement  of  the  
C-­‐‑terminal  helices  in  coordinating  the  uracil  moiety  of  the  substrate  (Fig.  1.16)  (100).    A  
number  of   residues   localized   to  helix  α1  of   the  C-­‐‑terminal  domain   form  a  pocket   that  
interacts  with  the  uracil  nucleotide.  For  example,  Asn198  forms  hydrogen  bonds  to  the  
nitrogen   and   oxygen   atoms   of   the   uracil   ring.   Although   LpxA   has   been   shown   to   be  
highly   specific   for   uridine,   it   can   process   thymidine   diphosphate-­‐‑GlcNAc   (TDP-­‐‑
GlcNAc),  albeit  at  20%  of  the  rate  of  UDP-­‐‑GlcNAc  (62).  This  can  be  explained  by  the  fact  
that   TDP   and   UDP   are   of   similar   size.   Although   cytidine   diphosphate   (CTD)   is   also  
comparable   in   size,   its   hydrogen   bonding   profile   is   rather   different   than   UDP,   thus  
providing   a   rationale   as   to  why   LpxA   cannot   turn   over   CDP-­‐‑GlcNAc.   The   remaining  
two   possible   nucleotide-­‐‑GlcNAc   substrates,   adenosine   diphosphate-­‐‑   and   guanosine
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Figure  1.16:  LpxA  structure  bound  to  UDP-­‐‑GlcNAc.  (a)  The  active  site  of  LpxA  
is   situated   between   two   adjacent   LpxA  monomers   (PDB   code:   2JF3).   (b)   The   GlcNAc  
moiety  interacts  with  the  LβH  domain,  and  the  uracil  group  interacts  with  the  CTD.  The  
dotted  lines  indicate  hydrogen  bonds.  His125  hydrogen  bonds  with  the  3-­‐‑OH  group  of  
the  GlcNAc,  and  its  alanine  substitution  completely  eliminates  LpxA  activity,  suggesting  
that  it  acts  as  a  catalytic  base  in  the  reaction  mechanism.  
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diphosphate-­‐‑GlcNAc,   are   bulky   and   are   not   able   to   be   accommodated   by   the   uridine  
binding  pocket.    
In   the  case  of  E.  coli,  LpxA  is  highly  specific   for  R-­‐‑3-­‐‑hydroxymyristoyl-­‐‑ACP  (R-­‐‑
3OH-­‐‑C14-­‐‑ACP),   whereas   Leptospira   interrogans   and   Pseudomonas   aeruginosa   LpxAs   are  
selective   for   R-­‐‑3-­‐‑hydroxylauroyl-­‐‑ACP   (R-­‐‑3OH-­‐‑C12-­‐‑ACP)   and   R-­‐‑3-­‐‑hydroxydecanoyl-­‐‑
ACP   (R-­‐‑3OH-­‐‑C10-­‐‑ACP),   respectively   (34,   62,   99,   101,   102).   Previous   studies   have  
demonstrated  the  molecular  basis  for  selectivity  toward  varying  acyl-­‐‑chain  lengths.  For  
example,   substitution   of   Gly173   with   an   alanine   in   E.   coli   LpxA   shifts   the   acyl-­‐‑chain  
specificity   to   C10   (103).   Additionally,   the   selectivity   of   LpxA   from   P.   aeruginosa   was  
shifted   to   C14-­‐‑specificity   when   Met169   was   mutated   to   glycine   (103).   Therefore,   it  
appears   that   LpxA   utilizes   a   precise   molecular   hydrocarbon   ruler   that   selects   for   the  
proper  length  of  acyl  substrate,  and  is  fine-­‐‑tuned  among  various  orthologs  of  LpxA.    
The   structure   of   E.   coli   LpxA   with   its   bound   lipid   product,   UDP-­‐‑3-­‐‑O-­‐‑(R-­‐‑3-­‐‑
hydroxymyristoyl)-­‐‑GlcNAc   (104),   and   L.   interrogans   LpxA   with   UDP-­‐‑3-­‐‑N-­‐‑(R-­‐‑3-­‐‑
hydroxylauroyl)-­‐‑GlcNAc3N   (105)   have   been   solved   (Fig.   1.17a,b).   These   structures  
confirmed   the   catalytic   mechanism   deduced   from   mutagenesis   studies   (99),   and  
provided  structural  evidence   for   the  presence  of  an  accurate  hydrocarbon  ruler  within  
LpxA.  In  both  structures,   the  acyl-­‐‑chain  is  packed  inside  a  hydrophobic  pocket  shaped  
by  two  adjacent  LβH  domains.  In  E.  coli  LpxA,  Gly173  and  His191  form  the  pocket  floor  
   40  
Figure  1.17:  LpxA  structure  bound  to  its  lipid  product.  (a)  E.  coli  LpxA  bound  to  
UDP-­‐‑3-­‐‑O-­‐‑acyl-­‐‑GlcNAc   (PDB   code:   2QIA).   (b)  L.   interrogans   LpxA   bound   to  UDP-­‐‑3-­‐‑N-­‐‑
acyl-­‐‑GlcNAc3N  (PDB  code:  3I3X).  The  acyl-­‐‑chain  is  packed  inside  a  cleft  formed  by  two  
neighboring   LβH   domains.      (c,d)   The   catalytic   histidine   (c,   His125,   d,   His120)   is  
hydrogen  bonded  to  the  nucleophile.  A  strictly  conserved  glycine  residue  (c,  Gly143,  d,  
Gly138)  acts  as  an  oxyanion  hole,  stabilizing  the  negatively  charged  carbonyl  oxygen  in  
the   transition  state.  The  β-­‐‑hydroxy  group  hydrogen  bonds  with  a  glutamine,  histidine,  
and  a  water  molecule  (W).  The  acyl-­‐‑chain  length  is  indicated.  His191  is  the  hydrocarbon  
ruler  in  E.  coli  LpxA  (c),  and  Lys171  is  the  hydrocarbon  ruler  in  L.  interrogans  LpxA  (d).  
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and  dictate  the  length  of  the  acyl-­‐‑chain  delivered  by  ACP  (Fig.  1.17c).  Interestingly,  the  
equivalent   hydrophobic   pocket   in   L.   interrogans   LpxA   is   truncated   by   Lys171,   which  
explains  its  specificity  for  C12  acyl-­‐‑chain  (Fig  1.17d).      
All  known  LpxA  variants  require  β-­‐‑hydroxy  containing  acyl-­‐‑chains  for  catalysis,  
with  the  exception  of  Chlamydia  trachomatis  LpxA,  which  shows  activity  with  myristoyl-­‐‑
ACP  (106).   In   fact  myristoyl-­‐‑ACP   inhibits  E.  coli  LpxA  reaction  with  an   IC50  value  of  2  
µμM,   suggesting   an   important   role   for   the   β-­‐‑hydroxy   group   (34).   The   E.   coli   LpxA  
structure   bound   to   its   lipid   product   revealed   that   the   β-­‐‑hydroxy   group   forms   direct  
hydrogen   bonds  with  His122   and  Gln73,   and   interacts  with  His99   through   a   bridging  
water  molecule  (104).  The  same  network  of  hydrogen  bonds  was  also  observed  between  
the   β-­‐‑hydroxy   group   of   UDP-­‐‑3-­‐‑N-­‐‑(R-­‐‑3-­‐‑hydroxylauroyl)-­‐‑GlcNAc3N   and   the   active   site  
cleft  of  L.  interrogans  LpxA  (Fig  1.17c,d)  (105).  Based  on  sequence  alignment,  His122  and  
Gln73   are   conserved,   whereas   His99   is   replaced   with   a   threonine   residue   in   C.  
trachomatis  LpxA  (106).  Further  biochemical  studies  are  necessary  to  show  whether  this  
replacement   is   responsible   for   loss   of   specificity   of   C.   trachomatis   LpxA   for   β-­‐‑
hydroxyacyl  substrates.  
Notably,  E.   coli   LpxA  does  not   recognize   the   coenzyme  A   substrate  derivative,  
suggesting  a  crucial  role  of  ACP  in  substrate  recognition  (36).  An  NMR-­‐‑based  docking  
experiment,  which  utilized  the  previous  mutagenesis  studies,  suggests   that  ACP  docks  
in   the   vicinity   of   the   active   site   cleft   of   LpxA   (107).   Based   on   chemical   shift  
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perturbations,   Asp35,   Asp38,   and   Glu41   of   ACP   form   salt   bridges   with   Lys76,   and  
Arg204   of   LpxA.   However,   the   structure   of   L.   interrogans   LpxA   solved   with   acyl-­‐‑4'ʹ-­‐‑
phosphopantetheine   suggests   that  ACP  binds   to  a  different   region  on  LpxA,  as   the  4'ʹ-­‐‑
phosphate   group   of   this   substrate   mimetic   is   situated   20   Å   away   from   Ser36   of   the  
docked  ACP  (Fig.  1.18).  
Previous   attempts   have   been  made   to   trap   the   LpxA–ACP   complex,   however,  
like   other   ACP-­‐‑based   complexes   this   has   been   proven   to   be   a   difficult   task.   This   is  
primarily   because   ACP   utilizes   a   “low   affinity,   high-­‐‑selectivity’   mechanism   for   acyl  
substrate  delivery.  The  dissociation  constant  of  LpxA:holo-­‐‑ACP  has  been  reported  (Kd  =  
1.8   µμM),   which   is   consistent   with   the   reported   KM   of   E.   coli   LpxA      for   its   R-­‐‑3-­‐‑
hydroxyacyl-­‐‑ACP    substrate  (KM  =  1.2  µμM)  and  the  IC50  value  for  non-­‐‑hydroxyated  acyl-­‐‑
ACP  (IC50  =2  µμM).  Trapping  ACP  in  complex  with  LpxA  will  be  the  focus  of  Chapter  3,  
which  describes  for  the  first  time  ACP  recognition  by  LpxA.  
LpxA   is   a   potential   target   for   the   design   of   novel   antibiotics   (108).   A  
pentadecapeptide   inhibitor   of   LpxA,   known   as   peptide-­‐‑920,   has   been   identified   by  
phage   display   (109).   It   is   shown   that   overexpression   of   peptide-­‐‑920   in   bacteria   as   a  
glutathione-­‐‑S-­‐‑transferase-­‐‑fusion   protein   inhibits   growth,   which   can   be   rescued   by  
overexpression   of   LpxA   (109).   Kinetic   studies   suggest   that   peptide-­‐‑920   inhibits   LpxA  
with   a   Ki   value   of   50   nM,   and   competes   with   acyl-­‐‑ACP   (108).   Although   the   crystal  
structure  of  E.  coli  LpxA  with  peptide-­‐‑920  has  been  solved  (108),  it  is  not  clear  whether  
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peptide-­‐‑920  competes  with  the  acyl-­‐‑phosphopantetheine  moiety  of  ACP,  or  if  it  disrupts  
direct  protein–protein  interactions  between  the  two  protein  partners.    
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Figure  1.18:  Comparing  ACP–LpxA  docking  model  with  L.  interrogans  LpxA–  
acyl-­‐‑4'ʹ-­‐‑phosphopantetheine  crystal   structure.   In   the  L.   interrogans   LpxA   structure,   the  
acyl-­‐‑chain   (black)   is   packed   inside   the   hydrophobic   pocket   formed   between   two   LβH  
domains,  and  the  thioester  bond  is  situated  near  the  catalytic  base  (E.  coli  LpxA  is  shown  
here).    Two  conformations  were  observed  for  the  4'ʹ-­‐‑PPT  arm,  both  of  which  place  the  4'ʹ-­‐‑
phosphate  group  approximately  20  Å  away  from  Ser36  of  ACP  (blue).  
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1.8 UDP-3-O-acyl-GlcN acyltransferase (LpxD) 
LpxD   catalyzes   the   third   step   in   lipid   A   biosynthesis   by   adding   an   R-­‐‑3-­‐‑
hydroxyacyl-­‐‑chain   to   the   2-­‐‑amine   group   of  UDP-­‐‑3-­‐‑O-­‐‑acyl-­‐‑GlcN   (36).   LpxD   follows   an  
ordered   sequential   reaction  mechanism   in  which  acyl-­‐‑ACP  associates  with   the  enzyme  
prior  to  UDP-­‐‑3-­‐‑O-­‐‑acyl-­‐‑GlcN  (110).  An  essential  histidine  residue  (His239  in  E.  coli  LpxD)  
acts  as  a  catalytic  base  to  extract  a  proton  from  the  amine  group  for  nucleophilic  attack  
on  the  thioester  carbonyl  of  acyl-­‐‑ACP  (110).  LpxD  possesses  a  strictly  conserved  glycine  
residue,  which   is   proposed   to   stabilize   the   negatively   charged   carbonyl   oxygen   in   the  
transition   state   (110).   After   catalysis,   UDP-­‐‑2,3-­‐‑diacyl-­‐‑GlcN   dissociates   from   LpxD,  
followed  by  holo-­‐‑ACP  (110).  
The  crystal  structure  of  LpxD  from  C.  trachomatis  (CtLpxD)  was  first  reported  in  
2007  by  Buetow  et.  al.,  verifying  the  LβH  architecture  that  was  previously  inferred  from  
the  amino  acid  sequence  (Fig.  1.19a)  (111).  LpxD  and  LpxA  are  structurally  homologous,  
however  the  domain  combination  of  LpxD  is  distinctive.  In  addition  to  the  LβH  domain,  
each  monomer   of   LpxD   contains   an  N-­‐‑terminal   domain   (NTD)   that   is   composed   of   a  
combination  of  α-­‐‑helices  and  β-­‐‑strands.  Unlike  LpxA,   the  C-­‐‑terminal  domain  (CTD)  of  
LpxD  has  only  two  α-­‐‑helices  that  are  connected  by  a  short  turn.  The  C-­‐‑terminal  helices  
from   adjacent  monomers   interact   to   form   a   three-­‐‑helix   bundle,   however,   they   do   not  
contribute   to   the   oligometric   stability,   as   their   removal   does   not   disrupt   the   trimeric  
structure  of  LpxD  (111).    
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The  E.  coli  LpxD  (EcLpxD)  structure  was  later  reported  by  Bartling  et.  al.,  which  
was   crystallized   in   the   absence   of   any   substrate   (Fig.   1.19b)   (39).   The   overall   fold   of  
EcLpxD  and  CtLpxD  are  similar,  however  there  are  some  differences  in  the  orientations  
of   the   NTD   and   CTD   relative   to   the   LβH   domain.   The   NTD   of   CtLpxD   is   tilted  
approximately  +20°  relative  to   the  three-­‐‑fold  axis  of  symmetry,  whereas   the  equivalent  
domain   of   EcLpxD   is   tilted   –10°   (39).   This   difference   is   attributed   to   the   length   of   the  
linker  region  between  the  NTD  and  LβH,  which  is  one  amino  acid  shorter  for  EcLpxD.  
The   most   distinctive   difference   between   the   two   orthologues   is   in   the   spatial  
arrangement   of   the  C-­‐‑terminal   helices   (Fig.   1.19c,d).   In   the   case   of   EcLpxD,   the   linker  
region  between  the  LβH  and  CTD  interdigitates  with  its  neighbor.    However,  in  CtLpxD  
a  glycine  (Gly310)  substitution  (Ser303  in  EcLpxD)  changes  this  ‘crossover’  arrangement,  
yet  still  enables  the  CTD  to  form  a  three-­‐‑helix  bundle  (39).  
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Figure   1.19:   Molecular   structure   of   C.   trachomatis   and   E.   coli   LpxD.   (a)   C.  
trachomatis   and      (b)   E.   coli   LpxD   are   trimers   with   each   monomer   composed   of   three  
domains:  NTD,  LβH,  and  CTD.  The  C-­‐‑terminal  helices  form  a  three-­‐‑helix  bundle.  (c)  C-­‐‑
terminal   domain   of  CtLpxD.   The   beginning   of   the   first   helix   is   located   just   below   the  
same  monomer.   (d)   C-­‐‑terminal   domain   of   EcLpxD.   The   beginning   of   the   first   helix   is  
located   below   the   neighboring  monomer.     Monomers  A,   B,   and  C,   are   colored   green,  
pink,  and  cyan,  respectively.  The  crossover  linker  is  indicated.  
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The   CtLpxD   structure   was   determined   in   complex   with   UDP-­‐‑GlcNAc   and  
palmitic   acid   (Fig.   1.20a)   (111).  UDP-­‐‑GlcNAc  was   bound   inside   a   cleft   formed  by   two  
neighboring  LpxD  subunits.  The  uracil  interacts  with  the  NTD  of  one  LpxD  subunit,  and  
the  glucosamine  ring  is  coordinated  by  the  LβH  from  of  the  adjacent  subunit;  the  ribose  
and  the  diphosphate  group  cross  between  the  two  domains.  Phe43  and  Tyr49  from  the  
NTD  provide  Π—Π  interactions  with  the  uracil  ring.  Glu32,  Glu34,  Gln248,  Asp46,  and  
His284   form   hydrogen   bonds  with   the   ribose   and   the   pyrophosphate   group   of   UDP-­‐‑
GlcNAc  (Fig  1.20b).    The  kinetic  studies  reported  by  Bartling  et.  al.  confirmed  the  role  of  
Phe43   and   His284   in   UDP-­‐‑3-­‐‑O-­‐‑acyl-­‐‑GlcN   binding.   However,   the   contribution   of   the  
remaining   residues   in   lipid   substrate   binding   could   not   be   verified,   as   alanine  
substitution  of  the  equivalent  residues  in  EcLpxD  did  not  raise  the  KM  value  for  the  lipid  
substrate  significantly.    
The  palmitate  fatty  acid  was  bound  to  a  hydrophobic  cavity  formed  between  two  
neighboring  LβH  domains   (111).  Buetow   et.  al.   claimed   that   this  pocket   represents   the  
binding  site  for  the  acyl-­‐‑moiety  of  the  lipid  substrate.  However,  Bartling  et.  al.  suggested  
that   this  pocket   is   likely  the  feature  that  binds  the  acyl-­‐‑chain  delivered  by  ACP,  which  
for  CtLpxD   is   20-­‐‑carbons   in   length   (39).  Notably,   in  E.  coli  LpxD  Met290   truncates   the  
equivalent   pocket   at   one   end,   and  when   substituted  with   an   alanine   the   specificity   of  
EcLpxD  shifts  from  R-­‐‑3-­‐‑OH-­‐‑C14-­‐‑ACP  to  R-­‐‑3-­‐‑OH-­‐‑C16-­‐‑ACP  (39).     Furthermore,  removal  
of  two-­‐‑carbons  units  from  R-­‐‑3-­‐‑OH-­‐‑C14-­‐‑ACP,  reduces  wild-­‐‑type  LpxD  specific  activity  
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Figure   1.20:   CtLpxD   bound   to   UDP-­‐‑GlcNAc   and   palmitate.   (a)   UDP-­‐‑GlcNAc  
bridges  the  NTD  and  LβH  domain.  The  uracil  ring  is  bound  to  the  NTD  and  the  GlcNAc  
interacts  with  the  LβH  domain.  Palmitate  is  bound  between  two  adjacent  LβH  domains.  
(b)   UDP-­‐‑GlcNAc   interaction  with   LpxD   residues.   The   dotted   lines   indicate   hydrogen  
bonds.   His247   is   proposed   to   act   as   a   catalytic   base.   His284   interacts   with   the  
pyrophosphate  groups.  Phe43  and  Tyr49  interact  with  the  uracil  ring  through  Π-­‐‑staking.  
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by  about  10-­‐‑fold,  suggesting  the  presence  of  a  molecular  hydrocarbon  ruler  (110).    
In  addition   to  acyl-­‐‑chain  selectivity,  binding  of  ACP  and  LpxD   is  necessary   for  
the  successful  delivery  of  acyl-­‐‑substrates  (110).  Substitution  of  acyl-­‐‑ACP  with  a  substrate  
mimetic,   R-­‐‑3-­‐‑hydroxylauroyl-­‐‑methylphosphopantetheine,   results   in   a   loss   of   specific  
activity   of   more   than   1000-­‐‑fold,   suggesting   that   protein–protein   interactions   between  
ACP   and   LpxD   play   a   key   role   in   the   reaction   mechanism   (110).      Divalent   cation  
inhibition   of   LpxD   activity,   which   can   be   reversed   by   addition   of   excess   acyl-­‐‑ACP,  
further   signifies   the   importance   of   the   protein–protein   interaction   in   LpxD   function  
(110).  Although  there  is  no  biochemical  evidence  as  to  where  ACP  might  dock  on  LpxD,  
Buetow   et.   al.   utilized   structural   knowledge   to   propose   that   the   NTD   is   involved   in  
recognition   of   ACP,   as   it   presents   an   electropositive   patch   near   the   UDP-­‐‑GlcNAc  
binding   locale.   Further   structural   and   biochemical   studies   are   required   in   order   to  
understand  how  LpxD  interacts  and  recognizes  its  protein  and  lipid  substrate,  and  how  
it  acquires  its  remarkable  selectivity  for  acyl-­‐‑chain  length.  
Although   the   paradigm   for   ACP   interaction   is   thought   to   be   exceedingly  
transient,  LpxD  binds  ACP  with  very  high  affinity  (Kd  =  59  nM)  (110).    Therefore,  LpxD  
represents  an  excellent  model  system  to  study  ACP-­‐‑based  interactions  and  is  presented  
first   in   Chapter   2.   A   better   understanding   of   ACP–LpxD   may   have   drug   discovery  
implications  as  well.   Inhibitors  of   this  enzyme  might  be  advantageous  over  the  known  
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LpxC   inhibitors   as   they   may   cause   buildup   of   the   toxic   detergent-­‐‑like   intermediate,  
UDP-­‐‑3-­‐‑O-­‐‑acyl-­‐‑GlcN,  thereby  contributing  to  cell  death  by  a  secondary  mechanism  (110).  
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Chapter 2. Chasing Acyl-Carrier-Protein Through a 
Catalytic Cycle of Lipid A Production 
Portions   of   the   following   chapter   have   been   published   in  Nature,   volume   505,  
pages  422-­‐‑426,  2014  January  16,  and  is  reprinted  with  permission.    
2.1 Introduction  
Acyl-­‐‑carrier-­‐‑protein  (ACP)  represents  one  of  the  most  highly  conserved  proteins  
across  all  domains  of  life  and  is  nature’s  way  of  transporting  hydrocarbon-­‐‑chains  in  vivo.    
Type   II   ACPs   found   in   most   microorganisms   and   plants   are   small   (70-­‐‑100   residues),  
dissociated   proteins   with   the   ability   to   diffuse   freely   throughout   the   cytosol   (58).    
Notably,  type  II  ACPs  have  evolved  the  ability  to  associate  with  a  substantial  number  of  
larger  enzymes   for  efficient  delivery  of  a  broad  assortment  of  acyl-­‐‑substrates   linked   to  
their  prosthetic  4′-­‐‑phosphopantetheine  (4′-­‐‑PPT)  group  (56).    ACPs  of  bacteria  serve  as  a  
crucial   interaction   hub   within   primary   cellular   metabolism   (67)   by   communicating  
transiently   between   partner   enzymes   of   the   numerous   biosynthetic   pathways.      The  
highly  transient  nature  of  such  interactions  and  the  inherent  conformational  mobility  of  
ACP  (56)  have  stymied  previous  attempts  to  structurally  visualize  ACP  tied  to  an  overall  
catalytic   cycle,   which   is   essential   to   understanding   a   fundamental   aspect   of   cellular  
metabolism   leading   to   compounds   that   are   not   only   useful   to   the   cell,   but   are   also   of  
therapeutic  value.  
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In  addition  to  their  well-­‐‑defined  roles  in  fatty  acid  and  phospholipid  biogenesis,  
ACPs   are   essential   in   the   biosynthesis   of   lipid   A   (Raetz   Pathway).      The   unique   cell  
envelope  of  Gram-­‐‑negative  microorganisms  requires   lipid  A  (endotoxin),  which  serves  
as   the   anchoring   unit   of   lipopolysaccharides   (LPS)   to   the   outer   membrane   leaflet   (5).    
Lipid  A  is  required  for  the  growth  and  survival  of  most  Gram-­‐‑negative  pathogens  (112,  
113)  and  activates  the  mammalian  host’s  immune  system  (114,  115),  thus  emerging  as  an  
important   therapeutic   target   for   novel,   broad-­‐‑spectrum   anti-­‐‑infectives   (116).      In  
Escherichia  coli,  lipid  A  synthesis  is  an  assembly  line  of  nine  discrete  enzymes  comprised  
of   cytosolic,   peripheral-­‐‑   and   integral-­‐‑membrane   proteins   (Fig.   2.1a).      Central   to   this  
pathway   is   the   thioester-­‐‑activated,   acyl-­‐‑ACP   which   shuttles  R-­‐‑3-­‐‑hydroxymyristoyl   (β-­‐‑
OH-­‐‑C14),   lauroyl   (C12),   or   myristoyl   (C14)   intermediates   among   four   ACP-­‐‑dependent  
acyltransferases:    LpxA,  LpxD,  LpxL,  and  LpxM.    Of  these,  the  crystal  structures  of  both  
LpxA   and   -­‐‑D   have   been   reported   and   revealed   an   unusual   left-­‐‑handed,   β-­‐‑helical   fold  
that  forms  the  core  of  the  homo-­‐‑trimerization  interface  (37,  39).  
LpxD  is  strictly  dependent  on  ACP-­‐‑mediated  delivery,  and  highly  specific  for  the  
transfer   of   β-­‐‑OH-­‐‑containing   acyl-­‐‑chains   that   measure   14-­‐‑carbons   in   length   to   uridine  
diphosphate   3-­‐‑O-­‐‑(β-­‐‑OH-­‐‑C14)-­‐‑α-­‐‑D-­‐‑glucosamine   (UDP-­‐‑acyl-­‐‑GlcN)   (110).      The   acyl-­‐‑chain  
delivered   by  ACP  has   been  proposed   to   bind   a   pronounced  hydrophobic   channel   (N-­‐‑
channel)  formed  between  LpxD  monomers,  which  serves  as  a  molecular  ‘hydrocarbon-­‐‑
ruler’.    The  conserved  catalytic  histidine,  His239  in  E.  coli  LpxD  (Fig.  2.2a),  activates  the  
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amino-­‐‑group  of  GlcN,  which  attacks   the   thioester  scissile  bond  of  acyl-­‐‑ACP  generating  
an  amide  (N-­‐‑linkage)  at  the  2-­‐‑position  of  the  sugar  (Fig.  2.1b),  as  opposed  to  an  ester  (O-­‐‑
linkage)  catalyzed  by  the  preceding  LpxA  acyltransferase.    Presumably  a  second  channel  
exists  (O-­‐‑channel)  on  the  surface  of  LpxD  that  accommodates  the  ester-­‐‑linked  acyl-­‐‑chain  
of  the  lipid  substrate.    Strictly  dependent  on  ACP-­‐‑mediated  delivery,  LpxD  is  incapable  
of   catalyzing   acyl-­‐‑transfer  when   the   carrier-­‐‑protein   component   is   replaced  with   either  
coenzyme   A   (CoA)   or   pantetheine   (110).      Interestingly,   LpxD   binds   ACP   with   high  
affinity   (Kd  =  59  nM)  and  uses  an  ordered  sequential  kinetic  mechanism   in  which  acyl-­‐‑
ACP  binds   first   and,   importantly,  holo-­‐‑ACP  dissociates   last   (110).     Given   the   canonical  
mode  of  ACP-­‐‑mediated   transfer   is  often  highly   transient,   thereby  permitting   the   rapid  
exchange   between   protein   partners   (72),   such   pronounced   association   between   these  
protein  partners  is  most  unusual.     This  suggests  that  the     ‘strong,  transient’  ACP-­‐‑LpxD  
interaction   requires   a  yet   to  be   identified   ‘molecular   trigger’   for  dissociation   (117)   and  
offers   a   unique   opportunity   to   gain   the   detailed  molecular   basis   for   ACP-­‐‑based   acyl-­‐‑
delivery  and  protein–protein  communication  more  generally.  
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Figure   2.1:   Biosynthesis   of   Kdo2-­‐‑lipid   A   in   E.   coli.      (a)   Nine   constitutive  
enzymes   (Lpx)   and   acyl-­‐‑ACP   (green)   coordinate   to   assemble   Kdo2-­‐‑lipid   A   (Kdo,   3-­‐‑
deoxy-­‐‑D-­‐‑manno-­‐‑oct-­‐‑2-­‐‑ulosonic  acid).    Two  equivalents  of  UDP-­‐‑diacyl-­‐‑GlcN,  as  indicated  
by   (2x),   are   required   to   generate   Kdo2-­‐‑Lipid   IVA,  which   represents   the   tetra-­‐‑acylated  
disaccharide  decorated  with  two  Kdo  sugars.    Highlighted  are  the  four  ACP-­‐‑dependent  
acyltransferases   (green   boxes).      (b)   Chemical   structure   of   the   LpxD   reaction   product,  
UDP-­‐‑diacyl-­‐‑GlcN.    Acyl-­‐‑transfer  occurs  at  the  2-­‐‑position  of  the  GlcN  ring,  generating  an  
amide-­‐‑linked  β-­‐‑OH-­‐‑C14  substituent,  as  opposed  to  the  ester-­‐‑linked  β-­‐‑OH-­‐‑C14  acyl-­‐‑chain  at  
the  3-­‐‑position  catalyzed  by  the  preceding  LpxA  acyltransferase.    LpxD  is  highly  specific  
for  the  transfer  of  β-­‐‑OH-­‐‑containing  acyl-­‐‑chains  that  measure  14-­‐‑carbons  in  length.  
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Figure   2.2:   Sequence   alignment   of   LpxD   and   ACP   homologs.      Secondary   structure  
assignment  and  residue  numbers  are  presented  above  and  are  for  E.  coli  LpxD  or  ACP.    
Red   boxes   indicate   strictly   conserved   residues   and   red   single   letter   amino   acids   show  
those  that  are  partially  conserved.    (a)  The  amino  acid  sequence  alignment  of  E.  coli  (EC)  
LpxD   with   Pseudomonas   aeruginosa   (PA),   Chlamydia   trachomatis   (CT),   and   Helicobacter  
pylori   (HP).   The   blue,   yellow,   orange,   and   purple   bars   above   the   aligned   sequences  
indicate   the  uridine   binding  domain   (UBD),   linker   region,   left-­‐‑handed  β-­‐‑helix  domain  
(LβH),   and   the  C-­‐‑terminal   domain   (CTD),   respectively.      The  ACP   recognition  domain  
(ARD)  is  indicated  by  a  green  bar  and  is  presented  below  the  alignment.    Residues  that  
contribute  to  catalysis  and  substrate  specificity  are   indicated  by  triangles  that  are  color  
matched   according   to   domain   association;   the   catalytic   His293   is   indicated   with   an  
asterisk.     The  Met290  residue  which  serves  as   the  molecular   ‘hydrocarbon  ruler’   for  E.  
coli  LpxD  is  also  indicated.    Although  this  is  indeed  the  case  for  E.  coli  LpxD,  orthologs  
often   have   other   chain-­‐‑length   specificity   and,   thus   require   fine-­‐‑tuning   of   the  
‘hydrocarbon  ruler,’  for  example  with  C.  trachomatis  LpxD  which  incorporates  a  twenty-­‐‑
carbon   acyl-­‐‑chain12.      (b)   Amino   acid   sequence   alignment   of   ACPs   from   E.   coli   (EC),  
Pseudomonas   aeruginosa   (PA),  Neisseria  meningitidis   (NM),  Burkholderia  pseudomallei   (BP),  
and  Bacillus  subtilis  (BS).    The  primary  sequence  of  ACP  begins  with  methionine,  which  
for  historical  reasons  (i.e.  due  to  aminopeptidase  action)  is  numbered  zero  and  the  serine  
that  is  next  in  sequence  is  denoted  number  one.    Regions  I  and  II  are  indicated  by  light  
and   dark   green   bars,   respectively.      Key   residues   that   make   strong   electrostatic  
interactions   within   regions   I   and   II   are   indicated   by   triangles   that   are   color   matched  
according   to   their   acidic   region   association.      An   asterisk   indicates   the   canonical  
phosphopantetheinylated  serine  (Ser36)  residue.  
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2.2 Results 
2.2.1  Overview  of  the  ACP-­‐‑LpxD  complexes  
We  determined  three  co-­‐‑crystal  structures  of  ACP  bound  to  LpxD,  each  of  which  
captured   a   different   form   of   the   carrier-­‐‑protein:      intact-­‐‑acyl-­‐‑ACP,   hydrolysed-­‐‑acyl-­‐‑ACP,  
and   holo-­‐‑ACP   (Fig.   2.3).      In   doing   so,   our   structures   visualize   stalled   substrate-­‐‑
intermediate  and  liberated  products  during  the  acyl-­‐‑delivery  process.     These  structures  
crystallized   in   the   P1   spacegroup   and   were   resolved   to   2.1   Å,   2.9   Å,   and   2.15   Å  
resolution,   respectively   (Table   2.1).      In   each   case,   the   triclinic   unit   cell   contained   two  
LpxD  trimers  with  different  bound  states  of  ACP  (Fig.  2.4).    It  is  well  established  that  the  
biologically   functional  unit  of  LpxD   is  a   single   trimer;   the   fact   that   there   is   a  dimer  of  
trimers  in  asymmetric  unit  is  most  likely  an  artifact  of  crystallization.  In  the   intact-­‐‑acyl-­‐‑
ACP   complex  we   observed   three  molecules   of   the   carrier-­‐‑protein   bound  per   trimer   of  
LpxD.      However,   in   both   the   hydrolysed-­‐‑   and   holo-­‐‑ACP   complexes  we   observed  weak  
density  for  ACP  in  two  or  three  of  the  six  total  LpxD  active  sites  in  which  only  portions  
of  ACP   could   be  modeled,   possibly   representing   dynamically   disordered  ACPs.      It   is  
worth  mentioning  that  ACP  was  mixed  with  LpxD  at  equal  molar  concentrations  prior  
to  crystallization,  which  may  contribute   to  partial  docking  of   carrier-­‐‑protein;  however,  
increasing   the   ACP   concentration   during   crystallization   had   no   effect   on   the   ratio   of  
bound  ACP.  The   overall   B-­‐‑values   for   all  ACPs  modeled   in   each   structure   are   2-­‐‑3   fold    
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Figure  2.3:  Stalled  ACPs  bound  to  LpxD.    (a)  The  three  forms  of  ACP:  intact-­‐‑acyl-­‐‑
ACP   (green),  hydrolysed-­‐‑acyl-­‐‑ACP   (salmon),   and  holo-­‐‑ACP   (red).     ACP  adopts   a   4-­‐‑helix  
bundle   (I-­‐‑IV)   with   several   loop   regions   (L1-­‐‑L3).      The   4′-­‐‑PPT   arm   and   acyl-­‐‑chains   are  
shown  as  stick  models  and  colored  orange  or  dark  gray,  respectively,  and  by  atom.    (b)  
Overall  architecture  of  the  ACP-­‐‑LpxD  complex.     For  simplicity,  only  the  representative  
intact-­‐‑acyl-­‐‑ACP  structure  is  shown.     Three  ACPs  (green)  bind  the  carboxy-­‐‑terminal  end  
of  the  LpxD  trimer  (colored  by  chain  purple/magenta/light  pink).    (c)  Cartoon  rendering  
showing   the   overall   fold   and   interaction   of   acyl-­‐‑ACP   with   LpxD.      Highlighted   dark  
purple   is   a   single  monomer   of   LpxD  with   the   subdomains   indicated:   uridine   binding  
domain  (UBD),  left-­‐‑handed  β-­‐‑helix  domain  (LβH),  and  C-­‐‑terminal  domain  (CTD).    ACP,  
interfacing  with  the  ACP  recognition  domain  (ARD),  and  its  acyl-­‐‑4′-­‐‑PPT  group  is  shown.    
The   locations   of   the   catalytic   base   (His239),   the   oxyanion   hole   (Gly257),   and   the  
molecular   ‘hydrocarbon   ruler’   (Met290)   are   indicated   within   the   ten   β-­‐‑helical   coils  
(orange  strands)  of  a  single  LβH.    
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Table  2.1:  Data  collection  and  refinement  statistics.  
   Intact-­‐‑Acyl-­‐‑ACP   Hydrolysed-­‐‑Acyl-­‐‑ACP   Holo-­‐‑ACP  
   (His239Ala-­‐‑LpxD)   (wild-­‐‑type-­‐‑LpxD)   (wild-­‐‑type-­‐‑LpxD)  
Data  collection*           
Space  group   P1   P1   P1  
Cell  dimensions               
        a,  b,  c  (Å)   84.30,  89.44,  112.25   84.18,  89.31,  111.93   89.47,  93.23,  114.30  
    α, β, γ (°)  104.06,  92.40,  118.47   104.09,  92.58,  118.64   75.93,  73.81,  58.95  
No.  of  Reflections   561496   235456   858856  
No.  of  Unique  Reflections   154031   59734   160164  






Rsym  or  Rmerge   0.10  (0.40)   0.09  (0.19)   0.09  (0.64)  
I  /  σI   14.6  (2.3)   13.8  (5.6)   21.9  (1.9)  
Completeness  (%)   97.7  (94.9)   98.3%  (91.1)   96.1  (85.6)  
Redundancy   3.6  (3.1)   3.9  (3.7)   5.4  (4.0)  
           
Refinement           
Resolution  (Å)   43.38–2.10   28.43–2.89   35.89–2.13  
No.  reflections     145543   57571   159778  
Rwork/  Rfree  (%)   16.8  /  21.6   20.4  /  25.3   17.8  /  21.6  
No.  atoms  /  B-­‐‑factors           
        LpxD   14835/39.1   14688/39.3   14914/32.1  
        ACP   3433/79.9   2631/78.6   2438/79.5  
        β-­‐‑OH-­‐‑C14-­‐‑4′-­‐‑PPT                                                  222/43.0   —   —  
        β-­‐‑OH-­‐‑C14OOH   —   136/36.5   —  
      4′-­‐‑PPT                                                   —   126/37.3   126/54.6  
        Water   919/42.5   145/30.4   885/34.8  
R.m.s  deviations           
        Bond  lengths  (Å)     0.01   0.01   0.01  
        Bond  angles  (º)   1.05   0.97   1.03  
Ramachandran  statistics             
        Favored  (%)   97.6   97.1   98.1  
        Disallowed  (%)   0.0   0.0   0.0  
   Data  were  collected  from  a  single  crystal  for  each  complex.  
   *Highest  resolution  shell  is  shown  in  parenthesis.    
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Figure   2.4:   The   asymmetric   unit   contents   of   the   (a)   intact-­‐‑acyl-­‐‑ACP   (b)  
hydrolysed-­‐‑acyl-­‐‑ACP  and  (c)  holo-­‐‑ACP  structures  in  complex  with  LpxD.  Two  trimers  of  
LpxD   (gray   or   colored   as   in   figure   1)   were   observed   in   the   triclinic   unit   cell.      Six  
molecules  of  ACP  were  completely  modeled  in  the  intact-­‐‑acyl-­‐‑ACP  structure  (green  with  
transparent  molecular  surface).  In  the  hydrolysed-­‐‑  and  holo-­‐‑ACP  structures  (salmon  or  red  
with  transparent  molecular  surfaces,  respectively)  three  or  two  molecules  of  ACP  were  
partially   modeled.      Representative   molecules   of   (d)   intact-­‐‑acyl-­‐‑ACP   (chain   H)   (e)  
hydrolysed-­‐‑acyl-­‐‑ACP   (chain   J)   and   (f)   holo-­‐‑ACP   (chain   J)   with   2Fo  –   Fc   composite   omit  
electron  density  covering  each  α-­‐‑carbon  trace,  contoured  at  0.9  σ.     (inset)  Rotated  view  
showing  the  backside  of  ACP.  
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higher   than  LpxD   (Fig.  2.5  and  Table  2.1).     Accordingly,   the  observed  electron  density  
for   fully   modeled   intact-­‐‑,   hydrolysed-­‐‑,   and   holo-­‐‑ACP   was   weaker   in   some   regions  
especially   on   the   solvent   exposed   faces   (Fig.   2.4)   –   further   implicating   conformational  
heterogeneity   throughout   the   lattice.      Nonetheless,   the   placement   of   side-­‐‑chains   was  
apparent  at  the  protein–protein  interface.  
In   order   to   trap   the   intact-­‐‑acyl-­‐‑ACP   complex,   the   catalytic  His239   of  LpxD  was  
mutated   to   alanine   and   inspection   of   the   electron   density   indicates   that   the   thioester  
scissile  bond   remained  unbroken   (Fig.   2.6).     By   contrast,   both   the  hydrolysed-­‐‑   and  holo-­‐‑
ACP  structures  were  crystallized   in   the  presence  of  wild-­‐‑type  LpxD  enzyme.     Electron  
density  for  the  prosthetic  group  and  acyl-­‐‑chain  of  hydrolysed-­‐‑acyl-­‐‑ACP  revealed  that  the  
thioester   bond   was   cleaved.      This   likely   occurred   through   the   activation   of   a   water  
molecule.      Serendipitously   we   discovered   a   second   molecule   of   β-­‐‑OH-­‐‑C14   fatty   acid  
bound   to   the   surface   of   LpxD,  which   likely   originated   from   excess   hydrolysis   of   acyl-­‐‑
ACP  within   the   crystallization  drop.     We  have   shown  by  using  a  gel-­‐‑based  assay   that  
both   dithiothreitol   (DTT)   and   LpxD   enhance   the   hydrolysis   of   acyl-­‐‑ACP   (Fig.   2.7).    
Notably,  this  molecule  of  β-­‐‑OH-­‐‑C14  fatty  acid  likely  represents  the  ester-­‐‑linked  acyl-­‐‑chain  
of  the  lipid  substrate.    Although  the  holo-­‐‑ACP  lacked  any  acyl-­‐‑chain  substituent,  electron  
density   for   its   pantetheinyl-­‐‑group   was   clear   and   revealed   a   different   arrangement   as  
compared  to  the  other  two  complexes.  
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Figure  2.5:  Temperature  factor  distribution  of  LpxD  and  ACP  between   the   (a)  
intact-­‐‑acyl-­‐‑ACP,  (b)  hydrolysed-­‐‑acyl-­‐‑ACP,  and  (c)  holo-­‐‑ACP  co-­‐‑crystal  structures.    A  single  
trimer  of  LpxD  and  all  bound  ACPs  observed  in  the  triclinic  unit  cell  are  represented  as  
ribbon-­‐‑putty   diagrams   and   colored   according   to   main-­‐‑chain   B-­‐‑value.      A   scale   bar   is  
indicated   for   the   thermal   distribution.      The   subdomains   of   LpxD   are   indicated.      The  
location  of  the  pantetheinylated  Ser36  residue  is  indicated  with  an  asterisk  symbol  and  
the  first  ACP  molecule  of  each  co-­‐‑crystal  structure  is   labeled  with  secondary  structural  
elements.    Partially  modeled  hydrolysed-­‐‑  and  holo-­‐‑ACPs  are  accented  with  a  box.  
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Figure   2.6:   4′-­‐‑PPT   and  β-­‐‑OH-­‐‑C14  moieties  of   (a)   intact-­‐‑acyl-­‐‑ACP,   (b)   hydrolysed-­‐‑
acyl-­‐‑ACP,  and  (c)  holo-­‐‑ACP  that  bound  in  the  active  site  cleft  of  LpxD.    Shown  covering  
Ser36   and   the   intact-­‐‑acyl-­‐‑4′-­‐‑PPT   and   holo-­‐‑4′-­‐‑PPT   groups   is   Fo   –   Fc  simulated   annealing  
omit  electron  density  contoured  at  3.5  σ.    Covering  the  hydrolysed-­‐‑acyl-­‐‑4′-­‐‑PPT  group  and  
the  β-­‐‑OH-­‐‑C14  fatty  acids  is  2Fo  –  Fc  composite  omit  electron  density  contoured  at  1.0  σ.  
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Figure  2.7:  Evidence  for  the  hydrolysis  of  acyl-­‐‑ACP.    Conformationally  sensitive  
2.5   M   urea   polyacrylamide   (19%)   gel-­‐‑shift   assay   investigating   the   cleavage   of   the  
thioester  bond  of  acyl-­‐‑ACP  in  the  presence  (+)  or  absence  (–)  of  0.3  mM  DTT  and  LpxD  
as  a  function  of  time.    The  assay  mixture  and  temperature  were  kept  consistent  with  the  
solution  used  for  crystallization  (0.1  M  MES  pH  6.5,  0.2  M  ammonium  sulfate,  20%  PEG  
8000,  and  incubation  at  15  ˚C).      The  well  numbers  are  indicated  above  the  gel.  Lanes  1  
and  2  indicate  holo-­‐‑  and  acyl-­‐‑ACP,  respectively,  and  serve  as  controls.    Holo-­‐‑ACP  even  in  
the  presence  of  DTT  shows  a  weak,  higher  molecular  weight  band  that  corresponds  to  a  
disulfide  bound  form  of  holo-­‐‑ACP  via  the  pantetheinyl  arm.    Lanes  3  and  4  indicate  the  
effect  of  DTT  alone  on  acyl-­‐‑ACP  after  76  hours.     Lanes  5   through  10  show  acyl-­‐‑ACP  in  
the  presence  of  both  DTT  and  LpxD  at  the  indicated  time  points.     The  data  indicate  an  
enhancement  of  acyl-­‐‑ACP  hydrolysis  by  DTT  and  LpxD.  
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Similar   to  other  NMR  and  X-­‐‑ray  structures,  ACP  adopts  a  4-­‐‑helix  bundle   (I-­‐‑IV)  
with   several   loop   regions   (L1-­‐‑L3)   (69,   118-­‐‑120)   and   the   pantetheine   arm   is   covalently  
attached   to   the   canonical   serine-­‐‑Oγ   oxygen   (Ser36   in  E.   coli)   located   on   the   ‘universal  
recognition   helix’   (helix-­‐‑II)   involved   in   the   electrostatic   association   with   partner  
enzymes   (77)   (Fig.  2.3a  and  Fig.  2.6).     Previous  structural   studies  have  shown  that   this  
architecture  forms  a  hydrophobic  cavity  extending  through  its  core,  which  is  designed  to  
accommodate  acyl-­‐‑chains  of  varying  length,  saturation,  or  hydroxylation  (52,  56,  74,  89).    
By  contrast,  our  structures  show  the  4′-­‐‑PPT  and  its  thioester-­‐‑linked  or  hydrolysed  β-­‐‑OH-­‐‑
C14  acyl-­‐‑chains   having   vacated   this   cavity,   pivoted   about   Ser36,   and   adopted   a   rather  
extended  conformation  –  all  of  which  require  considerable  movement  (Fig.  2.8).  In  doing  
so,  our  structures  represent  the  stalled  substrate-­‐‑intermediate  and  liberated  products  in  
the  acyl-­‐‑delivery  process.  
Despite   the   fact   that  LpxD   is  bound   to   the   intact-­‐‑,  hydrolysed,   and  holo-­‐‑forms  of  
ACP,   the   overall   relationship   and   stoichiometry   at   the   interface   between   the   carrier-­‐‑
protein   and   LpxD   remains   consistent.   The   characteristic   intact-­‐‑acyl-­‐‑ACP   structure   is  
represented   in   FIGURE   2.3b,   which   reveals   three   molecules   of   the   carrier-­‐‑protein  
localized  to  the  C-­‐‑terminal  end  of  LpxD.    Each  monomer  of  LpxD  can  be  subdivided  into  
three  domains  (39,  111).    First,  the  N-­‐‑terminal  uridine-­‐‑binding  domain  (UBD,  residues  1-­‐‑
90),  which   is   tethered   to  LpxD  by  a  short   linker   region,  binds   the  uridine-­‐‑diphosphate  
moiety  of  UDP-­‐‑acyl-­‐‑GlcN  (Fig.  2.3c).    Second,  and  perhaps  the  most  prominent  domain  
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is   the   left-­‐‑handed   β-­‐‑helix   domain   (LβH,   residues   100-­‐‑300).      It   is   composed   of   10   left-­‐‑
handed,  β-­‐‑helical   coils   forming  a   tower-­‐‑like  prism   that  measures   ~45Å   in   length.     The  
LβH  serves  as  the  major  trimerization  interface  (39,  110,  111),  forms  a  possible  acyl-­‐‑chain  
binding  surface  (39,  110,  111),  and  harbors  the  catalytic  His239  residue  (110),  as  well  as  
an   extended   loop   insertion   (loop  1)   that   interrupts   the   continuity  of   the  β-­‐‑helical   coils  
and  forms  part  of  the  catalytic  cleft.      
Finally,   there   is   a   C-­‐‑terminal   domain   (CTD,   residues   303-­‐‑341),   which   is  
composed   of   an   extended  α-­‐‑helix   that   is   disrupted   in   its  middle   by   a   small   kink.   The  
CTD  is  localized  to  one  end  of  LpxD,  and  in  the  trimer,   interdigitates  to  form  a  3-­‐‑helix  
bundle.    Our  structures  reveal  the  ACP  recognition  domain  (ARD),  which  is  formed  by  
the  CTD  and  includes  the  last  beta-­‐‑coil  of  the  LβH  domain  and  provides  the  molecular  
basis  for  ACP  association.    This  contrasts  with  a  previous  study  that  suggested  the  UBD  
domain  as  the  likely  ACP  docking  site  due  to  its  proximity  to  the  catalytic  cleft  and  the  
presence   of   an   electropositive   patch   (111),   and   correlates   with   a   study   that   showed  
acyltransferase   activity   is   abolished   when   the   C-­‐‑terminal   helices   of   the   ARD   are  
removed  (110),  even  though  the  truncated  LpxD  retains  its  trimeric  structure  (111).  It  is  
worth   mentioning   that   although   the   analogous   C-­‐‑terminal   region   of   the   LpxA  
acyltransferase   is   found   to  adopt  a   completely  different  orientation   from   that  of  LpxD  
(37,  108),  it  may  serve  a  similar  function  in  binding  ACP.    
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Figure  2.8:  Structural  comparison  of  acyl-­‐‑ACPs.    The  X-­‐‑ray  and  NMR  structures  
of   (a)   E.   coli   decanoyl-­‐‑ACP   (PDB   2FAE,   light   gray)   and   (b)   S.   coelicolor   R-­‐‑3-­‐‑
hydroxyoctanoyl-­‐‑ACP   (PDB   2KOQ,   blue),   respectively,   determined   in   the   absence   of  
partner   enzyme.      The   acyl-­‐‑chains   (dark   gray)   are   covalently   attached   via   a   thioester  
bond   to   the   4′-­‐‑PPT   arm   (colored   in   orange   and   by   atom)   and   are   tucked   inside   the  
hydrophobic  cavity.  (c)  Superposition  of  decanoyl-­‐‑  and  R-­‐‑3-­‐‑hydroxyoctanoyl-­‐‑ACP  with  
the   structure  of   intact-­‐‑acyl-­‐‑ACP  colored  green   (LpxD   is   omitted   for   simplicity).  The   4′-­‐‑
PPTs   are   colored   according   to  ACP   affiliation.      The   4′-­‐‑PPT   arm  of   intact-­‐‑acyl-­‐‑ACP  has  
pivoted  about  Ser36,  rotating  by  180°  to  present  the  acyl-­‐‑chain  to  the  active  site  of  LpxD.      
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2.2.2  The  ACP-­‐‑LpxD  interface  
By  virtue  of   the  LpxD   trimer   symmetry  and   the  complete  engagement  of  ACP,  
three   competent   active   sites   are   created   (Fig.   2.9a).     However,   it   remains  unclear   as   to  
whether  all  three  function  independently,  simultaneously,  or  perhaps  furnish  some  type  
of  cooperative  allostery.  The  ACP-­‐‑LpxD  interface  buries  a  surface  area  of  ~530  Å2  and  is  
predominated  by   electrostatic   interactions.      In   addition   to  van  der  Waals   contacts   and  
extensive  interactions  with  the  prosthetic  group,  the  large  binding  footprint  explains  the  
‘strong,  transient’  nature  of  these  two  protein  partners  and  correlates  with  their  reported  
high  affinity   (110).     An  overlay  of   the   electrostatic   surface   shows   the   complementarity  
between  the  ARD  and  ACP  (Fig.  2.9b).    A  combination  of  residues  located  on  helix-­‐‑II,  as  
well  as  portions  of  L1,  L2,  and  helix-­‐‑III  of  ACP  provide   the  acidic  surface   that  binds  a  
pronounced  basic  patch  on  LpxD.     This  surface  feature  of  ACP  can  be  subdivided  into  
two   highly   acidic   regions,   I   and   II,   which   include   residues   Glu30-­‐‑Met44   and   Ala45-­‐‑
Glu60,   respectively.      The   complementary   binding   surface   on   LpxD   forms   a   shallow  
groove   between   coiled-­‐‑coils   of   the   ARD   into   which   helix-­‐‑II   packs.   It   is   comprised   of  
residues   from   all   three   ARD-­‐‑helices   and   a   few   from   β-­‐‑coil-­‐‑10,   including   Pro306   from  
monomer   A,   Lys311′,   Trp313′,   Lys315′,   Ala317′,   Ala318′,   Leu319′,   Met321′,   Asn322′,  
Asp325′,   Met326′,   and   Arg329′   from   monomer   B,   and   Met292′′,   Arg293′′,   Pro294′′,  
Asp324′′,  Lys328′′,  Lys331′′,  and  Arg335′′   from  monomer  C   (Fig.  2.9c).     This   interaction  
orients  ACP  with  respect  to  the  LpxD  active  site  cleft  by  aligning  helix-­‐‑II  parallel  to  the  
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ARD   helical   bundle   and   positioning   the   pantetheinylated   Ser36   residue   toward   the  
catalytic  chamber.      
Within   region   I   Asp35,   Ser36,   Leu37,   Asp38,   Val40,   Glu41,   and   Met44   are  
important  for  binding  the  N-­‐‑terminal  end  of  the  recognition  helix  to  the  base  of  the  ARD  
domain   (Fig.   2.9c)   and   the   interactions   were   notably   present   in   each   of   the   intact-­‐‑,  
hydrolysed-­‐‑,  and  holo-­‐‑ACP  structures.    Most  of  these  residues  are  located  on  helix-­‐‑II  with  
the  exception  of  Asp35,  which  resides  on  L1.    Region  II  of  ACP  interacts  with  the  upper  
portion   of   the  ARD  domain,   the   details   of  which   differ   substantially   among   the   three  
stalled   ACP   complexes.      Most   of   the   residues   within   regions   I   and   II   are   conserved  
among   other   type   II   carrier-­‐‑proteins   (Fig.   2.2b)   and   have   been   implicated   as   key  
modulators  of  ACP  association  with  other  protein  partners,  such  as  cytochrome  P450Biol,  
holo-­‐‑ACP  synthase,  and  fatty  acid  megasynthases  (72,  86,  87).      
The   most   universal   electrostatic   interaction   displayed   across   the   intact-­‐‑,  
hydrolysed-­‐‑,  and  holo-­‐‑ACP  structures  is  between  Arg293  of  LpxD  and  Asp35,  Asp38,  and  
Glu41  of  ACP  that  flank  Ser36.     This  electrostatic   interaction  structurally  anchors  Ser36  
so  that  ACP  is  poised  to  extend  its  acylated  4′-­‐‑PPT  prosthetic  group  toward  the  His239  
catalytic   base.   Moreover,   this   coordination   point   is   crucial   for   ACP   association   as  
mutation   of   Arg293   to   alanine   results   in   a   23-­‐‑fold   increase   in   KM   for   acyl-­‐‑ACP   as  
compared   to   wild-­‐‑type   LpxD,   with   little   effect   on   kcat   (110).   Although   Arg293   clearly  
plays   an   important   role,   it   is   obvious   that   a   single   residue   cannot   explain   the   tight  
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association.  For  example,  LpxD  acyltransferase  activity  is  abolished  when  the  C-­‐‑terminal  
helices   are   removed   (110),   which   does   in   fact   remain   a   timer   (111).   This   occurs   even  
though  Arg293  remains  on  β-­‐‑coil-­‐‑10.    Therefore,  Arg293  contributes  to  ACP  binding  but  
is   not   sufficient  without   the   entire  ARD  domain.      In   fact,   the   intact-­‐‑acyl-­‐‑ACP   complex  
identified  several  additional  electrostatic  interactions  between  residues  located  at  the  top  
of  the  ARD  and  region  II  of  ACP.      




Figure   2.9:   Intermolecular   interactions   between   ACP   and   LpxD.      (a,   b)  
Overview   of   the   protein-­‐‑protein   interactions.      (a)   Top-­‐‑down   view   of   the   ACP-­‐‑LpxD  
complex   showing   three   molecules   of   ACP   bind   per   LpxD   trimer   (intact-­‐‑acyl-­‐‑ACP  
depicted   and   colored   as   in   figure   3.3).      (b)   Electrostatic   surface   representation   of   the  
ARD  and  ACP  (inset),  the  potential  contours  were  scaled  to  +79.2  (blue)  and  -­‐‑79.2  (red)  
kB  T  e-­‐‑1  (where  kB   is   the  Boltzmann  constant,  T   is   temperature  and  e-­‐‑1   is   the  charge  of  an  
electron;intact-­‐‑acyl-­‐‑ACP  depicted).   (c)   Stereoview  of   the   intact-­‐‑acyl-­‐‑ACP   complex.  Only  
those   residues   and   their   molecular   surfaces   that   contribute   at   the   protein-­‐‑protein  
interface  (chain  J)  are  shown.    Salt-­‐‑bridge  interactions  are  indicated  by  black  dashes.    The  
acyl-­‐‑4′-­‐‑PPT  group  attached  to  Ser36  is  omitted  for  clarity.  
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2.2.3  Acyl-­‐‑4′-­‐‑PPT  interactions  and  LpxD  functional  surfaces  
In   addition   to   the   protein–protein   interactions,   the   prosthetic   group   and   acyl-­‐‑
chain  of  the  intact-­‐‑acyl-­‐‑ACP  complex  extensively  contact  the  surface  of  LpxD  (Fig.  2.10a  
and  Fig.  2.11a).    The  β-­‐‑OH-­‐‑C14  acyl-­‐‑chain  packs  into  a  pronounced  hydrophobic  channel  
(N-­‐‑channel)   formed   by   residues   between   adjoining   LBH   domains,   including   Ala′250,  
Gly251′,  Gly269′,  Gly287′,  Met288′,  Phe183′′,  Gln236′′,  Ala238′′,  Ile254′′,  Met255′′,  Ala256′′,  
Gly257′′,  Val272′′,  Ile273′′,  Asn274′′,  Met290′′,  Val291′′,  and  Met292′′.    The  4′-­‐‑PPT  arm  and  
the   acyl-­‐‑chain   adopt   a   horseshoe-­‐‑like   conformation   relative   to   one   another,   which   in  
effect   buries   the   acyl-­‐‑chain   between   the   prosthetic   group   and   residues   lining   the  N-­‐‑
channel.      The   4′-­‐‑phosphate  moiety   of   4′-­‐‑PPT   is   coordinated   by  Asn310   and  Arg314   of  
LpxD.   This   is   in   contrast   to   both   the   crystal   structures   of   cytochrome   P450   and   BioH  
methyl  ester  esterase  that  were  solved  in  complex  with  acyl-­‐‑ACPs.    The  former  structure  
showed   a   network   of  water  molecules   that  mediate   interaction  with   the   4′-­‐‑phosphate  
(87),  whereas  the  latter  structure  displayed  no  interactions  at  all  (121).    Direct  contact  of  
the   prosthetic   group   with   LpxD   may   partially   explain   the   strong   binding   affinity  
reported   for   these   partners   (110)   and   conceivably   may   contribute   to   some   level   of  
specificity.   The   remainder   of   the   4′-­‐‑PPT   arm   adopts   a   rather   extended   conformation,  
stretching   over   14   Å,   and   interacts   with   residues   primarily   along   the   rim   of   the  N-­‐‑
channel.    The  functional  groups  along  one  side  of  the  pantetheinyl-­‐‑arm  hydrogen  bond  
with  the  amide  nitrogen  atoms  of  Gly269′  and  Gly287′,  whereas  the  opposing  side  makes  
   77  
  
Figure  2.10:  Detailed  interactions  between  LpxD  reaction  chamber  and  bound  
acyl-­‐‑4′-­‐‑PPT.    Molecular  surfaces  are  of  only  those  residues  that  contribute  to  interactions  
and   are   colored   as   in   figure   2.     Hydrogen   bonds   are   shown   as   black   dashes.      (a)   The  
intact-­‐‑acyl-­‐‑ACP  complex.     The  attached  β-­‐‑OH-­‐‑C14  binds  the  hydrophobic  N-­‐‑channel  and  
its   terminal  carbon-­‐‑atoms  pack  near  Met290′′.     The  thioester  scissile  bond  is  positioned  
above   His239Ala′′   and   hydrogen   bonds   with   Gly257′′   of   the   oxyanion   hole.      The   β-­‐‑
hydroxyl  group  is  coordinated  through  a  hydrogen  bond  network  with  residues  in  the  
catalytic   cleft.      The   4′-­‐‑PPT   hydrogen   bonds   with   residues   lining   both   sides   of   the  N-­‐‑
channel.      (b)   The  hydrolysed-­‐‑acyl-­‐‑ACP   complex.      The  newly   formed   carboxylate  makes  
hydrogen  bonds  with  His239′′  and  Gly257′′.    An  equivalent  β-­‐‑OH-­‐‑C14  acyl-­‐‑chain  is  shown  
bound  to  the  hydrophobic  O-­‐‑channel  adjacent  to  the  4′-­‐‑PPT.    (c)  The  holo-­‐‑ACP  complex.  
The  4′-­‐‑PPT  arm  interacts  at  the  far  end  of  the  channel,  positioning  the  terminal  thiol  near  
Met290′′.    
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Figure   2.11:   Stereoview   of   (a)   intact-­‐‑acyl-­‐‑ACP,   (b)   hydrolysed-­‐‑acyl-­‐‑ACP,   and   (c)  
holo-­‐‑ACP  complex  structures  detailing  the  interaction  of  the  acyl-­‐‑4′-­‐‑PPT  moieties  within  
the  reaction  chamber  of  LpxD.  Only  those  residues  that  contribute  to  ligand  contact  are  
shown   with   transparent   molecular   surfaces.      Hydrogen   bonds   are   shown   as   black  
dashes  and  the  color  scheme  is  as  in  figure  2.10.      
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a   hydrogen   bond   with   the   side-­‐‑chain   of   Asn274′′   mediated   by   a   water   molecule.   A  
number   of   additional   residues   interact   with   the   4′-­‐‑PPT   group,   the   majority   of   which  
provide   van   der   Waals   contacts   (Trp313,   Gly268′,   Thr286′,   Val300′,   Phe183′,   Ala256′′,  
Asn274′′,  Met290′′,  and  Met292′′).  This  conformation  of  4′-­‐‑phosphopantetheine  places  the  
thioester  bond  in  proximity  to  the  alanine-­‐‑substituted  His239  catalytic  base  and  orients  
the   carbonyl-­‐‑oxygen   of   β-­‐‑OH-­‐‑C14   toward   the   amide   nitrogen   atom   of   Gly257′′,  
corroborating  its  role  in  forming  the  oxyanion  hole  (122).      
Two  features  of  LpxD  acyl-­‐‑chain  specificity  are  explained  by  the  intact-­‐‑acyl-­‐‑ACP  
structure.      First,   the   terminal   two   carbon-­‐‑atoms   of   β-­‐‑OH-­‐‑C14   pack   against   Met290′′  
located   at   the   far   end   of   the  N-­‐‑channel.      This   correlates  with   the   preference   of  E.   coli  
LpxD  for  acyl-­‐‑chains  that  measure  14-­‐‑carbons  long  (110)  and  supports  the  role  of  Met290  
as  a   ‘hydrocarbon  ruler,’  which  discriminates  acyl-­‐‑chains  based  on   their   carbon-­‐‑length  
(39).      Second,  LpxD   is   specific   for   the  β-­‐‑hydroxyl   group  of   the   acyl-­‐‑chain;   its   removal  
completely   abrogates   acyltransferase   activity   (36).      Our   structures   reveal   an   intricate  
hydrogen   bond   network   between   the   β-­‐‑hydroxyl   group   and   Asp232′,   Gln236′,   and   a  
critical   water-­‐‑mediated   bridge   with   Asp216′′   and   the   main-­‐‑chain   nitrogen   atoms   of  
Phe183′′   and   His239Ala′′.      Selectivity   for   β-­‐‑OH-­‐‑C14   is   most   likely   an   amalgamation   of  
these  key   factors,  which   together  provide  proper   register  of   the   thioester   scissile  bond  
relative  to  His239  and  the  GlcN  amino-­‐‑nucleophile.    Any  adjustment  in  its  carbon-­‐‑atom  
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measurement  or  hydroxylation  would  displace   the   thioester  bond   from   the  active   site,  
resulting  in  improper  geometry  for  catalysis  to  occur.  
By   contrast   to   the   intact-­‐‑acyl-­‐‑ACP   complex,   the   thioester   bond   is   broken   in   the  
hydrolysed-­‐‑acyl-­‐‑ACP  structure.    The  4′-­‐‑PPT  and  acyl-­‐‑chain  make  similar  interactions  with  
only  minor  differences   (Fig.  2.10b  and  Fig.  2.11b).  The  newly   formed  carboxylate  head  
group   is   rotated  and  makes  a  hydrogen  bond  with   the  Nε2  nitrogen  atom  of  His239′′.    
Also,   the   terminal   thiol  of   the   liberated  4′-­‐‑PPT  arm  has   shifted   slightly  by  ~1.3  Å.  The  
discovery   of   a   second   molecule   of   β-­‐‑OH-­‐‑C14   fatty   acid   bound   to   the   LpxD   surface  
revealed   the  O-­‐‑channel,  which   likely   binds   the   acyl-­‐‑chain   of   the  UDP-­‐‑acyl-­‐‑GlcN   lipid  
substrate.      Lining   the   hydrophobic   cleft   are   residues   Tyr80′,   Ile230′,   Ala248′,   Val249′,  
Ala250′,   Met266′,   Ile267′,   Gly268′,   Thr284′,   Val285′,   Thr286′,   and   Val300′,   all   of   which  
belong   to   a   single  LβH  monomer.   The  O-­‐‑channel   is   solvent   exposed   and  because   it   is  
situated  adjacent  to  the  4′-­‐‑PPT  prosthetic  group,  the  ligands  generate  an  ‘acyl–PPT–acyl’  
sandwich.     The  carboxylate  head  group  of   the  β-­‐‑OH-­‐‑C14  bound  in   the  O-­‐‑channel   forms  
hydrogen  bonds  with  the  main-­‐‑chain  oxygen  atom  of  Phe183′′  and  the  thiol  of  the  4′-­‐‑PPT  
arm.    A  superposition  between  our  structure  and  the  C.  trachomatis  LpxD  determined  in  
complex   with   UDP-­‐‑GlcNAc   (111)   illustrates   the   proximity   of   this   head   group   to   the  
anticipated  binding  locale  of  the  3-­‐‑hydroxyl  position  of  the  GlcN  ring  (Fig.  2.12).  
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Figure  2.12:  Comparison  between  the  E.  coli  hydrolysed-­‐‑acyl-­‐‑ACP  complex  and  
LpxD  from  C.  trachomatis  bound  to  UDP-­‐‑GlcNAc  (PDB  2UIA).      (a)  Close-­‐‑up  view  of  
the  binding  of  UDP-­‐‑GlcNAc  (cyan,  colored  by  atom)  in  the  catalytic  cleft  of  LpxD.    The  
position  of  the  UDP-­‐‑GlcNAc  relative  to  the  nucleotide  binding  pocket,  His239,  the  acyl-­‐‑
chains   within   the   N-­‐‑   and   O-­‐‑channels,   and   the   hydrolysed-­‐‑4′-­‐‑PPT   arm   is   shown.      For  
clarity,   the  cartoon  representation  of  CtLpxD  is  not  shown.      (b)  Rotated  view  showing  
the  orientation  of  the  GlcNAc  ring.    A  ~30°  clockwise  rotation  (arrow)  is  needed  for  the  
attachment  sites  of  both  acyl-­‐‑chains   to  properly  align  with   their   respective  carboxylate  
head  groups,  i.e.  the  2-­‐‑  and  3-­‐‑positions  of  GlcNAc.  
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The   holo-­‐‑ACP   structure   revealed   an   alternate   conformation   of   the   prosthetic  
group  (Fig.  2.10c  and  Fig.  2.11c).    Although  a  short  portion  of  the  4′-­‐‑PPT  including  the  4′-­‐‑
phosphate  moiety  overlays  with   the   intact-­‐‑  and  hydrolysed-­‐‑   structures,   the   latter  half  of  
the   pantetheinyl-­‐‑arm   has   moved   considerably   to   pack   against   the   far   end   of   the  N-­‐‑
channel.    Because  of  this  dramatic  change  and  the  absence  of  any  acyl-­‐‑substrate,  only  a  
subset   of   residues  within   the  N-­‐‑channel   provides   surface   contacts  with   the   prosthetic  
group.     Notably,   the  terminal  thiols  among  all  modeled  prosthetic  groups  of  each  holo-­‐‑
ACP  remain  situated  near  Met290,  and  we  believe  that  their  conserved  positioning  has  
functional  importance  (see  below).  
  
2.2.4  ACP-­‐‑partner  communication  
What   is  striking  about  both   the   intact-­‐‑  and  hydrolysed-­‐‑acyl-­‐‑ACP  structures   is   the  
conformational   similarity   between   the   4′-­‐‑PPT   prosthetic   groups,   which   completely  
enclose   the   reaction   chambers   (Fig.   2.13a).     Although   this   architecture   likely   stabilizes  
substrate  binding  within  the  hydrophobic  N-­‐‑channel,   it   raises  a  key  question.     Given  a  
sequential   ordered   reaction  mechanism,   how  does   the  di-­‐‑acylated-­‐‑GlcN  product   leave  
LpxD   prior   to   holo-­‐‑ACP   if   the   reaction   chamber   is   completely   blocked?      A   structural  
comparison   between   intact-­‐‑   and   holo-­‐‑ACP   sheds   light   on   this   matter   by   exposing   a  
substantial  movement  that  the  4′-­‐‑PPT  arm  has  undergone  (Fig.  2.13b).    The  4′-­‐‑PPT  pivots  
about   the   seventh-­‐‑atom  position,   and   consequently,   the   terminal   thiol   has  vacated   the  
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catalytic   cleft   and   moves   ~15   Å   to   be   situated   near   Met290.      Notably,   the   thiol   now  
occupies  the  same  position  as  was  observed  for  the  terminal  carbon-­‐‑atoms  of  β-­‐‑OH-­‐‑C14.    
A   sizable   region   of   the   reaction   chamber   closest   to   the   catalytic   cleft   is   now   open   to  
solvent,  thereby  giving  the  diacyl-­‐‑GlcN  product  an  opportunity  to  dissociate  prior  to  the  
release  of  holo-­‐‑ACP.  
The  remarkable  difference  in  conformation  displayed  by  the  4′-­‐‑PPT  arm  between  
the   intact-­‐‑  and  holo-­‐‑ACP  structures,  together  with  the  ordered  sequential  mechanism  of  
acyl-­‐‑transfer,  prompted  us  to  propose  that  this  ‘swing’  motion  may  in  fact  be  involved  in  
the   release  of   lipid-­‐‑product.      To   confirm   the   role   of  ACP   in   this  process,  we  modified  
LpxD   in   an   attempt   to   trap   the   holo-­‐‑ACP   product   following   catalysis.      Since   every  
terminal   thiol   of   holo-­‐‑ACP   was   positioned   ~3.7   Å   away   from   Met290   of   LpxD,   we  
envisaged  the  possibility  of  mutating   this  residue   to  a  cysteine   in  an  effort   to   induce  a  
mixed-­‐‑disulfide   linkage.      Biochemically,   the   Met290Cys   mutation   abrogated   acyl-­‐‑
transfer   to   UDP-­‐‑acyl-­‐‑GlcN   as   compared   to   wild-­‐‑type   LpxD,   although   the   data   do  
indicate  a   small,   but  measurable   turnover   (Fig.   2.14).     This   is   consistent  with  what  we  
would  expect  with  forming  a  covalent  bond  between  the  cysteinyl  and  4′-­‐‑PPT  thiols.      
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Figure  2.13:  ACP  conformations  and  reorganization  of  its  prosthetic  group.    (a)  
Top-­‐‑down   view   of   LpxD   (intact-­‐‑acyl-­‐‑ACP   depicted)   showing   three   reaction   chambers  
enclosed  by  the  4′-­‐‑PPT.    Molecular  surfaces  are  of  only  those  residues  that  contribute  to  
acyl-­‐‑4′-­‐‑PPT  interactions.    (b)  Structural  comparison  between  the  intact-­‐‑  (green)  and  holo-­‐‑
4′-­‐‑PPT   (red)   prosthetic   groups.      The   4′-­‐‑PPT   rearrangement   is   indicated   (gray   dotted  
arrow).    (c)  Difference  distance  matrix  calculated  between  fully  modeled  intact-­‐‑  (chain  K)  
and  holo-­‐‑ACP  (chain  G).     Deviations  between   like  atoms  are  shown  as  a  putty-­‐‑sausage  
representation.    Both  the  thickness  and  heat-­‐‑map  coloring  indicate  regions  of  least  (thin,  
blue)   to   highest   (thick,   red)   displacement.      (d)   Schematic   summarizing   differences   in  
electrostatic  interactions  between  ACP  complexes.    Residues  are  indicated  as  red  (acidic)  
or  blue  (basic)  circles  and  subdivided  according  to  region  I  or  II  affiliation.    Interactions  
made  by  intact-­‐‑acyl-­‐‑ACP  alone  are  depicted  (dashed  lines)  and  those  common  among  all  
complexes  are  represented  with  an  asterisk.    The  gray  zigzag  indicates  those  electrostatic  
interactions  that  are  broken  in  the  hydrolysed-­‐‑  and  holo-­‐‑ACP  product  complexes.  
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Figure  2.14:  Biochemical  evidence  for  the  role  of  ACP  in  product  release.  Bar 
chart showing the effects of DTT on the in vitro specific activity of wild-type LpxD (wt) or the 
Met290Cys (M290C) LpxD mutant.  The assay mixture contained 40 mM HEPES (pH 7.4), 0.02 
mg/mL BSA, 6 µM β-OH-C14-ACP, and 4 µM [α-32P]-UDP-acyl-GlcN (0.005-0.04 µCi/µL). The 
reaction was initiated by the addition of either 1.4 nM wild-type E. coli LpxD or 4.2 nM 
Met290Cys LpxD enzyme. Compared to wild-type enzyme, the cysteine mutation abrogates 
activity, although the data do indicate a small, but measurable turnover.  The addition of reductant 
to the assay mixture (rescues the Met290Cys mutant, within error, to near wild-type levels of 
activity assayed in the presence or absence of DTT.  
   88  
Owing   to   earlier   work   that   showed   mutation   of   Met290   to   alanine   retained  
activity   (39),   albeit   shifting   chain-­‐‑length   specificity   toward   longer   acyl-­‐‑chains,   we  
reasoned   that   if   Met290Cys-­‐‑LpxD   is   in   fact   bound   to   holo-­‐‑ACP   through   a   mixed-­‐‑
disulfide,  then  the  addition  of  reducing  agent  would  rescue  acyl-­‐‑transfer.    Accordingly,  
titration  of  DTT  into  the  reaction  mixture  recovers  activity  of  Met290Cys-­‐‑LpxD  to  levels  
indistinguishable   from   that   of   wild-­‐‑type   enzyme   also   assayed   in   the   presence   of  
reductant  (Fig.  2.14).    These  data  suggest  the  presence  of  a  post-­‐‑catalytic  mixed-­‐‑disulfide  
bond  formed  between  the  4′-­‐‑PPT  and  cysteine  residue   introduced  at   the   far  end  of   the  
hydrophobic  N-­‐‑channel.    We  postulate  that  following  hydrolysis  of  the  thioester  scissile  
bond,  the  4′-­‐‑PPT  thiolate  moves  from  its   location  near  His239  to  a  position  close  to  the  
‘hydrocarbon-­‐‑ruler’  in  the  course  of  product  release.    Moreover,  as  typically  shown  with  
‘strong,   transient’   interactions   (117)   this   substantial  movement   of   the   pantetheine   arm  
likely   serves   as   the   ‘molecular   trigger’   that   promotes   the   collapse   of   the  ACP-­‐‑partner  
complex.  
Because   our   structures   show  different   states   of  ACP   stalled   at   the  LpxD  active  
site,   an   alignment   of   LpxD   domains   between   them   allows   visualization   of   the  
movements  within  ACP  as   it   relates   to   the  overall   catalytic   cycle   (Fig.   2.13c),  which   to  
the  best  of  our  knowledge  is  unprecedented.    Helix-­‐‑I,  helix-­‐‑II,  and  portions  of  L1  remain  
relatively  unchanged  (RMSD  of  ~1  Å)  and  are  preserved  for  the  purpose  of  docking  with  
LpxD  and  allows  for  the  ‘swing’  motion  of  the  4′-­‐‑PPT  arm.    The  largest  differences  occur  
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downstream   of   the   recognition   helix   (Fig.   2.13c),   including   helices-­‐‑III,   -­‐‑IV,   L2   and   L3  
(RMSD   of   ~3  Å)   and   are   an   indication   of  what   interactions  must   ultimately   break   for  
dissociation.      A   closer   inspection   reveals   that   the   intact-­‐‑complex   makes   electrostatic  
interactions   with   the   entire   ARD   interface   that   involves   region   II,   whereas   both   the  
hydrolysed-­‐‑  and   holo-­‐‑ACP   structures   completely   lack   any   contact  with   this   region   (Fig.  
2.13d).      For   example,   Glu48   interacts   with   Arg329′   through   an   intervening   water  
molecule  and  Glu53  and  Asp56  form  a  salt-­‐‑bridge  with  Lys331′′  and  Lys  328′′  of  LpxD,  
respectively.    The  more  extensive  interactions  observed  with  the  intact-­‐‑complex  provide  
molecular   recognition   that   ‘zippers’   the   two   protein   partners   together   during  
association.     Moreover,   these  data   indicate   that   following   acyl-­‐‑transfer,   the   substantial  
movement   of   pantetheinyl   group   ‘triggers’   both   helix-­‐‑III   and   L2   to   undergo   a  
conformational   change   that   cause   residue   interactions   within   region   II   to   break,  
ultimately   destabilizing   the   protein–protein   complex.      In   this   context,   one   particular  
molecule   of   holo-­‐‑ACP   is   displaced   from   the   others   and   possibly   represents   a   different  
binding   state   (Fig.   2.15).   Consequently,   Ser36   and   the   4′-­‐‑phosphate   of   its   pantetheine  
group   have   moved   by   nearly   5   Å   in   the   direction   away   from   LpxD,   breaking   key  
interactions  with  Asn310  and  Arg314.    Because  holo-­‐‑ACP  should  be  leaving  LpxD  at  this  
point   in   the   sequential   ordered   reaction,   these   structural   differences   reveal   additional  
interactions  that  must  break  leading  to  ACP-­‐‑partner  dissociation.  
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Figure   2.15:   Structural   differences   between   molecules   of   holo-­‐‑ACP.  The 
superimposed holo-ACPs are colored light (chain I) or dark green (chain K) and their 4′-PPT 
groups are colored salmon or red, respectively.  All four helices have displaced from one another. 
The 4′-PPT group (chain I) shifts by ~5 Å and splays apart from chain K (inset, rotated 90°).  The 
terminal thiols remain affixed at the far end of the N-channel near Met290, identical to the other 
molecules of holo-ACP.   
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2.3 Discussion 
The   crystal   structures   presented   in   this   chapter   represent   the   first   to   have  
captured   several   stalled   complexes   of  ACP  along   its   acyl-­‐‑delivery   reaction   coordinate:  
intact-­‐‑acyl-­‐‑ACP,  hydrolysed-­‐‑acyl-­‐‑ACP,  and  holo-­‐‑ACP.     On   the  basis  of   these  structures,  a  
model   is   presented   for  ACP-­‐‑based   synthesis   of   lipid  A   precursors   catalyzed   by   LpxD  
(Fig.  2.16).      (i)  β-­‐‑OH-­‐‑C14  acyl-­‐‑intermediates  are  shuttled  by  ACP  to  LpxD,  although   the  
mechanism  for  extracting  the  β-­‐‑OH-­‐‑C14  from  within  the  core  of  ACP  is  not  known.      (ii)  
Acyl-­‐‑ACP  is   the  first   to  bind  LpxD  in  the  bi-­‐‑substrate  reaction  and  does  so  with  rather  
high   affinity   (110).      The   extensive   interactions   at   the   interface   explain   the   ‘strong,  
transient’  nature  of  these  protein  partners,  which  not  only  involve  residues  that  extend  
the  length  of  ACP,  but  also  the  entire  4′-­‐‑PPT  prosthetic  group.    The  structures  presented  
here  have  revealed  that  LpxD  is  capable  of  binding  three  molecules  of  the  carrier-­‐‑protein  
at  a  time,  yet  it  is  not  clear  whether  this  is  required  to  reach  its  highest  level  of  activity.    
The  interfacial  contacts  made  by  helices-­‐‑II  and  –III  as  well  as  nearby  loop  regions  of  ACP  
play   a  major   role   in   docking   the   carrier-­‐‑protein   securely   to   the   newly   identified  ARD  
domain.    This  properly  orients  ACP  to  deliver  its  acyl-­‐‑4′-­‐‑PPT,  which  adopts  an  unusual  
horseshoe-­‐‑like  conformation  within   the  catalytic  cleft.     Packing  of   the   terminal  carbon-­‐‑
atoms  and  β-­‐‑hydroxyl   substituent  provides   the   correct   register   of   the   thioester   scissile  
bond  relative  to  His239.    The  4′-­‐‑PPT  serves  an  important  role  in  this  process,  providing  
an  enclosure   for   each   reaction  chamber.   (iii)  UDP-­‐‑acyl-­‐‑GlcN  binds  next   in   the  ordered  
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sequential   reaction   with   the   β-­‐‑OH-­‐‑C14   substituent   carried   from   the   lipid   substrate  
packing  into  the  O-­‐‑channel  located  on  one  side  of  the  4′-­‐‑PPT  arm.    (iv)  Following  acyl-­‐‑
transfer  the  liberated  pantetheinyl-­‐‑arm  remains  fully  extended  and  sandwiched  between  
both   lipid   acyl-­‐‑chains.      However,   this   organization   completely   occludes   any   obvious  
path   for   the   di-­‐‑acyl-­‐‑GlcN   product   to   leave   prior   to   holo-­‐‑ACP.   We   postulate   that   the  
substantial  rearrangement  observed  by  the  holo-­‐‑ACP  pantetheinyl-­‐‑arm  is  the  ‘molecular  
trigger’   that   initiates   the  release  of   lipid  product  and  is   followed  by  the  collapse  of   the  
protein–protein  complex.    Relocating  the  terminal  thiol  in  proximity  of  Met290  at  the  far  
end  of  the  N-­‐‑channel,  unblocks  the  active  site  chamber  enabling  the  (v)  release  of  UDP-­‐‑
diacyl-­‐‑GlcN;  thus,  providing  the  essential  building  blocks  for  synthesis  of  the  Kdo2-­‐‑lipid  
A   anchor   of   LPS.      (vi)   Finally,   the   movement   of   the   4′-­‐‑PPT   initiates   conformational  
changes  within   helix-­‐‑III   and   L2   that   destabilize   region   II   of  ACP,   ultimately   breaking  
interactions  within  region  I  that  lead  to  the  dissociation  of  holo-­‐‑ACP.  
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Figure   2.16:   Molecular   basis   for   the   ordered-­‐‑sequential   reaction   mechanism  
and  involvement  of  ACP  in  lipid-­‐‑product  release.    Acyl-­‐‑ACP  binds  first  (i)  to  free  LpxD  
forming   the   (ii)   binary   complex.      ACP   associates   with   the   ARD   and   the   acyl-­‐‑4′-­‐‑PPT  
packs   into   the  hydrophobic  N-­‐‑channel,   thus   (iii)   enabling  UDP-­‐‑acyl-­‐‑GlcN   to  bind  next  
and   initiate   acyl-­‐‑transfer.      In   the   ternary   product   complex   (iv)   the   4′-­‐‑PPT   arm   of  
hydrolysed-­‐‑acyl-­‐‑ACP   (transparent   orange   squiggle)   completely   encloses   the   reaction  
chamber,  blocking  UDP-­‐‑diacyl-­‐‑GlcN  from   leaving.     By  moving   toward  Met290   (dotted  
arrow),  the  4′-­‐‑PPT  (dark  orange  squiggle)  drives  the  (v)  eventual  release  of  UDP-­‐‑diacyl-­‐‑
GlcN   by   opening   up   the   catalytic   chamber.      This   motion   also   ‘triggers’   (vi)  
conformational  changes  downstream  of  helix-­‐‑II  leading  to  holo-­‐‑ACP  dissociation.  
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The   structures   captured   in   this   study   begin   to   establish   key   molecular  
movements  within  ACP  that  initiate  molecular  recognition  and  a  mechanism  with  which  
associations   can   be   ultimately   broken.      In   this   context,   we   can   extract   some   general  
principles  for  these  types  of  interactions.    First,  although  there  does  not  yet  appear  to  be  
a   consensus-­‐‑sequence   binding  motif   on   the   surface   of   partner   proteins,   both   regions   I  
and  II  of  ACP  seem  to  be  frequently  involved,  with  the  majority  of  the  small  number  of  
other   ACP-­‐‑based   complexes   determined   revealing   that   helix-­‐‑II,   -­‐‑III,   L1   and   L2   are  
consistently   utilized   (86,   87,   121,   123).      Second,   because   these   regions   are   broadly  
universal,  exploiting  specific  residue  contacts  at  the  interface  and  fine-­‐‑tuning  the  buried  
surface   area   at   these   regions   likely   dictate   how   ACP-­‐‑based   associations   can   be   both  
specific  and  temporary.     For   instance,  our  structures  reveal  the  first  direct,  electrostatic  
coordination   with   the   4′-­‐‑phosphate   of   both   acyl-­‐‑   and   holo-­‐‑ACP,   which   in   addition   to  
extensive   protein–protein   contacts   provide   the   ‘strong,   transient’   nature   of   the   ACP-­‐‑
LpxD   complex.      Third,   because   we   observe   ACP   tied   to   an   entire   catalytic   cycle,   a  
substantial  conformational  change  downstream  of  the  recognition  helix-­‐‑II  may  represent  
a   more   general   communication   mechanism   for   breaking   ACP-­‐‑partner   complexes.    
Finally,   the   stalled   ACPs   captured   herein   have   revealed   an   unprecedented   role   for  
carrier-­‐‑proteins   in   product   release   and   the   contribution   of   the   pantetheinyl   group   in  
both  the  formation  and  dissociation  of  the  ACP-­‐‑partner  complex.    Perhaps  motion  of  the  
pantetheinyl   group   in   other   ACP-­‐‑based   complexes   provokes   dissociation   in   a   similar  
manner,  especially  when  considering  other  ‘strong,  transient’  protein  partners.  
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2.4 Methods 
2.4.1  Expression  and  purification  of  His6-­‐‑LpxD  
E.   coli   LpxD   was   over-­‐‑expressed,   and   purified   as   previously   reported   (110).  
Briefly,  His6-­‐‑LpxD  was  expressed   in  E.  coli  Rosetta/pLysS.  The  membrane-­‐‑free   fraction  
was  loaded  onto  a  5  mL  Ni-­‐‑NTA  (Qiagen,  CA)  column  and  eluted  in  one  step  with  200  
mM  imidazole.  The  His6-­‐‑tag  was  left  intact  and  the  resulting  LpxD  was  concentrated  to  
~4-­‐‑10  mL  and   loaded  onto  a  High  Load  26/60  Superdex  200  gel   filtration   column   (GE,  
NJ)   equilibrated  with   10  mM   Tris-­‐‑HCl   (pH   7.5),   500  mM  NaCl,   and   1  mM  DTT.   The  
protein   peak   had   an   elution   profile   consistent   with   that   of   the   LpxD   homotrimer.  
Fractions  were  pooled  and  concentrated  to  ~40  mg  mL-­‐‑1  and  stored  in  aliquots  at  −80  ˚C.  
The  wild-­‐‑type  LpxD  enzyme  utilized  in  the  LpxD  assay  was  purified  and  stored  in  the  
absence  of  DTT.  
  
2.4.2  Construction,  expression  and  purification  of  His6-­‐‑LpxD  point  mutants  
Site-­‐‑directed   mutants   designed   to   alter   Met290   (Met290Cys),   and   His239  
(His239Ala)  were  accomplished  using  the  QuikChange  PCR  mutagenesis  kit  (Stratagene,  
CA).   The   LpxD   variants  were   recombinantly   expressed   in   C41(DE3)  E.   coli   (124)   cells  
and  purified  in  the  same  manner  as  described  for  wild-­‐‑type  His6-­‐‑LpxD.  The  His239Ala  
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LpxD  was   stored   in   10  mM   Tris-­‐‑HCl   (pH   7.5),   500  mM  NaCl,   and   1  mM   TCEP,   and  
Met290Cys  LpxD  was  purified  and  stored  in  the  absence  of  a  reductant.  
  
2.4.3  LpxD  lipid  substrate  preparation    
LpxD   radioactive   substrate   [α-­‐‑32P]-­‐‑UDP-­‐‑3-­‐‑acylGlcN  was   synthesized   according  
to  established  methods  with  minor  modifications  (36).  Briefly,  a  typical  62.5  µμL  reaction  
mixture   containing   25   µμl   of   [α-­‐‑32P]-­‐‑UTP   (800   Ci   mmol-­‐‑1,   PerkinElmer,   MA),   0.5   mM  
glucosamine-­‐‑1-­‐‑phosphate,   1   mM  MgCl2,   5   mM  DTT,   100  mM   Tris-­‐‑HCl   (pH   8.0),   12.5  
units   of   inorganic   pyrophosphatase,   and   3.13   units   of   UDP-­‐‑glucose   pyrophosphatase  
was   incubated  at   room   temperature   for   1  hour   to  generate   [α-­‐‑32P]-­‐‑UDP-­‐‑GlcN.     The  N-­‐‑
acetylation   of   the   product  was   initiated   by   adding   63   µμL  H2O,   75   µμL  methanol,   5   µμL  
saturated   sodium  bicarbonate,   and  2.0  µμL  acetic   anhydride   to   the  mixture.   20  minutes  
later,  H2O  was  added  to  the  mixture  to  adjust  the  volume  to  1.75  ml.  Subsequently,  the  
reaction   was   loaded   onto   a   1   ml   DEAE-­‐‑Sepharose   column   equilibrated   with   10   mM  
triethylammonium  bicarbonate  (TEAB,  pH  8.5).  After  washing  the  column  with  10  ml  of  
H2O,   [α-­‐‑32P]-­‐‑UDP-­‐‑GlcNAc  was   eluted   in   1   ml   fractions   by   applying   8   ml   of   100  mM  
TEAB  (pH  8.5)  to  the  column.  The  relevant  eluted  fractions  were  dried  under  a  vacuum  
in  a  Speed-­‐‑Vac  centrifuge  and  redissolved  in  250  µμL  H2O.    
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In   order   to   synthesize   high   specific   radioactivity   [α-­‐‑32P]-­‐‑UDP-­‐‑3-­‐‑acyl-­‐‑GlcN,   0.1  
µμM  [α-­‐‑32P]-­‐‑UDP-­‐‑GlcNAc  (100  µμCi  mL-­‐‑1)  and  1.3  µμM  β-­‐‑OH-­‐‑C14-­‐‑ACP  were  reacted  for  15  
minutes  at  30  ˚C  in  a  mixture  that  contained  40  mM  HEPES  (pH  8.0),  1  mg  mL-­‐‑1  bovine  
serum  albumin  (BSA),  0.03  mg  mL-­‐‑1  purified  E.  coli  His6-­‐‑LpxA,  and  100  µμg  mL-­‐‑1  purified  
E.   coli   LpxC.   The   low   specific   radioactivity   substrate   was   synthesized   in   a   similar  
manner  by  mixing  100  µμM  [α-­‐‑32P]-­‐‑UDP-­‐‑GlcNAc  (2  µμCi  mL-­‐‑1)  with  50  µμM  β-­‐‑OH-­‐‑C14-­‐‑ACP  
for  30  minutes.    
Using   a   combination   of  DEAE-­‐‑Sepharose   and  C18   Sep-­‐‑Pak   columns   the   [α-­‐‑32P]-­‐‑
UDP-­‐‑3-­‐‑acyl-­‐‑GlcN  substrate  was  isolated.  The  DEAE-­‐‑Sepharose  column  was  pre-­‐‑washed  
serially   with   5   mL   of   1   M   Bis-­‐‑Tris   (pH   6.0),   3   mL   of   50   mM   Bis-­‐‑Tris   (pH   6.0)  
supplemented  with   1  M  NaCl,   and   4  ml   of   10  mM  Bis-­‐‑Tris   (pH  6.0).  One  C18   Sep-­‐‑Pak  
column,   pre-­‐‑washed   sequentially   with   10   mL   of   acetonitrile   and   20   mL   of   H2O,   was  
attached   to   the   bottom   of   the   DEAE-­‐‑Sepharose   column.   The   reaction   mixture   was  
diluted   to   2   mL   with   H2O   and   loaded   onto   the   columns.   After   washing   both   of   the  
columns  with  0.2  M  NaCl,  the  Sep-­‐‑Pak  column  was  detached  and  washed  with  20  mL  of  
H2O.  The  [α-­‐‑32P]-­‐‑UDP-­‐‑3-­‐‑acyl-­‐‑GlcN  substrate  was  eluted  from  the  Sep-­‐‑Pak  column  in  0.5  
mL  fractions  with  5  mL  of  50%  acetonitrile.  The  fractions  containing  the  lipid  substrate  
were   lyophilized,  redissolved   in  150  µμL  Bis-­‐‑Tris   (pH  6.0),  and  stored   in  aliquots  at  –20  
˚C.    
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Using   a   liquid   scintillation   counter   the   concentration   of   the   low   specific  
radioactivity   substrate,   [α-­‐‑32P]-­‐‑UDP-­‐‑3-­‐‑acyl-­‐‑GlcN,   was   measured   by   comparing   its  
specific  radioactivity  to  that  of  the  starting  material,  [α-­‐‑32P]-­‐‑UDP-­‐‑GlcNAc.  
  
2.4.4  In  vitro  assay  of  LpxD  
The   LpxD   catalyzed   conversion   of      [α-­‐‑32P]-­‐‑UDP-­‐‑3-­‐‑acylGlcN   to   [α-­‐‑32P]-­‐‑UDP-­‐‑2,3-­‐‑
diacylGlcN  was  monitored    by  thin  layer  chromatography  (TLC)  as  previously  reported  
(36).  The  20  µμL  assay  mixture  containing  40  mM  HEPES  (pH  7.4),  0.02  mg  mL-­‐‑1  BSA,  1.4  
nM  pure  wild-­‐‑type  E.  coli  LpxD  (or  4.2  nM  Met290Cys  LpxD),  6  µμM  β-­‐‑OH-­‐‑C14-­‐‑ACP,  and  
4   µμM   [α-­‐‑32P]-­‐‑UDP-­‐‑3-­‐‑acyl-­‐‑GlcN   (0.005-­‐‑0.04   µμCi/µμL)   was   equilibrated   at   30   ˚C,   and   the  
reaction  was  initiated  by  the  addition  of  the  enzyme.  DTT  (100  mM)  was  added  to  assess  
its   effect   on   the   catalysis   of   the  wild-­‐‑type   and   the  mutant   LpxD.   1   µμL   of   the   reaction  
mixture  was   spotted   onto   a   silica   gel   60   plate   (EMD  Chemicals,   Germany)   at   various  
time-­‐‑points.   After   drying   under   a   cold   air   stream,   plates   were   developed   with   a  
chloroform/methanol/water/acetic  acid  solvent  (25:15:4:2,  v:v:v:v).  The  plates  were  dried  
and   exposed   overnight   to   a   Molecular   Dynamics   PhosphorImager   Screen.   The  
conversion   rate   of   the   lipid   substrate   to   product   was   measured   using   ImageQuant  
software.  
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2.4.5  Expression  and  purification  of  holo-­‐‑ACP    
The  acp  gene  was  amplified  from  E.  coli  W3110A  genomic  DNA  using  the  ACP-­‐‑
forward   and  ACP-­‐‑reverse   primers   (Table   2.2)   engineered   to   introduce   downstream   of  
the   ACP   coding   region   a   spacer   sequence,   a   ribosome   binding   site,   followed   by   a  
translation   spacer   element   (denoted   PCR   product   A).   The   ACPS-­‐‑forward   and   ACPS-­‐‑
reverse  primers  (Table  2.2)  were  used  to  amplify  acps  gene  from  W3110A  genomic  DNA,  
which   contained   a   spacer   sequence,   a   ribosome   binding   site,   and   a   translation   spacer  
element   upstream   of   the   ACPS   coding   region   (denoted   PCR   product   B).   The   ACP-­‐‑
forward  and  ACPS-­‐‑reverse  primers  were  subsequently  used  to  generate  PCR  product  C,  
which  contained  acp  and  acps  genes  separated  by  the  spacer  sequence,  ribosome  binding  
site,   and   the   translation   spacer   element.   PCR   product   C   was   cloned   into   a   pET16b*  
vector,  which  contained  an  engineered   tobacco  etch  virus   (TEV)  protease  cleavage  site  
instead  of  Factor  Xa,  using   the  NdeI   and  XhoI  restriction   sites.  E.   coli  DH5α  competent  
cells   (Invitrogen,  CA)  were  subsequently   transformed  with  plasmid  and   transformants  
were  selected  at  37  ˚C  on  a  LB-­‐‑agar  plate  supplemented  with  100  µμg  mL-­‐‑1  ampicillin.  The  
sequence   of   the   plasmid   encoding   the   N-­‐‑terminally   histidine-­‐‑tagged   ACP   and   non-­‐‑
tagged  ACPS  (pET16b*-­‐‑AM)  was  confirmed  by  DNA  sequencing.  
ACP  and  ACPS  were  co-­‐‑expressed  using  the  pET16b*-­‐‑AM  vector  in  C41(DE3)  E.  
coli  cells  (124)  and  cultured  at  37  ˚C  in  1  L  of  LB  broth  supplemented  with  100  µμg  mL-­‐‑1  
ampicillin.  Upon  reaching  an  OD600  of  0.6  the  expression  was  induced  for  6  hours  with  1  
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mM   isopropyl-­‐‑β-­‐‑D-­‐‑thiogalactopyranoside   (IPTG)   at   30   ˚C.   All   the   subsequent  
procedures  were  carried  out  at  4  ˚C.  The  cells  were  harvested,  washed,  resuspended  and  
lysed  in  20  mM  HEPES,  pH  8.0  containing  10%  glycerol,  200  mM  NaCl,  and  2  mM  DTT  
(Buffer   A),   supplemented   with   20   mM   imidazole.   After   removal   of   cell   debris   by  
centrifugation  at  100,000  x  g  for  1  hour,  the  soluble  fraction  was  loaded  onto  a  Ni-­‐‑NTA  
(Qiagen,   CA)   column   equilibrated  with   Buffer  A   and   20  mM   imidazole.   The  Ni-­‐‑NTA  
column  was  washed  with  10  column-­‐‑volumes  and  His10-­‐‑ACP  was  eluted  in  one  step  by  
Buffer   A   supplemented   with   250   mM   imidazole   over   the   equivalent   of   5   column-­‐‑
volumes.  Although  ACPS  was  not  histidine-­‐‑tagged,   it   co-­‐‑purified  with  His10-­‐‑ACP.  The  
elution  fraction  was  allowed  to  slowly  rock  with  1  mg  of  TEV  protease  and  2  mM  EDTA  
overnight.  Subsequently,  the  protein  mixture  was  dialyzed  against  20  mM  MES,  pH  6.0,  
and  2  mM  DTT  overnight.  The  TEV  protease  and  residual  His10-­‐‑ACP  were  removed  by  
passing   the   mixture   through   a   2   mL   Ni-­‐‑NTA   column.   The   resulting   flow-­‐‑through  
fraction   containing  ACP  was   loaded  onto   a   5  mL  QFF   ion   exchange   column   (GE,  NJ).  
ACP  eluted  separately  from  ACPS  by  applying  a  linear  gradient  of  20  mM  MES,  pH  6.0,  
0-­‐‑500  mM  NaCl,  and  2  mM  DTT  over  50  column-­‐‑volumes.  The  fractions  corresponding  
to  ACP  were  pooled   together  and  dialyzed  against  100  mM  Tris-­‐‑HCl,  pH  7.1,  and  200  
mM   NaCl   (Buffer   B)   overnight.   Holo-­‐‑ACP   was   separated   from   residual   apo-­‐‑ACP  
(inactive  form)  by  mixing  the  ACP  sample  with  5  mL  of  Thiopropyl  Sepharose  6b  resin  
(Sigma-­‐‑Aldrich,   MO)   overnight.  Apo-­‐‑ACP,   which   lacks   any   free   thiol   group,   did   not  
bind   to   the   resin,  whereas,   holo-­‐‑ACP   covalently   attached   to   the   resin   via   the   terminal  
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thiol  group  of  its  phosphopantetheine  moiety.  After  washing  the  Thiopropyl  Sepharose  
6b  with  25  mL  of  Buffer  B,  holo-­‐‑ACP  was  eluted  in  25  mL  of  Buffer  B  supplemented  with  
25   mM   DTT.   The   complete   removal   of   apo-­‐‑ACP   was   confirmed   by   electrospray  
ionization  mass   spectrometry.   The   elution   fraction  was   concentrated   to   ~4-­‐‑10  mL   and  
loaded   on   a  High  Load   26/60   Superdex   200   gel   filtration   column   equilibrated  with   10  
mM  Tris-­‐‑HCl,  pH7.5,  200  mM  NaCl,  and  2  mM  DTT.  The  relevant  eluted  fractions  were  
concentrated  to  ~20  mg  mL-­‐‑1  and  stored  in  aliquots  at  −80  ˚C.  
Table  2.2:  Summary  of  primer  sequences  used  in  molecular  cloning.  
Name   Sequences  
ACP  Forward   5′-­‐‑GCGCGCGCCATATGAGCACTATCGAAGAACGC-­‐‑3′  
ACP  Reverse     5′-­‐‑TTTAAATTCTCCTTCCCGGGCCCGGTCACGCCTGGTGGCCGTT-­‐‑3′  
ACPS  Forward   5′-­‐‑CCGGGCCCGGGAAGGAGAATTTAAAATGGCAATCTTAGGTTTAGGC-­‐‑3′  
ACPS  Reverse     5′-­‐‑GCGCGCGCCTCGAGTCAACTTTCAATAATTACCGT-­‐‑3′  
   The underlined letters indicate the restriction sites for NdeI and XhoI endonucleases. The 
bold letters indicate the sequence of the template gene. The green and blue letters show the 
sequence of the translation spacer element and ribosome binding site, respectively. Orange letters 
represent the spacer sequence. 
  
2.4.6  Production  of  β-­‐‑OH-­‐‑C14-­‐‑ACP  
Holo-­‐‑ACP  was  charged  enzymatically  with  R-­‐‑3-­‐‑hydroxymyristic  acid  (Santa  Cruz  
Biotechnology,  Inc.)  by  soluble  acyl-­‐‑ACP  synthetase  from  Vibrio  harveyi  (125).  The  soluble  
acyl-­‐‑ACP   synthetase   (aasS)   gene   was   synthesized   by   GenScript.      The   aasS   gene   was  
subcloned   into   pET-­‐‑16b   expression   vector,   overexpressed,   and   the   His6-­‐‑AasS   was  
purified   using   nickel   affinity   chromatography   as   reported   by   Jiang   et   al.   (125).   To  
generate  β-­‐‑OH-­‐‑C14-­‐‑ACP,   0.1  mM  of  holo-­‐‑ACP  was  mixed  with   0.001  mM  AasS   and   0.3  
   102  
mM  of  the  fatty  acid  (β-­‐‑OH-­‐‑C14)  at  room  temperature  for  3  hours  in  a  buffer  containing  
100  mM  Tris-­‐‑HCl,  pH  7.8,  10  mM  ATP,  and  10  mM  MgCl2.  To  separate  acyl-­‐‑ACP  from  
AasS,   the   reaction   mixture   was   loaded   onto   a   High   Load   26/60   Superdex   200   gel  
filtration   column   equilibrated   with   10   mM   Tris-­‐‑HCl,   pH7.5,   and   200   mM   NaCl.   The  
complete  conversion  of  holo-­‐‑ACP  to  β-­‐‑OH-­‐‑C14-­‐‑ACP  was  confirmed  by  both  electrospray  
ionization   mass   spectrometry   and   2.5   M   urea   (19%)   polyacrylamide   (pH   9.5)   gel  
electrophoresis  (126).  
  
2.4.7  Crystallization  and  structure  determination  
Prior   to   crystallization,   either   acyl-­‐‑ACP   or   holo-­‐‑ACP  was  mixed  with   the  wild-­‐‑
type   or   the   catalytically   inactive   His239Ala   LpxD   in   order   to   preform   the   protein–
protein   complex.   Initial   crystallization   hits   were   identified   by   screening   each   protein  
complex   against   the  Protein  Complex  Suite   (Qiagen,  CA)  using   the   sitting-­‐‑drop  vapor  
diffusion   method.      Crystals   of   holo-­‐‑ACP-­‐‑LpxD   were   grown   at   15   ˚C   by   mixing   the  
protein  solution  with  the  precipitant  (0.1  M  MES  pH  6.0,  0.2  M  lithium  sulfate,  20%  PEG  
4000)  in  ratios  of  1:1  and  1:1.5.    Crystals  achieved  full  size  in  approximately  45  days.    The  
crystals  were  transferred  to  a  cryo-­‐‑solution  using  a  50:50  ratio  of  paratone  to  mineral  oil  
and  immediately  cryo-­‐‑cooled  to  −180  ˚C   in   liquid  nitrogen.     Hydrolysed-­‐‑acyl-­‐‑ACP-­‐‑LpxD  
crystals   were   obtained   by   equilibrating   the   protein   mixture   against   a   well   solution  
containing  0.1  M  MES  pH  6.5,  0.2  M  ammonium  sulfate,  20%  PEG  8000  and  incubating  
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at   15   ˚C.   The   crystals   were   harvested   on   day   10   and   cryo-­‐‑cooled   using   a   solution  
containing   ammonium   sulfate,   33%  PEG   8000,   5  mM  Tris-­‐‑HCl   pH   7.5,   190  mM  NaCl,  
and  20%  of  the  cryoprotectant  ethylene  glycol.  In  order  to  trap  the  intact-­‐‑acyl-­‐‑ACP-­‐‑LpxD  
complex  the  His239Ala-­‐‑LpxD  mutant  was  purified  in  the  presence  of  the  reducing  agent  
TCEP   instead   of   DTT   in   an   attempt   to   reduce   hydrolysis   of   the   thioester   bond.  
His239Ala-­‐‑LpxD   and   acyl-­‐‑ACP   were   premixed   using   a   1:1   molar   ratio   prior   to  
crystallization   trials.      The  well   solution   and   the   cryoprotectant  were   the   same   as   that  
described   for   the   hydrolysed-­‐‑acyl-­‐‑ACP   structure,   however,   a   ratio   of   1.5:1   of   protein   to  
well  solution  was  required.  
The  diffraction  data  were  collected  on  the  SER-­‐‑CAT  22-­‐‑BM  and  22-­‐‑ID  beamlines  
at   the   Advanced   Photon   Source   (APS)   at   Argonne   National   Laboratory.   Data   were  
processed  using  the  HKL2000  (127)  software  suite  (Table  2.1).  Although  the  data  for  both  
intact-­‐‑   and   holo-­‐‑ACP   complexes   were   processed   to   2.1   and   2.13   Å,   respectively,   the  
hydrolysed-­‐‑acyl-­‐‑ACP  complex  was  trimmed  to  2.9  Å  due  to  the  data  completeness  being  
unsatisfactory   in  higher  resolution  bins,   i.e.  well  below  70%.     This   resulted   in  a  higher  
signal  to  noise  ratio  in  the  2.9  Å  resolution  bin  as  well  as  a  much  lower  Rmerge  value.  
Even   though   360   degrees   of   data   were   collected,   the   most   likely   cause   for   this  
phenomenon   is   the   combination   of   an   unfortunate   crystal   mount   orientation   with  
respect  to  the  incident  X-­‐‑ray  beam,  the  quality/hardiness  of  the  crystal,  and  the  fact  that  
the  complex  crystallized  in  the  P1,  triclinic  space  group.  The  structures  were  solved  by  
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the   molecular   replacement   method   using   the   program   PHASER   within   the   PHENIX  
software   suite   (128,   129)   and   the   previously   determined   E.   coli   LpxD   structure   (PDB  
code:   3EH0)  as   the   search  model.     Two   trimers  of  LpxD  were  observed   in   the   triclinic  
unit  cell  for  the  intact-­‐‑acyl-­‐‑ACP,  hydrolysed-­‐‑acyl-­‐‑ACP,  and  holo-­‐‑ACP  co-­‐‑crystal  structures.    
In  each  case,  however,  ACP  was  intentionally  omitted  during  the  molecular  replacement  
process,  and   instead  was  manually   rebuilt   into  unbiased,   contiguous  Fo  –  Fc  difference  
electron  density  by   first   rigid-­‐‑fitting   the  E.   coli   apo-­‐‑ACP   coordinates   (PDB   code:   1T8K)  
(130)  into  the  resulting  maps.    The  models  were  rebuilt  using  COOT  (131)  and  iterative  
structure   refinement  with   restrained   and   TLS   options  was   carried   out   using   PHENIX  
(128).   For   the   lower   resolution  hydrolysed-­‐‑acyl-­‐‑ACP  structure  hydrogens  were   included  
for  refinement  with  automated  optimization  of  X-­‐‑ray/stereochemistry  and  ADP  weights  
selected.   Additionally,   we   utilized   the   high   resolution  E.   coli   apo-­‐‑ACP   structure   (PDB  
code:  1T8K)  as  a  reference  model.  The  molecular  coordinates  and  restraints  of  the  4′-­‐‑PPT,  
β-­‐‑OH-­‐‑C14  -­‐‑4′-­‐‑PPT,  and  free  β-­‐‑OH-­‐‑C14  fatty  acid  ligands  were  generated  by  using  either  the  
Dundee   PRODRG2   Server   (132)   or   PHENIX   Elbow   (128).      Composite   omit   map   and  
simulated   annealing   omit   map   calculations   were   conducted   using   CNS   (133).      The  
protein-­‐‑ligand  interactions  were  identified  by  AREAIMOL  calculations  within  the  CCP4  
suite   (134).   The   quality   of   the   final  models  was   validated   using  MOLPROBITY   (135).    
The   data   statistics   are   reported   in   Table   2.1.     Molecular   figures  were   generated   using  
PyMOL  (136).    
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A  total  of  six  ACP  molecules  were  present   in  the   intact-­‐‑acyl-­‐‑ACP  structure  (Fig.  
2.4).   Both   the   hydrolysed-­‐‑   and   holo-­‐‑ACP   structures   exhibited   partially   bound   states   of  
ACP   within   two   or   three   LpxD   active   sites   as   interpreted   by   the   lack   of   contiguous  
electron  density   for   the  majority   of   the  ACP  backbone.     As   a   result,   only   a  portion   of  
ACP   that   includes   Ser36   and   its   4′-­‐‑PPT   prosthetic   group   were   included   in   the   final  
model:  (i)  hydrolysed-­‐‑acyl-­‐‑ACP,  residues  35-­‐‑44  of  chain  L,  residues  6-­‐‑15,  27-­‐‑53,  and  62-­‐‑73  
of   chain   I,   residues  1-­‐‑15  and  27-­‐‑73  of   chain  G,   (ii)  holo-­‐‑ACP,   residues  35-­‐‑44  of   chain  H  
and  chain  L.    The  remaining  LpxD  active  sites  in  the  hydrolysed-­‐‑  and  holo-­‐‑ACP  structures  
contain  fully  modeled  ACPs.    In  all  three  co-­‐‑crystal  structures,  the  electron  density  maps  
indicated   that   the  N-­‐‑terminal  methionine   of  ACP  was  present   and   forms   a   key   lattice  
contact  with  neighboring  molecules  of  LpxD.     Two  additional  residues  (Ser-­‐‑His)   in   the  
holo-­‐‑ACP  structure  that  remain  from  the  TEV  cleavage  site  could  also  be  modeled.  
The   observed   electron   density   for   fully   modeled   intact-­‐‑,   hydrolysed-­‐‑,   and   holo-­‐‑
ACPs  were  weaker  in  some  regions  especially  on  the  backside  of  the  molecule  that  faces  
solvent.      This   implicates   conformational   heterogeneity   throughout   the   lattice.    
Nonetheless,   in   all   three   co-­‐‑crystal   structures   electron   density   was   apparent   in   every  
active   site   for   all   atoms   of   the   4′-­‐‑PPT  group.      In   both   the   intact-­‐‑   and  hydrolysed-­‐‑forms,  
pronounced  electron  density  was  also  present  for  the  β-­‐‑OH-­‐‑C14  acyl-­‐‑chains  located  in  the  
N-­‐‑channel.    In  addition,  electron  density  indicated  that  the  hydrolysed-­‐‑acyl-­‐‑ACP  complex  
included  two  additional  molecules  of  β-­‐‑OH-­‐‑C14  fatty  acid  bound  to   the  hydrophobic  O-­‐‑
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channel,  although  the  density  was  weaker  toward  the  terminal  carbon-­‐‑atoms  of  the  acyl-­‐‑
chains.    To  investigate  the  origin  of  this  second  fatty  acid,  we  mixed  acyl-­‐‑ACP  (12.86  mg  
mL-­‐‑1)  in  a  1:2.25  v:v  ratio  with  wild-­‐‑type  LpxD  (26.38  mg  mL-­‐‑1)  pre-­‐‑incubated  with  1  mM  
DTT   in  a   solution   that  was   consistent  with   the   condition  used   for   crystallization.     The  
protein  solution  was  incubated  at  15  ˚C,  and  aliquots  were  taken  at  different  time  points  
and  stored  at    –80  ˚C.    Samples  were  run  on  a  2.5  M  urea  (19%)  polyacrylamide  (pH  9.5)  
gel   (126),   which   revealed   that   both   DTT   (a   known   phenomenon   (137))   and   LpxD  
enhance  the  cleavage  of  the  thioester  bond  of  acyl-­‐‑ACP  (Fig.  2.7).    This  observation  most  
likely  explains  why  free  β-­‐‑OH-­‐‑C14  fatty  acid  was  available  to  bind  the  O-­‐‑channel  of  LpxD.  
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Chapter 3. Crystal Structure of O-acyltransferase of 
Lipid A Biosynthesis Bound to Acyl-Carrier-Protein 
3.1 Introduction  
The   characteristic   outer  membrane  of  Gram-­‐‑negative  bacteria   is   an   asymmetric  
bilayer   composed   of   phospholipids   and   lipopolysaccharides   (LPS)   that   shield   bacteria  
from   noxious   compounds   (e.g.   antibiotic   and   detergents)   (138).   The   oligosaccharide  
portion   of   LPS   is   anchored   into   the   outer   membrane   by   an   essential   hexa-­‐‑acylated  
glucosamine-­‐‑based   saccharolipid   known   as   lipid   A   (endotoxin)   (5,   138).   During  
infection,   lipid  A  stimulates   the  mammalian  host   innate   immune  system  by  binding  to  
the  toll-­‐‑like  receptor  4/  myeloid  differentiation-­‐‑2  complex  (114,  139).  Although  this  event  
is   desirable   for   clearing   infection,   overproduction   of   pro-­‐‑inflammatory   cytokines   can  
lead  to  septic  shock  and  be  lethal  (5).  Lipid  A  is  required  for  viability  and  pathogenesis  
of  Gram-­‐‑negatives   (140,  141)  and   thus   its  biosynthesis   (Raetz  pathway)   is  an  attractive  
antibacterial  drug  target.    
In   Escherichia   coli   nine   highly   conserved   enzymes   assemble   lipid   A   that   is  
decorated  with  two  molecules  of  Kdo  sugars  (3-­‐‑deoxy-­‐‑d-­‐‑manno-­‐‑oct-­‐‑2-­‐‑ulosonic  acid)  (Fig.  
1.5)  (5).  LpxA  is  the  first  enzyme  in  the  assembly  line  and  a  validated  antibacterial  target  
(109).   It   catalyzes   the   transfer   of   the  R-­‐‑3-­‐‑hydroxymyristoyl   to   the   3-­‐‑hydroxyl  group  of  
UDP-­‐‑GlcNAc  to  generate  UDP-­‐‑3-­‐‑O-­‐‑(R-­‐‑3-­‐‑hydroxymyristoyl)-­‐‑GlcNAc  (62).  LpxA  follows  
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an   ordered   sequential   reaction   mechanism,   however,   the   binding   order   is   yet   to   be  
determined   (99).   The   acylation   reaction   is   thermodynamically   unfavorable   (Keq   =   0.01)  
(34),  and  thus  the  deacetylation  reaction  of  the  LpxA  product  by  LpxC  is  the  committed  
step  of  the  pathway  (142,  143).    
The  acyltransferases  of  lipid  A  biosynthesis  (LpxA,  –D,  –L,  and  –M)  rely  on  type  
II   acyl-­‐‑carrier-­‐‑protein   for  acyl-­‐‑chain  delivery,   suggesting  a   crucial   role  of  ACP   in  acyl-­‐‑
substrate  recognition  (5).  Type  II  acyl-­‐‑ACP  diffuses  freely  in  the  cytoplasmic  matrix,  all  
the  while  protecting  the  acyl-­‐‑cargo  that   is  thioester   linked  to  its  4′-­‐‑phosphopantetheine  
group   (4′-­‐‑PPT)   within   an   interior   hydrophobic   pocket   (Fig.   1.11)   (50,   58).   Upon  
interaction  with  partner  proteins,  ACP  must  undergo  a  conformational  change  to  extract  
and   present   its   cargo   to   the   active   site   of   its   partners   (50,   56).   The   carrier-­‐‑protein  
interacts  with   numerous   enzymes   of   the   primary   and   secondary  metabolic   pathways,  
however  due  to  the  transient  nature  of  ACP  interactions  and  conformational  mobility  of  
many  ACP  domains,   the   structural   information   about  ACP–protein   interaction   is   very  
limited.    
LpxA   is   the   founding  member   of   a   large   family   of   enzymes   that   adopt   a   left-­‐‑
handed   parallel   beta-­‐‑helix   fold   (37),   and   provides   an   excellent   system   to   study  
protein:lipid  and  protein:protein  interactions.  Previous  crystallographic  studies  of  LpxA  
bound   to   UDP-­‐‑GlcNAc   (100),   and   UDP-­‐‑acyl-­‐‑GlcNAc   (104)   revealed   key   active   site  
residues  and  the  lipid  binding  pocket,  yet  failed  to  identify  the  binding  site  of  ACP.  Our  
recent  success   in  crystalizing  LpxD  N-­‐‑acyltransferase  bound  to  ACP  at  different  stages  
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of  catalysis   (144)  prompted  us  to  determine  the  structure  of  LpxA  in  complex  with  the  
carrier-­‐‑protein.    
We  herein  present  the  2.1  Å  crystal  structure  of  E.  coli  LpxA  O-­‐‑acyltransferase  in  
complex  with  its  liberated  ACP  product  (holo-­‐‑ACP).  The  complex  structure  revealed  that  
similar   to   the  LpxD:ACP  complex   (144),  ACP   is   localized   to   the  C-­‐‑terminal  domain  of  
LpxA.   Notably,   a   different   binding   mode   of   ACP   was   observed.   On   the   basis   of   the  
structural   differences   between   the   two   acyltransferases,   we   hypothesize   that   the   C-­‐‑
terminal   domain   of   LpxA   forces   ACP   to   bind   differently,   and   also   dictates   LpxA  
specificity  for  ester-­‐‑linkage  acylation  of  lipid  A  precursors  as  opposed  to  amide-­‐‑linkage.    
  
3.2 Results 
3.2.1  Overview  of  the  LpxA-­‐‑ACP  complex  
To   visualize   how   LpxA   recognizes   the   acyl-­‐‑carrier-­‐‑protein,  we   crystallized   the  
acyltransferase   in   the  presence  of  a  3-­‐‑fold  molar  excess  holo-­‐‑ACP,  and  resolved   the  co-­‐‑
crystal  structure  to  2.1  Å  resolution  (Table  3.1).  The  structure  crystalized  in  the  H3  space  
group  and  contained  one  LpxA  monomer  bound  to  a  single  molecule  of  holo-­‐‑ACP  in  the  
asymmetric   unit.   The   biological   functional   unit   of   LpxA   (37),   is   generated   via  
crystallographic   symmetry   operations,   forming   the   homotrimeric   structure.      Each  
monomer  is  related  to  its  adjacent  monomer  by  a  120°  rotation  around  the  trimeric  axis  
of  symmetry  (Fig.  3.1a).    
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Similar   to   other   known  NMR   and   crystal   structures,   ACP   adopts   a   four-­‐‑helix   bundle  
architecture   with   various   loops   (L1-­‐‑L3)   that   connect   the   helices   (69,   118-­‐‑120).   Three  
major  helices  (helix-­‐‑I:  residues  2-­‐‑15,  helix-­‐‑II:  residues  36-­‐‑50,  and  helix-­‐‑IV:  residues  65-­‐‑75)  
run  approximately  parallel   to  each  other,   forming  a  hydrophobic  scaffold  capped  by  a  
short   helix   (helix-­‐‑III:   residues   56-­‐‑61),  which   is   almost   perpendicular   to   the   axes   of   the  
other  helices  (Fig.  3.1a).  The  role  of  this  hydrophobic  pocket  is  to  protect  the  acyl-­‐‑chain  
and   the   reactive   thioester   bond   located   at   the   end   of   the   phosphopantetheine   from  
hydrolysis   (Fig.   1.11).   The   electron   density   is   weaker   in   some   regions   of   ACP,  
particularly  at  Asp35,  and  Glu47-­‐‑Glu53  which  flank  helix-­‐‑II   (Fig.  3.2).  Accordingly,   the  
B-­‐‑values   of   these   residues   are   relatively   higher   than   the   rest   of   ACP   suggesting  
conformational   mobility   in   these   regions   (Fig.   3.3).   Moreover,   only   the   4′-­‐‑phosphate  
group   of   the   4′-­‐‑phosphopantetheine,   which   is   covalently   attached   to   Ser36,   was  
visualized  in  the  structure,  as  the  electron  density  for  the  remaining  pantetheine  moiety  
was  extremely  weak.  Therefore,  the  pantetheine  arm  was  not  included  in  the  final  model.  
Nonetheless,   the   positions   of   the   side-­‐‑chains   were   clear   at   the   LpxA–ACP   binding  
interface.  
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Table  3.1:  Data  collection  and  refinement  statistics.  
   LpxA:Holo-­‐‑ACP  
Data  collection     
Space  group   H3  
Cell  dimensions         
        a,  b,  c  (Å)   104.20,  104.20,  82.09  
        α,  β,  γ    (°)     90.00,  90.00,  120.00  
No.  of  Reflections     112997  
No.  of  Unique  Reflections   19460  
Resolution  (Å)   20.00-­‐‑2.10  
Rsym  or  Rmerge   0.07  (0.76)  
I  /  σI   29.1  (2.4)  
Completeness  (%)   100.0  (99.9)  
Redundancy   5.8  (5.7)  
     
Refinement     
Resolution  (Å)   19.77-­‐‑2.10  
No.  reflections   19413  
Rwork  /  Rfree   18.8  /  22.4  
No.  atoms     
        LpxA   3927  
        ACP   580  
        Water   100  
B-­‐‑factors     
        LpxA   43.3  
        ACP   70.9  
        Water   50.3  
R.m.s.  deviations     
        Bond  lengths  (Å)  
        Bond  angles  (º)  
0.01  
0.68  
Ramachandran  statistics       
        Favored  (%)   97.3  
        Disallowed  (%)   0.0  
Data  were  collected  from  a  single  crystal  for  each  complex.  
*Highest  resolution  shell  is  shown  in  parenthesis.    
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Figure  3.1:  ACP  bound  to  LpxA.    (a)  Overall  architecture  of  LpxA:ACP  complex.  
Three   holo-­‐‑ACP   molecules   (purple,   cylindrical   helices)   are   bound   to   the   carboxy   (C)-­‐‑
terminal  helices  of  LpxA  trimer  (each  monomer  is  colored  by  a  different  shade  of  green).  
The  amino  (N)-­‐‑  terminal  end  of  LpxA  is  composed  mostly  of  beta  strands.  (b)  Cartoon  
representation   of   the   LpxA   ternary   complex   with   acyl-­‐‑ACP,   and   UDP-­‐‑GlcNAc.   Each  
monomer   of   LpxA   consists   of   a   left-­‐‑handed   β-­‐‑helix   (LβH),   and   a   C-­‐‑terminal   domain  
(CTD).   LβH   and   CTD   are   composed   of   ten   equilateral   β-­‐‑triangles   (blue   strands),   and  
four   α-­‐‑helices   (green).   UDP-­‐‑GlcNAc,   ACP   and   its   acyl-­‐‑4′-­‐‑PPT   group   are   shown.   The  
position  of  the  catalytic  base  (His125),  the  oxyanion  hole  (Gly143),  and  the  hydrocarbon  
ruler  (His191)  are  indicated  within  LβH.  
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Figure   3.2:   The   electron   density   map   of   holo-­‐‑ACP.   2Fo   –   Fc   composite   omit  
electron  density  covering  each  α-­‐‑carbon  trace.  The  map  is  contoured  at  1.5  σ  and  colored  
in   gray.      The   asterisk   symbol   indicates   the   location   of   residues   with   poor   electron  
density.  
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Figure   3.3:   Overview   of   temperature   factor   distribution   of   LpxA:holo-­‐‑ACP.  
Side   view   of   the   LpxA:holo-­‐‑ACP   complex.      A   single  monomer   of   LpxA   and  ACP   are  
represented  as  ribbon-­‐‑putty  cartoon  and  colored  according   to  main-­‐‑chain  B  value.  The  
thickness  and  heat-­‐‑map  coloring   indicates   the  regions  with   least   (thin,  blue)   to  highest  
(thick,   red)   temperature   factor.   The   subdomains   of   LpxA   and   ACP   as   well   as   the  
location  of  the  4′-­‐‑phosphate  group  are  indicated.  
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As   depicted   in   FIGURE   3.1B,   each   monomer   of   LpxA   is   composed   of   two  
domains:  an  N-­‐‑terminal  domain,  which  adopts  an  unusual   left-­‐‑handed  parallel  β-­‐‑helix  
fold  (LβH,  residues  1-­‐‑186)  that  extends  approximately  50  Å  in  length,  and  a  globular  α-­‐‑
helical   C-­‐‑terminal   domain   (CTD,   residue   187-­‐‑262).   The   LβH   is   composed   of   ten  
equilateral   triangles   that   are   characterized   by   three   hexapeptide   segments   with   the  
consensus  sequence  of  [LIV]-­‐‑[GAED]-­‐‑X2-­‐‑[STAVE]-­‐‑X  (37).  For  each  18-­‐‑residue  triangle,  6  
hydrophobic   side-­‐‑chains   are   oriented   toward   the   center,   where   there   is   no   solvent  
present,  and  12  side-­‐‑chains  are  directed  outward.  LpxA  possesses  a  conserved  histidine  
residue   (His125)   on   triangle   #7   that   acts   as   a   general   base   and   is   stabilized   by   a  
negatively  charged  residue,  Asp126.  In  the  ternary  complex,  His125  activates  the  lipid  A  
precursor   by   extracting   a   proton   from   the   3-­‐‑hydroxyl   group   of   UDP-­‐‑GlcNAc   which  
subsequently   undergoes   nucleophilic   attack   on   the   thioester   bond   of   acyl-­‐‑ACP   (99).  
Forming  the  oxyanion  hole  is  Gly143  that  stabilizes  the  negative  charge  associated  with  
forming  the  tetrahedral  transition  state  (104).    
Different   LpxA   orthologs   are   selective   toward   different   acyl-­‐‑chain   lengths   that  
are   delivered   by   the   carrier-­‐‑protein.   In   E.   coli,   LpxA   is   highly   specific   for   R-­‐‑3-­‐‑
hydroxymyristoyl-­‐‑ACP,   yet   it   can   utilize   R-­‐‑3-­‐‑hydroxylauroyl-­‐‑ACP   and   R-­‐‑3-­‐‑
hydroxypalmitoyl-­‐‑ACP,   albeit   with   two   orders   of   magnitude   reduction   in   rate   as  
compared   to   its   natural   substrate,   demonstrating   the   existence   of   a   precise  molecular  
hydrocarbon   ruler   (62,   99,   103).   This   notion   is   recapitulated   by   the   fact   that   in  E.   coli  
LpxA  substitution  of  Gly173,  which   is  positioned  on   triangle  #9,  with  an  alanine  shifts  
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the  enzyme’s  preference  to  R-­‐‑3-­‐‑hydroxydecanoyl-­‐‑ACP  (103).  Furthermore,  the  structure  
of  E.  coli  LpxA  with  its  bound  lipid  product,  UDP-­‐‑3-­‐‑O-­‐‑(R-­‐‑3-­‐‑hydroxymyristoyl)-­‐‑GlcNAc  
(UDP-­‐‑acyl-­‐‑GlcNAc),  has  been  resolved  (104)  and  identified  His191  on  triangle  #10  as  the  
hydrocarbon  ruler  that  dictates  acyl-­‐‑chain  length  selectivity  (Fig.  3.4).    
The  CTD  domain  of  LpxA  is  tethered  to  the  top  of  the  LβH  domain  and  does  not  
appear  to  play  a  role  in  trimerization  of  the  acyltransferase.  The  bottom  side  of  the  CTD  
is  involved  in  binding  the  uridine  moiety  of  UDP-­‐‑GlcNAc,  and  generates  the  active  site  
of  LpxA  along  with   the  adjacent  LβH  domain  and  two   loops   that  are   inserted   into   the  
corners  of  triangle  #5  and  #6  (100,  104).  Our  structure  revealed  that  one  ACP  molecule  is  
docked  between   two  CTD  domains  of  LpxA,  which   contradicts   an  NMR/mutagenesis-­‐‑
directed  docking  study  (107)  that  had  suggested  the  region  between  the  bottom  side  of  
CTD   and   the   two   loop   insertions   to   be   involved   in   modulating   ACP   molecular  
recognition  (Fig.  3.5).  




Figure  3.4:  The  Structure  of  LpxA  solved   in  complex  with  UDP-­‐‑acyl-­‐‑GlcNAc.  
The  LpxA  trimer  and  a  single  UDP-­‐‑acyl-­‐‑GlcNAc  molecule  are  shown  (PDB  code:  2QIA).  
The  subdomains  of  LpxA  (different  shades  of  green)  are   indicated.  The  side-­‐‑chain  and  
molecular  surface  of  the  catalytic  histidine  (His125),  the  hydrocarbon  ruler  (His191),  and  
glycine  173  are  shown.  The  acyl-­‐‑chain  of  the  lipid  is  colored  in  black.  The  glucosamine  
ring  and  UDP  moiety  are  colored  in  cyan  and  pink,  respectively.  
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Figure  3.5:  The  docking  model  of  LpxA:ACP  complex.  The   side  view,  and   the  
top-­‐‑down  view  (inset)  of  the  LpxA:ACP  docking  model.  ACP  (cyan)  is  docked  to  UDP-­‐‑
GlcNAc  binding  site.    
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3.2.2  The  LpxA:holo-­‐‑ACP  binding  interface  
Three  ACP  molecules  are  bound  per  LpxA  homotrimer  (Fig.  3.6a),  revealing  the  
stoichiometry  of  ACP  binding  to  LpxA  and  suggesting  that  each  active  site  is  capable  of  
transferring   acyl-­‐‑chains   simultaneously.   Each   ACP   molecule   exclusively   contacts   two  
adjacent   CTD   domains,   which   provide   a   binding   surface   area   that   measure  
approximately   630   Å2.      An   overlay   of   the   electrostatic   surfaces   of   ACP   and   LpxA  
recapitulates   the   functional   relevance   of   the   CTD   and   shows   the   charge  
complementarity  between  the  two  protein  partners  (Fig.  3.6b).  Portions  of  L1  and  helix-­‐‑II  
in  combination  with  portions  of  L2  and  helix-­‐‑III  form  an  electronegative  surface  on  ACP  
that   coordinates   with   two   electropositive   surface   patches   on   LpxA.   Importantly,   This  
interaction  orients  ACP  and  its  Ser36  towards  the  active  site  of  LpxA.    
The  binding  surface  of  LpxA  provides  a  V-­‐‑shaped  groove  between  the  adjoining  
ARD  domains  into  which  ACP  is  inserted  (Fig.  3.6c).  There  are  only  a  few  strong  charge-­‐‑
mediated   interactions  between   the   two  partners   that   include  Asn25,  Glu30,  and  Asp31  
from   L1   of   ACP   with   Thr228,   Glu231,   Gln179,   Arg262,   and   Asp230   all   exclusively  
provided  by  one  monomer  of  LpxA  (chain  A).  Furthermore,  His160  and  Arg258  that  are  
located   on   the   same   LpxA   subunit   coordinate   the   4’-­‐‑phosphate   group,   which   is  
covalently  attached   to  Ser36  of  ACP.  This  explains  why  mutating  His160   to  alanine  or  
phenylalanine  reduces  but  does  not  completely  abrogate  LpxA  enzymatic  activity   (99).  
There   is   a   multitude   of   other   residues   provided   by   the   same   LpxA   monomer   that  
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interact  with  Ser36  of  helix-­‐‑II  and  a  portion  of  L1  of  ACP.  These  residues  include  Gln161,  
His191,   Ala178,   Thr257,   Gly259,   Leu260,   and   Lys233,   some   of   which   are   highly  
conserved  (Fig.  3.7).  The  adjacent  LpxA  monomer  (symmetry  related  chain  A’)  provides  
weak  electrostatic  as  well  as  van  der  Waals  interactions  with  helix-­‐‑II  residues  and  Glu53  
and  Asp56  that  are  located  on  L2  and  helix-­‐‑III  of  ACP.  The  residues  provided  by  chain  A’  
(denoted   by   prime   symbols)   are   Glu’188,   Phe’195,   Ile’186,   Glu’200,   Gly’196,   Ile’199,  
Lys’203,  Arg’224,  Val’197,  Arg’216,  Lys’220,  and  Arg’209.    
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Figure  3.6:  Overview  of  the  LpxA:holo-­‐‑ACP  interactions.  (a)  Top-­‐‑down  view  of  
the   LpxA:holo-­‐‑ACP   complex.      Three   ACP   molecules   bind   per   LpxA   trimer.      (b)  
Electrostatic  surface  representation  of   the  CTD  and  ACP  (insets).  The  surface  potential  
contours  were   scaled   to   +79.2   (blue)   and   -­‐‑79.2   (red)   kB  T   e-­‐‑1  (where   kB   is   the  Boltzmann  
constant,   T   is   temperature   and   e-­‐‑1   is   the   charge   of   an   electron).   (c)   Stereoview   of   the  
LpxA:holo-­‐‑ACP   complex.   Residues   at   the   protein-­‐‑protein   interface   are   shown.   The  
molecular   surfaces   of   LpxA   residues   are   displayed.      Electrostatic   interactions   are  
indicated  by  dashed  lines.  
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Figure  3.7:  Sequence  alignment  of  LpxA  orthologs.  Protein  sequence  alignment  
of   E.   coli   LpxA   with   Pseudomonas   aeruginosa,   Leptospira   interrogans,   Helicobacter   pylori,  
Burkholderia   thailandensis,  Acinetobacter  baumannii,   and  Neisseria  meningitides.   The   amino  
acid  numbers  are  presented  above   the  aligned  sequences  and  marked  by  black  circles.  
The   catalytic   histidine   (His125   in  E.   coli)   and   the   oxyanion   hole   (Gly143   in  E.coli)   are  
indicated   by   green   rectangles   above   the   aligned   sequences.   The   charged   and   polar  
residues   in   the  protein–protein   interface   are   indicated  by  purple   triangles.   The  purple  
box  highlights  those  polar  residues  at  the  binding  interface  that  display  absolute  charge  
conservation.      
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A   mutagenesis   study   of   Vibrio   harveyi   acyl-­‐‑ACP,   which   shares   86%   sequence  
identity  with   its  E.   coli   counterpart,   revealed   that   neutralizing  Asp30   (glutamate   in  E.  
coli),  Asp35,  and  Asp38  (site  A  residues)  by  substituting  them  to  asparagine  reduces  E.  
coli   LpxA   activity   by   40%   as   compared   to   LpxA   activity  measured   in   the   presence   of  
wild-­‐‑type   V.   harveyi   acyl-­‐‑ACP   (79).   Moreover,   neutralizing   Glu47,   Asp51,   Glu53,   and  
Asp56  (site  B  residues)  reduces  LpxA  activity  by  95%,  implying  a  role  for  these  residues  
in   LpxA   interaction   (79).   Surprisingly,   based   on   our   structure,   none   of   these   residues  
form   a   salt   bridge  with   LpxA.   Our   recently   published   comparison   between   holo-­‐‑ACP  
and  acyl-­‐‑ACP  bound  to  LpxD  N-­‐‑acyltransferase,  sheds  light  on  this  paradox  (144).  Acyl-­‐‑
ACP  binding  to  LpxD  involved  electrostatic  interaction  of  Asp35,  Asp38,  Glu41,  Glu48,  
Glu53,  and  Asp56  with  basic  amino  acids  of  LpxD.  In  contrast,  because  of  considerable  
conformational   change   in   L2   and   helix-­‐‑III,   holo-­‐‑ACP   lacked   any   strong   electrostatic  
contacts  at  Glu48,  Glu53,  and  Asp56  sites.  The  collapse  of  these  electrostatic  interactions  
appears   to   initiate   the  dissociation  event   that  must  occur  with  holo-­‐‑ACP.   In   the  case  of  
LpxA,   perhaps   strong   electrostatic   interactions  with   site  A   and  B   residues   could   have  
been  visualized  had  acyl-­‐‑ACP  been  captured  bound  to  LpxA  instead  of  the  holo-­‐‑form.    
  
3.2.3  Mechanism  of  acyl-­‐‑chain  delivery  by  ACP  
Superimposing  holo-­‐‑ACP  with  the  X-­‐‑ray  structure  of  E.  coli  acyl-­‐‑ACP  (74),  whose  
decanoyl  acyl-­‐‑chain  is  buried  inside  the  carrier-­‐‑protein  and  covalently  attached  to  the  4′-­‐‑
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phosphopantetheine   group,   suggests   that   acyl-­‐‑ACP   must   undergo   a   conformational  
change   in   order   to   present   its   cargo   to   LpxA   and   properly   orient   the   thioester   bond  
relative   to   the   active   site   histidine   (His125)   for   acyl-­‐‑transfer   to   occur   (Fig.   3.8).   The  
crystallographic  study  of  Leptospira  interrogans  LpxA  bound  to  a  substrate  mimetic,  R-­‐‑3-­‐‑
hydroxylauroyl-­‐‑methyl-­‐‑phosphopantetheine   (R-­‐‑3-­‐‑OHC12-­‐‑methyl-­‐‑4′-­‐‑PPT),   has   revealed  
the  conformation  of  4′-­‐‑phosphopantetheine  as  it  relates  to  acyl  substrate  delivery  (105).  
The   electron   density   was   poor   in   some   regions   of   the   phosphopantetheine,   and   two  
conformations  were  modeled   for   the  methyl-­‐‑phosphopantetheine  moiety  of   the   ligand  
with   the  4′-­‐‑phosphate  groups  positioned  approximately  7  Å  apart.  Both  conformations  
place   the   thioester  bond   in  proximity  of   the  catalytic  base  histidine  and  pack   the  acyl-­‐‑
chain   inside   the   hydrophobic   pocket   formed   by   adjacent   LβH   domains.   When  
superimposed  with  our  structure,  the  location  of  the  4′-­‐‑phosphate  group  associated  with  
conformation  1  overlays  with   little  deviation,   indicating  its  catalytic  relevance  over  the  
alternate  conformation  in  E.  coli  LpxA  (Fig.  3.9).  
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Figure  3.8:  Overlay  of  acyl-­‐‑ACP  with  LpxA:holo-­‐‑ACP  complex.  Decanoyl-­‐‑ACP  
(blue,  PDB  code:  2FAE)   superimposed  with  holo-­‐‑ACP   (Purple).  The   two  basic   residues  
(His160,  and  Arg125)  that  interact  with  4′-­‐‑phosphate  of  holo-­‐‑ACP  and  the  catalytic  base  
(His125)  are  shown.  ACP  needs  to  eject  the  acyl-­‐‑chain  (black)  to  place  the  thioester  bond  
(green  circle)  in  the  active  site  of  LpxA  that  is  approximately  22  Å  away  (inset).  
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Figure  3.9:  Superposition  of  R-­‐‑3-­‐‑OHC12-­‐‑methyl-­‐‑4′-­‐‑PPT  bound  to  L.  interrogans  
LpxA   (PDB   code:   3I3A)  with   the  LpxA:holo-­‐‑ACP   complex.   Two   conformations   of   4′-­‐‑
PPT  moiety  are  shown  by  two  shades  of  pink  and  colored  by  atom  type.  The  acyl-­‐‑chain  
is   colored   in   black   with   its   length   indicated.   Ser36   of   holo-­‐‑ACP   and   its   attached   4′-­‐‑
phosphate  group,   the   catalytic   base   (His125)   and   the  hydrocarbon   ruler   (His191)   of  E.  
coli   LpxA   are   shown   and   are   colored   as   in   figure   3.6.   The   4′-­‐‑phosphate   group   of  
conformation  1  overlaps  with  the  phosphate  group  of  holo-­‐‑ACP.  
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3.2.4  Inhibition  of  LpxA  by  peptide-­‐‑920  
As  an  essential   enzyme   in   the   lipid  A  biosynthesis,  LpxA   remains   a  promising  
candidate  for  the  design  of  novel  antibiotics.  It  has  been  shown  that  a  pentadecapeptide  
inhibitor   of   LpxA,   termed   peptide-­‐‑920   (SSGWMLDPIAGKWSR),   when   expressed   as  
GST-­‐‑fusion   protein,   could   inhibit   bacterial   growth   (109).   Kinetic   studies   suggested  
peptide-­‐‑920   binds   tightly   to   LpxA   (Ki   =   50   nM)   (108).  Moreover,  when   assayed   in   the  
presence   of   1   µμM   UDP-­‐‑GlcNAc   and   1   µμM   R-­‐‑3-­‐‑hydroxymyristoyl-­‐‑ACP,   peptide-­‐‑920  
inhibited  LpxA  reaction  with  an  IC50  of  60  nM.  Changing  the  concentration  of  acyl-­‐‑ACP  
in   the   inhibition  assay   to  100  µμM   increased   the   IC50  value  by  approximately  12-­‐‑fold   to  
730  µμM,  whereas   increasing   the   concentration  of  UDP-­‐‑GlcNAc   to  5  mM  had  no  major  
effect  on  the  IC50  value.  Based  on  these  data,  it  was  concluded  that  peptide-­‐‑920  inhibits  
LpxA  reaction  by  competing  with  acyl-­‐‑ACP  (108).     The  crystal  structure  of  E.  coli  LpxA  
with  peptide-­‐‑920  has  been  reported  (108).   It   is  clear   from  superimposing   this  structure  
with   LpxA:holo-­‐‑ACP   and   LpxA:R-­‐‑3-­‐‑OHC12-­‐‑methyl-­‐‑4′-­‐‑PPT   complex   that   peptide-­‐‑920  
competes  with  the  acyl-­‐‑phosphopantetheine  moiety  of  ACP,  and  does  not  prevent  direct  
protein:protein   interactions   (Fig.   3.10a).   Notably,   overlaying   the   structure   of   LpxA  
bound   to  UDP-­‐‑GlcNAc   (100)   reveals   that   Leu6,   and   Trp13   of   peptide-­‐‑920   occlude   the  
uridine   and   β-­‐‑phosphate   binding   site   (Fig.   3.10b).      Our   study   on   holo-­‐‑ACP   bound   to  
LpxA   provides   new   insights   into   the   optimization   of   peptide-­‐‑920   that   exploits  
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disruption   of   the   protein:protein   interface   in   an   effort   to   design   new   antibiotic  
therapeutics.    
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Figure   3.10:   Overlay   of   LpxA:holo-­‐‑ACP   with   other   LpxA   complexes.   (a)  
Superposition  of  peptide-­‐‑920  complex  (PDB  code:  2AQ9,  blue)  with  holo-­‐‑ACP  and  R-­‐‑3-­‐‑
OHC12-­‐‑methyl-­‐‑4′-­‐‑PPT  complexes.  The  side  chains  of  peptide-­‐‑920  are  shown  and  colored  
by  atom.  The  peptide  blocks  binding  of  acyl-­‐‑4′-­‐‑PPT  to  LpxA.  (b)  Superposition  of  UDP-­‐‑
GlcNAc  complex  structure  (PDB  code:  2JF3,  green)  with  peptide-­‐‑920  complex.  Peptide-­‐‑
920  inhibits  LpxA  activity  by  binding  to  the  UDP-­‐‑GlcNAc  and  acyl-­‐‑4′-­‐‑PPT  binding  sites.    
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3.2.5  LpxA  O-­‐‑acyltransferase  versus  LpxD  N-­‐‑acyltransferase  
LpxA  and  LpxD  are   closely   related  acyltransferases   that   share   the  unique  LβH  
trimeric   structure   and   the   use   of   R-­‐‑3-­‐‑hydroxymyristoyl-­‐‑ACP   as   a   substrate.   Two  
adjacent   LβH   domains   in   both   LpxA   and   LpxD   form   a   hydrophobic   pocket   that  
accommodates   the   acyl-­‐‑chain   delivered   by   ACP   (104,   144).   We   recently   identified   a  
second   hydrophobic   surface   feature   on   LpxD   that   is   formed   by   a   single   LβH,  
accommodating  the  acyl  moiety  of  its  lipid  substrate,  UDP-­‐‑acyl-­‐‑GlcN  (Fig.  3.11)  (144).  In  
comparing   LpxA   and   LpxD   structures,   it   appears   that   a   similar   hydrophobic   pocket  
exists  on  LpxA  that  could  potentially  accommodate  an  additional  acyl-­‐‑chain  (Fig.  3.12a).  
Given   the   resemblance   between   the   substrates   and   products   of   LpxA   and   LpxD  
reactions,   as   well   as   the   structural   similarity   between   the   two   acyltransferases,   the  
question  arises  whether  LpxA  is  able  to  catalyze  the  LpxD  reaction.  Interestingly,  when  
assayed   in   the   presence   of   LpxD   substrates   (acyl-­‐‑ACP   and   UDP-­‐‑acyl-­‐‑GlcN),   LpxA  
showed   no   acyl-­‐‑transfer   activity,   indicating   its   strong   specificity   for   ester-­‐‑linkage  
formation   (Fig.   3.12b).  We   hypothesize   that   the   CTD   domain   of   LpxA   locks   the  UDP  
moiety  of   the   substrate   in  a   conformation   that  only  allows   the  3-­‐‑hydroxyl  group   to  be  
properly   oriented   relative   to   the   catalytic   residue   (His125)   in   the   active   site   for  
nucleophilic  attack  to  occur.   It   is  worth  mentioning  that  LpxD  utilizes   its  CTD  domain  
solely  for  ACP  binding  and  instead  has  evolved  an  additional  globular  domain  at  its  N-­‐‑
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terminal   end   to   bind   the   uridine   moiety   of   UDP-­‐‑acyl-­‐‑GlcN   such   that   amide-­‐‑linkage  
formation  would  take  place.  
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Figure   3.11:   Structure   of   E.   coli   LpxD   bound   to   hydrolysed-­‐‑acyl-­‐‑ACP.   LpxD  
trimer  (gray)  and  a  single  molecule  of  ACP  (blue)  are  shown  (PDB  code:  4IHG).  ACP  is  
bound   to   the   C-­‐‑terminal   helices   of   LpxD.   The   thioester   bond   between   the   4′-­‐‑
phosphopantetheine  (pink)  and  the  acyl  chain  (black)  delivered  by  ACP  is  hydrolyzed.  
The   catalytic   base   (His239)   and   the   hydrocarbon   ruler   (M290)   are   shown.   (inset)   N-­‐‑
linked   acyl-­‐‑chain   delivered   by   ACP   is   packed   into   a   pocket   provided   by   two  
neighboring  LβH  domains.  O-­‐‑linked  acyl-­‐‑chain  represents  the  acyl  moiety  of  the  LpxD  
substrate,  UDP-­‐‑acyl-­‐‑GlcN,  and  is  bound  to  a  single  LβH  domain.  
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Figure   3.12:   Functional   surface   of   LpxA   and   comparison   with   LpxD.   (a)  
Putative   acyl-­‐‑chain   pocket   on   LpxA   surface.   The   molecular   (top)   and   electrostatic  
(bottom,  scaled  to  +79.2  (blue)  and  -­‐‑79.2  (red)  kB  T  e-­‐‑1)  surfaces  of  LpxA  structure  bound  
to  UDP-­‐‑acyl-­‐‑GlcNAc  are  shown  (PDB  code:  2QIA).  The   location  of   the  additional  acyl-­‐‑
chain  pocket  is  indicated  by  dots.  (b)  TLC-­‐‑based  radiographic  UDP-­‐‑acyl-­‐‑GlcN  acylation  
assay.   25   µμL   assay   mixture   contained   40   mM   HEPES   (pH   7.5),   10   µμM   R-­‐‑3-­‐‑
hydroxymyristoyl-­‐‑ACP,   10   µμM   [α-­‐‑32P]-­‐‑UDP-­‐‑3-­‐‑O-­‐‑(R-­‐‑3-­‐‑hydroxymyristoyl)-­‐‑glucosamine  
(~2  ×  104  cpm  µμL-­‐‑1),  and  1  mg  ml-­‐‑1  bovine  serum  albumin.  The  reaction  was  initiated  at  30  
°C  by  adding  10  nM  LpxD  or  100  nM  LpxA  to  the  mixture,  and  time  points  were  taken  
by  spotting  2  µμL  of  the  mixture  onto  a  silica  gel  60  TLC  plate.  The  plate  was  developed  
with   chloroform/methanol/water/acetic   acid   (25:15:4:2,   v:v:v:v)   and   analyzed   with   a  
Phosphor   Imager.   UDP-­‐‑acyl-­‐‑GlcN   substrate   and   UDP-­‐‑diacyl-­‐‑GlcN   product   are  
indicated.  
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3.3 Discussion 
Acyltransferases  are  the  single  most  abundant  class  of  partner  enzymes  in  Gram-­‐‑
negative  microorganisms   that   associate  with  ACP   (56).  The   structure  presented   in   this  
study   shows   holo-­‐‑ACP   engaging   LpxA   and   helps   to   better   understand   ACP-­‐‑based  
interactions.  ACP  binding  to  LpxA  and  LpxD  (144)  highlights  a  remarkable  promiscuity  
that  ACP  displays  towards  its  numerous  partner  enzymes  (Fig.  3.13).  Although  helix-­‐‑II  
is   the  key  modulator  of  ACP  recognition  providing   interaction  with  LpxA  and  –D,   the  
contribution   of   helix-­‐‑III,   L1,   and  L2   to   the   interfacial   contacts   is   different   between   the  
two   acyltransferases.   Helix-­‐‑III   and   L2   provide   extensive   molecular   interaction   with  
LpxD,   whereas   their   contribution   in   the   case   of   LpxA   is   subsidiary.   Instead,   ACP  
provides  more  molecular   interaction  with   LpxA   along  L1.   The   spatial   arrangement   of  
the   C-­‐‑terminal   helices   of   the   two   enzymes   determines   what   regions   on   ACP   surface  
participate   in   binding.      The   C-­‐‑terminal   helices   in   LpxA   fold   back   on   themselves   and  
interact   solely  with   their   respective   LβH   domain,   but   the   C-­‐‑terminal   helices   of   LpxD  
monomers  interdigitate  to  form  a  three-­‐‑helix  bundle  (Fig.  3.14).  Nonetheless,  ACP  relies  
on  “electrostatic  steering”  and  shape  complementarity  for  association.    
Crystallizing   acyl-­‐‑ACP   with   LpxA   will   be   invaluable,   as   it   may   uncover  
additional   molecular   interactions   at   the   protein–protein   interface   and   provide   insight  
into   intra-­‐‑ACP  movements.   It   is   an   interesting   possibility   that   based   on   the   structural  
analyses  presented  here  a  chimera  LβH  acyltransferase  could  be  engineered  to  fulfill  the  
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catalytic  role  of  both  LpxA  and  LpxD.  Furthermore,  given  that  specific  LpxA  inhibitors  
have   been   reported   (109,   145)   it   is   reasonable   to   envision   that   the   high-­‐‑resolution  
structural   insights   gleaned   from  our  work  may   facilitate   such   efforts   to   design  potent  
anti-­‐‑bacterial  agents.  
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Figure   3.13:   Binding   surface   of   holo-­‐‑ACP   in   LpxA   and   –D   complexes.   ACP  
(purple)   binds   LpxA   and   –D   differently.   Surface   residues   of   holo-­‐‑ACP   involved   in  
interaction  with  LpxA  (left)  and  –D  (right,  PDB  code:  4IHH)  are  highlighted  in  green.  L1  
region  of  holo-­‐‑ACP  makes  more  contacts  with  LpxA,  whereas  helix-­‐‑II,  L2,  and  helix-­‐‑III  
are  more  involved  in  interaction  with  LpxD.  	     
   139  
  
Figure  3.14:  Structural  comparison  of  E.  coli  LpxA  and  LpxD.   (a)  Side  view  of  
LpxA  (green)  and  LpxD  (gray)  superimposition.  The  subdomains  of  each  structure  are  
shown.  The  globular  NTD  domain  of  LpxD  has  no  counterpart  in  LpxA.  (b)  Top-­‐‑down  
view  of  superimposed  LpxA  and  LpxD.  The  C-­‐‑terminal  helices  of  LpxD  monomers  form  
a   three-­‐‑helix   bundle.   The   CTDs   of   LpxA  monomers   are   collapsed   and   interact   solely  
with  their  representative  LβH  domains.    
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3.4 Methods 
3.4.1  Cloning  of  His6–LpxA  
The   lpxA   gene  was   amplified   by   polymerase   chain   reaction   (PCR)   from  E.   coli  
W3110A   genomic   DNA   using   the   KOD  Hot   Start   Kit   (EMD   Chemicals,   CA)   and   the  
following  primer  pair  (Integrated  DNA  Technologies,  IA):  
5′–GCGCGCGCCATATGGGCCATCATCATCATCATCATGGCATGATTGATAAATCC  
GCCT–3′   and   5′–GCGCGCGCGGATCCTTAACGAATCAGACCGCGCGT–3′.   The  
former  primer  was  designed   to   confer   an  NdeI   restriction   site   and   a   coding   region   for  
Met–Gly–His6–Gly   upstream   of   the   lpxA   start   codon.   The   latter   primer   introduced   a  
BamHI  restriction  site  downstream  of  the  lpxA  stop  codon.  The  linear  PCR  product  was  
isolated   from   an   agarose   gel   following   gel   electrophoresis   using   the   QIAquick   Gel  
Extraction   Kit   (Qiagen,   CA),   and   subsequently   digested   with  NdeI   and   BamHI   (New  
England  Biolabs,  MA).  The  digested  linear  DNA  was  purified  using  the  QIAquick  PCR  
Purification  Kit  (Qiagen,  CA),  and  ligated  into  a  similarly  cut  pET21b  expression  vector  
(EMD  Millipore,  MA)  with  T4  DNA  ligase  (New  England  Biolabs,  MA).  The  expression  
vector   was   transformed   into   DH5α   chemically   competent   cells   (Invitrogen,   CA),   and  
transformants   were   selected   on   a   LB-­‐‑agar   plate   supplemented   with   100   µμg   mL-­‐‑1  
ampicillin   at   37   ˚C.     Minipreparation  of   the   expression  vector   encoding  LpxA  with   an  
uncleavable  N-­‐‑terminal  histidine-­‐‑tag   (designated  pET21b-­‐‑SAM)  was  performed  with  a  
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Qiagen   Mini-­‐‑Prep   Kit   (Qiagen,   CA),   and   its   sequence   was   confirmed   by   DNA  
sequencing  (Eton  Bioscience,  CA)  using  T7–promoter  and  –terminator  primers.    
  
3.4.2  Expression  and  purification  of  His6–LpxA  
A   15   mL   culture   of   C41(DE3)   bacterial   cells   harboring   the   pET21b-­‐‑SAM  
expression  vector  was  grown  overnight  at  37  °C  and  used  to  inoculate  1.5  L  of  lysogeny  
broth  (LB)  supplemented  with  100  µg  mL-­‐‑1  ampicilin.  When  the  culture  reached  an  OD600  
of  0.6,  the  expression  of  His6–LpxA  was  induced  by  the  addition  of  1  mM  isopropyl-­‐‑β-­‐‑D-­‐‑
thio-­‐‑galactoside  (IPTG).  After  3.5  hours  of  induction  at  37  °C,  the  cells  were  harvested  by  
centrifugation   at   8,000   ×   g   for   20   minutes   at   4   °C,   and   washed   with   20   mM   4-­‐‑(2-­‐‑
hydroxyethyl)-­‐‑1-­‐‑piperazineethanesulfonic   acid   (HEPES),   pH   8.0.      The   following  
procedures   were   carried   out   at   0-­‐‑4   °C.   Approximately   6   g   of   wet   cell   pellet   was  
resuspended   in  Buffer  A   (20  mM  HEPES,   pH  8.0,   500  mM  NaCl,   10%  glycerol,   1  mM  
DTT)   supplemented   with   25   mM   imidazole,   and   lysed   by   two   passage   through   a  
FRENCH   pressure   cell   (Spectronic   Instruments   Inc.,   NY)   at   11,000   psi.   The   unbroken  
cells,   cell  debris,   and  membranes  were   removed  by   centrifugation  at   100,000  ×   g   for   1  
hour.  The  soluble  fraction  was  rocked  with  5  ml  of  Ni-­‐‑NTA  (Qiagen,  CA)  for  30  minutes,  
and  the  mixture  was  loaded  onto  an  empty  Econo-­‐‑Column  (Bio-­‐‑Rad  Laboratories,  CA).  
The  column  was  washed  with  Buffer  A  and  25  mM  imidazole  over  10  column-­‐‑volumes,  
and  His6–LpxA  was  eluted  in  one  step  with  5  column-­‐‑volumes  of  Buffer  A  and  200  mM  
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imidazole.  The  elution  sample,  was  then  concentrated  to  ~10  mL  and  loaded  onto  a  High  
Load   26/60   Superdex   200   gel   filtration   column   (GE   Healthcare,   WI)   attached   to   an  
ÄKTAFPLC   system   (GE  Healthcare,  WI)   and  equilibrated  with  10  mM  Tris-­‐‑HCl,  pH  7.5,  
200  mM  NaCl,  and  10%  glycerol.  The  protein  sample  was  run  over  the  column  at  a  flow  
rate  of  1.0  mL  min-­‐‑1,  and  the  fractions  corresponding  to  the  major  A280  peak  were  pooled  
based   on   their   purity   as   determined   by   sodium   dodecyl   sulfate-­‐‑polyacrylamide   gel  
electrophoresis  (SDS-­‐‑PAGE).  His6–LpxA  was  concentrated  to  ~67  mg  mL-­‐‑1  and  saved  in  
aliquots  at  –80  ˚C.    
  
3.4.3  Production  of  holo-­‐‑ACP  and  acyl-­‐‑ACP  
E.   coli   holo-­‐‑ACP  was   preloaded  with   its   4′-­‐‑PPT   prosthetic   group   by   expressing  
pET16b*-­‐‑AM  vector   (144)   in  C41(DE3)  E.  coli   cells   (124),   cultured  at  37   ˚C   in  1  L  of  LB  
broth,   and   purified   by   nickel   affinity,   anion   exchange,   covalent   chromatography   that  
exploits  disulfide  bond  formation  between  the  4′-­‐‑PPT  group  and  Thiopropyl  Sepharose  
resin   (Sigma-­‐‑Aldrich,  MO),   and   finally   size-­‐‑exclusion   chromatography   as   described   in  
Chapter  2.  Upon  purifying  holo-­‐‑ACP  to  homogeneity  it  was  concentrated  to  ~19  mg  mL-­‐‑1,  
and  stored  in  aliquots  at  −80  ˚C  to  be  utilized  for  crystallization  trials.  
To  generate  acyl-­‐‑ACP,  purified  holo-­‐‑ACP  was  charged  with  R-­‐‑3-­‐‑hydroxymyristic  
acid   enzymatically   using   the   soluble   form   of   acyl-­‐‑ACP   synthetase   from  Vibrio   harveyi,  
and  purified  as  explained   in  Chapter  2.  Purified  acyl-­‐‑ACP  was  concentrated  to  ~18  mg  
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mL-­‐‑1,  and  stored  at  −80  ˚C  in  a  buffer  containing  10  mM  Tris-­‐‑HCl  (pH  7.5),  and  200  mM  
NaCl  to  be  used  in  crystallization  trials.  
  
3.4.4  LpxA  radioactive  substrate  prep  and  in  vitro  assay  
The   [α-­‐‑32P]-­‐‑UDP-­‐‑GlcNAc   substrate   was   prepared   as   previously   reported   (99).  
The   LpxA-­‐‑catalyzed   conversion   of   [α-­‐‑32P]-­‐‑UDP-­‐‑GlcNAc   to   [α-­‐‑32P]-­‐‑UDP-­‐‑3-­‐‑O-­‐‑(R-­‐‑3-­‐‑
hydroxymyristoyl)-­‐‑GlcNAc   was   monitored   by   thin-­‐‑layer   chromatography   (TLC)   on   a  
silica   gel   60   plate   (EMD  Chemicals,  Germany).   The   standard   reaction  mixture   (25  µμL)  
contained  40  mM  HEPES,  pH  7.5,  1  mg  mL-­‐‑1  bovine  serum  albumin  (BSA),  10  µμM  R-­‐‑3-­‐‑
hydroxymyristoyl-­‐‑ACP,   and   10   µμM   [α-­‐‑32P]-­‐‑UDP-­‐‑GlcNAc   (~2   ×   104   cpm   µμL-­‐‑1   ).   The  
mixture  was  equilibrated  at  30  °C  for  3  minutes,  and  the  reaction  was  initiated  with  the  
addition  10  µμM  His6–LpxA  enzyme.    A  volume  of  2  µμL  per  representative  time  point  of  
the   reaction   course   was   spotted   on   the   TLC   plate.   The   silica   gel   60   TLC   plate   was  
developed  with  chloroform/methanol/water/acetic  acid  (25:15:4:2,  v:v:v:v)  and  analyzed  
with  a  Phosphor  Imager.  The  specific  activity  of  His6–LpxA  was  measured  in  triplicate  
(130  nmol  min-­‐‑1  mg)   and  was  approximately  3-­‐‑fold  higher   than   the   specific   activity  of  
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3.4.5  Thin-­‐‑layer  chromatography  based  radiographic  UDP-­‐‑acyl-­‐‑GlcN  acylation  assay  
  The  [α-­‐‑32P]-­‐‑UDP-­‐‑3-­‐‑O-­‐‑(R-­‐‑3-­‐‑hydroxymyristoyl)-­‐‑GlcNAc  substrate  was  prepared  as  
previously  reported  (36).  25  µμL  assay  mixture  contained  40  mM  HEPES  (pH  7.5),  10  µμM  
R-­‐‑3-­‐‑hydroxymyristoyl-­‐‑ACP,   10   µμM   [α-­‐‑32P]-­‐‑UDP-­‐‑3-­‐‑O-­‐‑(R-­‐‑3-­‐‑hydroxymyristoyl)-­‐‑
glucosamine  (~2  ×  104  cpm  µμL-­‐‑1),  and  1  mg  ml-­‐‑1  BSA.  The  reaction  was  initiated  at  30  °C  
by  adding  10  nM  LpxD  or  100  nM  LpxA  to  the  mixture,  and  time  points  were  taken  by  
spotting  2  µμL  of  the  mixture  onto  a  silica  gel  60  TLC  plate  (EMD  Chemicals,  Germany).  
The  plate  was  developed  with  chloroform/methanol/water/acetic  acid  (25:15:4:2,  v:v:v:v)  
and  analyzed  with  a  Phosphor  Imager.    
  
3.4.6  Crystallization  and  structure  determination  of  LpxA:holo-­‐‑ACP  
Purified  His6-­‐‑LpxA   and   holo-­‐‑ACP  were  mixed   in   various  molar   ratios   (1:1   and  
1:3,   LpxA:holo-­‐‑ACP)   and   incubated   at   0-­‐‑4   °C   to   preform   the   protein:protein   complex  
prior   to   crystallization   trials.   Crystallization   experiments   were   carried   out   using   the  
sitting-­‐‑drop   vapor   diffusion  method   in   96  well   Intelliplates   (Art  Robbins   Instruments,  
CA)   and   a   Phoenix   crystallization   robotic   system   (Art   Robbins   Instruments,   CA)   to  
screen  the  protein  complex  against  several  commercially  available  screens  (Qiagen,  CA  
and  Hampton   Research,   CA).   1   µμL   sitting   drops,   containing   1:1,   or   1:1.5   v:v   ratios   of  
protein   to   crystallant   solution  were   allowed   to   equilibrate   against   71  µμL  of   crystallant  
solution   at   15   °C   and/or   20   °C   using   the   Minstrel   HT   Incubator   Gallery   system   and  
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Autoimaging   robotics   platform   (Rigaku,   TX).   Initial   crystallization   condition   hit  
consisted  of  0.1  M  HEPES,  pH  7.0,  and  40  %  (v/v)  2-­‐‑Methyl-­‐‑2,4-­‐‑pentanediol  (MPD)  was  
identified  from  MPD  suite  (Qiagen,  CA)  at  15  °C.     The  crystals  were  reproduced  using  
the   LpxA:holo-­‐‑ACP   protein   solution   (His6-­‐‑LpxA   and   holo-­‐‑ACP   9.5   mg   ml-­‐‑1)   mixed   in  
equal  volume  with  the  crystallant  solution  at  15  °C  .  Crystals  reached  full  size  in  14  days,  
and  were  cryo-­‐‑protected  by  adding  2  µμL  of  the  crystallant  solution  to  the  crystallization  
drop,  and  immediately  cryo-­‐‑cooled  to  −180  °C  in  liquid  nitrogen.  
X-­‐‑ray  diffraction  data  (λ  =  1.0  Å)  were  collected  on  the  SER-­‐‑CAT  22-­‐‑BM  beamline  
at   the   Advanced   Photon   Source   at   Argonne  National   Laboratory.   Data   were   indexed  
and  scaled  using  the  HKL2000  software  suite  (127)  (Table  3.1).  The  data  for  LpxA:holo-­‐‑
ACP   complexes   were   processed   to   2.1   Å,   and   the   structure   was   solved   by  molecular  
replacement  using   the  program  PHASER  within   the  PHENIX  software   suite   (128,   129)  
and  the  uncomplexed  E.  coli  LpxA  structure  (PDB  code:  2AQ9)  as  the  search  model.    One  
monomer   of   His6-­‐‑LpxA   was   present   in   the   asymmetric   unit.   Since   ACP   was   omitted  
during  the  molecular  replacement  process,  it  was  built  manually  by  first  rigid-­‐‑fitting  the  
E.   coli   holo-­‐‑ACP   coordinates   (PDB   code:   4IHH)   (144)   into  unbiased,   contiguous  Fo   –  Fc  
difference   electron   density.      The   model   was   rebuilt   using   COOT   (131)   and   iterative  
structure  refinement  was  carried  out  using  PHENIX  (128).  Hydrogens  were  added  to  the  
model   and   refinement   was   performed   with   restrained   and   TLS   options,   as   well   as  
automated  optimization  of  X-­‐‑ray/stereochemistry  and  ADP  weights  selected.    
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All   residues   of   LpxA   (1-­‐‑262)   and   residues   2-­‐‑75   of   ACP   were   modeled.   Six  
additional   residues   (His5-­‐‑Gly)   forming   a   key   lattice   contact   with   the   neighboring  
molecule   of   ACP   were   also   modeled   at   the   N-­‐‑terminal   end   of   LpxA.   A   pronounced  
electron  density  was  observed  attached  to  Ser36  of  ACP,  which  corresponded  to  the  4′-­‐‑
phosphate  group  of   4′-­‐‑phosphopantetheine  prosthetic   arm.  The  electron  density  of   the  
remaining  part  of  4′-­‐‑phosphopantetheine  was  poor  and  thus  the  pantetheine  moiety  was  
not   included   in   the   final   model.   This   implicates   conformational   heterogeneity   of   the  
pantetheine   arm   throughout   the   lattice.      The   overall   B-­‐‑values   for   the   ACP   were  
approximately  2-­‐‑fold  higher  than  LpxA  (Table  3.1,  Fig.  3.3).  
  The  final  refined  model  of  LpxA:holo-­‐‑ACP  complex  had  Rwork  and  Rfree  values  of  
18.8   and   22.4,   respectively.   The   protein–protein   interactions   were   specified   by  
AREAIMOL  calculations  within  the  CCP4  suite  (134).  The  quality  of  the  final  model  was  
evaluated  using  MOLPROBITY  server  (135),  which  reported  97.3  %  of  the  residues  in  the  
Ramachandran  favored  regions  and  0.0  %  in  the  disallowed  regions.    The  data  collection  
and  refinement  statistics  are  summarized  in  Table  3.1.    Molecular  figures  were  generated  
using  PyMOL  (136).    
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Chapter 4. Conclusion and Future Directions 
Understanding  the  transient  involvement  of  ACP  in  important  cellular  processes,  
such  fatty  acid,  phospholipid,  and  lipid  A  biosynthesis,   is  fundamental  to  primary  and  
secondary   metabolism.   There   are   a   number   of   intriguing   questions   concerning   ACP-­‐‑
based  interactions  that  have  long  puzzled  the  scientific  community,  which  have  not  been  
previously   addressed   due   to   the   transient   nature   of   ACP-­‐‑partner   complexes,   and   the  
high   conformational   mobility   of   many   ACP   domains.      Some   of   these   key   questions  
include:   i)   the  detailed  molecular  basis   for   recognition  of  ACP  by   its  multiple  partners  
which  leads  to  complex  formation,  and  how  such  complexes  can  be  at  once  specific  and  
temporary;  ii)  the  role  of  the  phosphopantetheine  prosthetic  group  in  substrate  delivery,  
and  its  contribution  to  both  the  formation  and  dissociation  of  the  ACP-­‐‑based  complexes;  
iii)   the  way   in  which   the  associations  between  the  ACP  and   its  partners  are  ultimately  
broken;  iv)  the  detailed  molecular  view  of  ACP  tied  to  an  overall  catalytic  cycle;  v)  how  
ACP   communicates   with   representative   partner   enzymes;   and   vi)   the   mechanism   by  
which  the  acyl-­‐‑substrate  is  ejected  from  the  hydrophobic  core  of  ACP  in  order  to  interact  
with   its   partner.      Insights   into   these   questions  will   not   only   allow  us   to  understand   a  
fundamental  aspect  of  primary  metabolism,  but  they  have  relevance  to  elucidating  how  
similar  ACP-­‐‑based  communication  occurs   in   the  numerous  biosynthetic  pathways   that  
are  of  therapeutic  value.      
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  ACP  delivers  the  acyl-­‐‑chains  that  get  incorporated  into  the  glucosamine  sugar  of  
lipid   A   by   the   essential   acyltransferases   of   the   Raetz   Pathway,   including   LpxA   and  
LpxD  (5).    The  biochemical  machinery  required  for  the  constitutive  synthesis  of  lipid  A  
is   a   highly   conserved  process,   as   lipid  A   is   an   essential   anchor   of   lipopolysaccharides  
(LPS)   to   the   cell   envelope   of   Gram-­‐‑negative   bacteria   (4).      This   glucosamine-­‐‑based  
saccharolipid   represents   one   of   the   most   conserved   microbial   structures   that   are  
required   for   the   growth   and   survival   of   this   class   of   microorganisms,   with   few  
exceptions  (4,  13,  14).  The  endotoxic  lipid  A  molecules  are  recognized  by  the  TLR4/MD2  
receptor   during   an   infection.      Although   this   is   desirable   for   clearing   infections,  
overproduction   of   pro-­‐‑inflammatory   cytokines   inundates   the   host   immune   system  
potentiating   the   sepsis   pathology   (4).   Thus,   lipid  A   biosynthesis   not   only   provides   an  
ideal   model   system   to   glean   structural   knowledge   of   ACP-­‐‑based   complexes   but   also  
offers  an  appealing  target  for  developing  novel  antibiotics  against  infective  bacteria.    
The  structural  and  biochemical  studies  presented  in  Chapter  2  make  a  substantial  
contribution   to   resolving   the   questions   concerning   ACP-­‐‑based   interactions,   namely  
those  labeled  i-­‐‑v,  for  the  interaction  between  a  representative  bacterial  ACP  from  E.  coli  
and  one  of  its  enzymatic  partners,  the  N-­‐‑acyltransferase  LpxD  from  lipid  A  biosynthesis  
pathway.  Our   study   represents   the   first   to  have   captured   several   stalled   complexes  of  
ACP   along   its   acyl-­‐‑delivery   reaction   coordinate:   intact-­‐‑acyl-­‐‑ACP,   hydrolysed-­‐‑acyl-­‐‑ACP,  
and  holo-­‐‑ACP.  Moreover,  these  structures  are  the  first  to  show  ACP  engaging  LpxD,  or  
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any  acyltransferase  for  that  matter,  which  are  the  single  most  abundant  class  of  partner  
enzymes  that  associate  with  carrier-­‐‑protein  (56).    
The  ACP  complexes  revealed  the  stoichiometry  of  ACP  binding  to  LpxD,  and  the  
amino  acid  residues  on  both  partners  that  form  the  interaction  interface.  The  interaction  
with   ACP   takes   place   on   the   C-­‐‑terminal   end   of   LpxD,   and   is   predominantly   of  
hydrophilic   character.  Three   electropositive  patches  on   the  C-­‐‑terminal  helices  of  LpxD  
bind   three   molecules   of   ACP,   and   orient   the   phosphopantetheinylated   serine   residue  
relative   to   the   active   site   of  LpxD.  The   intact-­‐‑   and  hydrolysed-­‐‑acyl-­‐‑ACP   revealed   the   4′-­‐‑
phosphopantetheine  disengages  from  ACP  to  bury  the  acyl-­‐‑chain  inside  a  hydrophobic  
pocket,   termed  the  N-­‐‑channel,  which   is   located  between  two  adjacent  LβH  domains  of  
LpxD.   This   conformation   corroborated   the   previously   proposed   catalytic   mechanism  
that  was  deduced   from  mutagenesis   studies,  and  also   revealed   the  molecular  basis   for  
the  specificity  of  LpxD  for  14-­‐‑carbon  chains  containing  a  β-­‐‑hydroxyl  group,  and  the  role  
of  Met290   as   a  hydrocarbon   ruler.   Fortuitously,   an   additional   fatty   acid  was  observed  
bound  to  the  surface  of  LpxD,  which  likely  represents  the  O-­‐‑channel  that  binds  the  acyl-­‐‑
chain   of   the   UDP-­‐‑O-­‐‑acyl-­‐‑GlcN.      Determining   the   structure   of   LpxD   in   complex   with  
UDP-­‐‑O-­‐‑acyl-­‐‑GlcN  will   complete   the   “molecular   landscape”   of   the   active   site   that  will  
facilitate   the   design   and   optimization   of   compounds   for   developing   novel   antibiotics  
against  infective  bacteria.  
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ACP   binding   to   LpxD   is   unusually   tight   (Kd   =   59   nM)   (110),  which   suggests   a  
‘molecular   trigger’   is   required   to   initiate   the   collapse   of   protein–protein   interactions  
following   acyl-­‐‑delivery   (117).   Moreover,   the   4′-­‐‑phosphopantetheine   closes   off   the   N-­‐‑
channel  and  raises  a  key  question  as   to  how  the   lipid  product  of  LpxD  reaction,  UDP-­‐‑
2,3-­‐‑diacyl-­‐‑GlcN,   is  able   to  dissociate   from  the  enzyme  prior   to  holo-­‐‑ACP  as   inferred  by  
kinetic   studies   (110).  Comparison  of   the   intact-­‐‑acyl-­‐‑   and  holo-­‐‑ACP  structures   shed   light  
on   this  matter   and   revealed   that   the   liberated   4′-­‐‑PPT  group  of   the  holo-­‐‑ACP   is   able   to  
form   new   interactions   at   the   far   end   of   the   N-­‐‑channel,   which   necessitates   a   15   Å  
displacement   of   the   thiol   end   of   the   arm.   This   movement   has   several   consequences.  
Firstly,   it  opens  the  catalytic  chamber  to  solvent,  allowing  the  product  UDP-­‐‑2,3-­‐‑diacyl-­‐‑
GlcN  to   leave   the  active  site  prior   to   the  ACP  domain,   in  accordance  with   the  ordered  
catalytic   mechanism.   Product   exit   is   apparently   aided   by   a   steric   clash   between   the  
newly-­‐‑positioned   terminal   thiol   and   the   acyl-­‐‑chain.   And   finally,   the   4′-­‐‑PPT   motion  
provokes  a   substantial   conformational   change   in   the  ACP  domain,  downstream  of   the  
recognition   helix   II.   This   structural   shift   breaks   the   electrostatic   contacts   of   ‘region   II’  
with  LpxD,   a   loss  which   is   likely   responsible   for   the  dissociation   of   the  ACP  domain.  
Thus,   the   catalytic   mechanism   of   LpxD   has   been   shown   to   depend   strongly   on   the  
presence   of   the  ACP  domain,   exploiting   both   the   chemical   nature   and  mobility   of   the  
prosthetic  group,  and  the  dynamic  character  of  the  protein.    
   151  
Chapter  3  reports  another  example  of  holo-­‐‑ACP  bound  to  LpxA  acyltransferase,  
which  also  contains  a  similar  LβH  core.  The  structure  revealed  the  stoichiometry  of  ACP  
binding,   and   the   identity   of   residues   that   contribute   to   ACP   recognition.   Three   ACP  
molecules   utilize   a   binding   mode   different   from   the   holo-­‐‑ACP:LpxD   complex   to  
complement  electropositive  patches  presented  by  the  C-­‐‑terminal  helices  of  LpxA  trimer.  
This  structural  study  revealed  that  the  functional  role  of  the  C-­‐‑terminal  domain  of  LpxA  
is   2-­‐‑fold:   ACP   recognition   and   UDP-­‐‑GlcNAc   binding.   The   structural   comparison   of  
LpxA  with   LpxD   shows   how   their   variation   of   domain   construction   at   the  N-­‐‑   and  C-­‐‑  
termini  allows  them  to  acylate  the  glucosamine  ring  at  a  specific  site.  LpxA  adds  an  acyl-­‐‑
chain   to   the   3-­‐‑hydroxy   group,   whereas   LpxD   transfers   an   acyl-­‐‑chain   to   the   2-­‐‑amino  
group   of   the   glucosamine   ring.   By   adopting   a   rather   extended   conformation,   the   C-­‐‑
terminal  helices  of  LpxD  untie  themselves  from  UDP  binding,  and  alternatively  the  N-­‐‑
terminal   globular   domain,   which   has   no   counterpart   in   LpxA,   takes   over   this   role   to  
orient  the  glucosamine  ring  such  that  N-­‐‑acyltransfer  takes  place.    
Targeting  enzymes  within  the  Raetz  pathway  of  lipid  A  biosynthesis  represents  
an   important   therapeutic  approach   for   the  development  of  novel  antibiotics.  All  of   the  
structural   insights   gleaned   from   Chapter   2   and   3   will   feed   into   our   global   effort   in  
discovering  antibiotics  that  target  lipid  A  biosynthesis.  Recently,  Jenkins  et.  al.  reported  a  
high-­‐‑throughput   fluorescence   polarization   binding   assay   for   LpxA   and   LpxD  
acyltransferases,   which   utilizes   fluorescein-­‐‑labeled   peptides   known   to   bind   to   these  
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enzymes   by   competing   with   acyl-­‐‑ACP   (145).   This   competitive   binding   assay   can   be  
utilized   to   screen   for   compounds   that   reduce   the   fluorescence   polarization   through  
binding  to  LpxA  or  LpxD  and  displacing  the  labeled  peptide.  Candidate  inhibitors  can  
be   further   characterized   by   our   established   radioactivity-­‐‑based   assay,   and   fed   into  
crystallization  trials  for  the  iterative  process  of  compound  evaluation  and  optimization.    
To  complete  our  structural  knowledge  of  ACP-­‐‑mediated  acyl  delivery  in  lipid  A  
biosynthesis,  it  is  our  vision  that  similar  structural  studies  could  be  performed  with  the  
remaining   two  acyltransferase,  LpxL  and  LpxM,  whose   structures  are  unknown.  LpxL  
and  –M  are  integral  membrane  enzymes  that  display  a  significant  sequence  homology  to  
each  other  but  not  to  LpxA  or  LpxD  (5).  Solving  the  structure  of  LpxL  and  LpxM  with  
ACP   at   different   stages   of   catalysis   is   important   not   only   for   understanding   the  
mechanism  of  acyl-­‐‑chain  delivery  by  ACP,  but  also  for  expanding  our  limited  structural  
knowledge  of  membrane-­‐‑bound  enzymes.    
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